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Chapter 1 Introduction 
1.1 Motivation 
 
The distinguishing characteristic between malignant and benign tumors is the ability to 
invade and metastasize. This hallmark of cancer appropriates chemotaxis, cell migration 
in response to chemokine gradients, to direct cancer cells to specific sites. In this thesis, 
we focus on the most highly chemotactic proponent in cancer, the CXCL12/CXCR4 
signaling axis. In this work, we construct mechanistic and statistical models to better 
understand how to target this pathway in breast cancer.  
1.2 The CXCL12/CXCR4/CXCR7 pathway in cancer 
1.2.1 CXCL12/CXCR4: a strong proponent of metastasis 
The CXCL12/CXCR4 pathway is perhaps the best example of how chemokine signaling 
has been co-opted by cancer. CXCR4 is a seven-transmembrane G-protein coupled 
receptor (GPCR) that is constitutively expressed on cells of the immune and central 
nervous systems, including hematopoietic progenitor cells, neutrophils, B cells, naïve T 
cells, microglia and neurons [1-5]. All of these cells migrate in gradients of CXCL12, the 
only known ligand for CXCR4. More than 75% of all cancers, including breast, prostate, 
and brain, exhibit CXCR4 overexpression, whereas the receptor is typically low or absent 
in normal tissue [6]. High CXCR4 gene expression in primary tumors is correlated with 
metastasis and worse survival outcomes in numerous cancer types [7-15]. CXCR4 is also 
a cancer stem cell marker, suggesting that blocking CXCR4 activity may be one strategy 
to target cancer subpopulations refractory to treatment [16-20]. Not only is CXCR4 
upregulated on cancer cells of primary tumors, but CXCR4 is also expressed on cancer 
cells in metastatic lesions [21]. CXCL12 is constitutively expressed in organs of first 
metastasis; such as the lung, liver, and bone; suggesting that cancer cells hijack 
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chemotaxis mechanisms for more efficient invasion, migration and dissemination of 
cancer [20-26].  
 
In Chapters 2 and 3, we use statistical and mechanistic models to understand how 
CXCL12 can play a role in the tumor environment. Tumor stroma produce chemokines 
and other factors that support growth, proliferation, and alteration of cancer cells [27-29]. 
In breast cancer, carcinoma-associated fibroblasts have been shown to produce CXCL12, 
whereas the expression is absent in fibroblasts of normal breast tissue [22]. As a result, 
CXCL12 gradients produced by tumor stroma can stimulate tumor angiogenesis by 
recruiting circulating endothelial progenitor cells to the primary site and may promote 
directional movement of cancer cells towards blood vessels or the invasive tumor edge 
[24]. Although CXCL12 is often discussed as a single protein, the CXCL12 gene 
undergoes alternative splicing to produce six distinct CXCL12 isoforms: α, β, γ, δ, ε, ϕ 
[30]. Recent studies suggest that CXCL12 isoforms can have different outcomes in 
experimental assays of cell migration [31-33]. In Chapter 2, we investigate the expression 
of CXCL12 isoforms to clinical and molecular staging parameters, as well as patient 
survival outcomes. In Chapter 3, we model CXCL12 isoforms using a mechanistic 
approach to study how their molecular properties affect gradient formation and cell 
responses.  
1.2.2 Role of CXCR7 
Until 2005, CXCR4 was the only known receptor for CXCL12. Since then, it has been 
established that the atypical chemokine receptor, CXCR7 (also known as ACKR3), can 
also bind to and signal via CXCL12 [34]. CXCR7 is a seven-transmembrane receptor that 
is unable to signal through G proteins. Instead, CXCR7 primarily signals via β-
arrestin1/2 [35, 36]. Due to its high affinity for CXCL12, CXCR7 plays a large role in 
internalizing and degrading extracellular CXCL12 [35].  
 
CXCR7 is associated with malignancy in cancer. Although not expressed on normal 
breast epithelia or vasculature, CXCR7 is expressed on malignant cells of about 30% of 
primary breast tumors and is highly expressed on tumor-associated vasculature of nearly 
all breast tumors [37, 38]. Independent of CXCR4 expression, the presence of CXCR7+ 
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cancer cells has been shown to promote tumor growth and metastasis in breast and lung 
cancers [38]. In vitro and in vivo studies demonstrate an enhancement of CXCR4 
chemotaxis when CXCR7 levels are elevated [32, 37, 39]. This may be in part due to role 
CXCR7 plays in reducing CXCL12 levels in extracellular space [37]. These data suggest 
that by scavenging CXCL12, CXCR7+ cells may enhance the chemotaxis of CXCR4+ 
cells by creating gradients directing migration out of the tumor and/or by maintaining 
CXCL12 concentrations below receptor saturation levels. How might CXCR7 affect 
CXCL12/CXCR4 signaling? We take two approaches to look at this. In Chapter 3, we 
model CXCR7 as a scavenger of extracellular ligand and demonstrate how it can shift 
responses in cells only expressing the CXCR4 receptor. In Chapter 4, we probe how co-
expression of CXCR7 with CXCR4 may alter CXCR4 signaling. Both chapters aim to 
understand how these two receptors should be targeted to mitigate malignant 
CXCL12/CXCR4 signaling. 
1.2.3 Signaling 
Upon binding CXCL12, CXCR4 can trigger a number of intracellular signaling pathways 
with diverse cellular responses. Via Gαi, CXCL12 binding to CXCR4 results in calcium 
flux, cAMP inhibition, and activation of the AKT, MAPK, and PI3K pathways [23, 40]. 
Independently of G proteins, CXCR4 can also signal by forming a complex with β-
arrestin1/2. Traditionally, β-arrestin1/2 has been thought to serve primarily as a 
desensitizer to GPCR signaling; however, it is now accepted that association with β-
arrestin1/2 results in signaling beyond internalization and trafficking [41]. Via β-
arrestin1/2, CXCR4 scaffolds with MEK to promote ERK activation [23, 42-44]. In 
addition to its scavenging ability, CXCR7 can also signal through β-arrestin1/2. CXCR7 
signaling via β-arrestin1/2 can elicit Akt, MAPK, and JAK/STAT3 pathways, although 
whether this is by direct modification or by heterodimerization with CXCR4 is unclear 
[45, 46].  
1.2.4 Targeting CXCR4/CXCR7 
Several compounds have been developed to target CXCL12/CXCR4 signaling. A 
CXCR4 antagonist, AMD3100 (also called Plerixafor or Mozobil), is FDA-approved to 
mobilize hematopoetic stem cells for collection and autologous stem cell transplantation 
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in patients with non-Hodgkins lymphoma and multiple myeloma [47-55]. Currently, 
AMD3100 is only approved for short-term use, but has recently been shown to be safe at 
low-doses for at least six months to alleviate panleukopenia in WHIM syndrome [50, 56]. 
In acute myeloid leukemia (AML), immature white blood cells (blasts) occupy the bone 
marrow and interrupt the production of normal blood cells. It is thought that the 
CXCL12-rich bone marrow microenvironment provides a protective effect to the AML 
blasts. A Phase 1 and 2 clinical trial demonstrated that after mobilization, AML blasts 
collected from the blood display increased surface CXCR4 [49].  
 
For cancers with solid tumors, the benefits of blocking CXCL12/CXCR4 signaling have 
been mixed. Some CXCR4 drugs have been shown to impede tumor growth, whereas 
others are not as effective [57-61]. CTCE-9908, the CXCL12 analog approved for 
osteosarcoma, has been shown to prevent metastasis in prostate and breast cancers in 
mouse models [62, 63], but has not yet been tested in humans.  
 
One potential targeting strategy is to inhibit CXCR7 function in conjunction with 
CXCR4. AMD3100 is not a potential candidate for such duel inhibition, as it is an 
allosteric agonist of CXCR7 at pharmacologic levels [64]. Efforts to develop CXCR7-
specific agents are currently underway [45, 65].  The CXCR7 antagonist CCX771 has 
been used to demonstrate the role of CXCR7 in cancer. CCX771 blocks human brain 
microvascular endothelial cell migration and inhibits transendothelial migration of 
CXCR4+ cells in CXCL12 gradients in mouse models [45, 66].  
1.2.5 CXCL12 isoforms and glycosaminoglycans 
In vivo chemokine gradients are influenced by the presence of negatively-charged 
glycosaminoglycan (GAG) groups, such as heparin sulfates, that reside on cell surfaces 
and the extracellular matrix. GAG interaction can restrain chemokines on cell surfaces 
and may influence gradient formation [67]. GAGs may also facilitate the receptor binding 
process by increasing local chemokine availability [68]. The six CXCL12 isoforms differ 
in the number of BBXB domains, which are positively charged, resulting in differences 
in affinity to GAGs due to the negative-positive charge interaction [31, 69]. However, 
most experimental studies demonstrating the role of CXCL12 in cancer and chemotaxis 
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focus on the α isoform or do not discriminate between isoforms [30]. CXCL12 isoforms 
have physiological differences in tissue expression, and may also differ in tumor-specific 
expression [30, 70]. In Chapter 2, we present the first study examining the expression of 
all six CXCL12 isoforms breast cancer.  
1.2.6 Receptor organization on the plasma membrane 
During chemotaxis, cells appear to distribute their receptors asymmetrically across their 
length to maximize gradient sensing [71]. Spatial reorganization of receptors and other 
cell membrane-bound molecules may be used to amplify signaling in other cellular 
processes. Macropinocytosis, a process where the cell membrane folds over itself to 
entrap and ingest extracellular fluid, is highly dependent on the organization of the 
cellular membrane [72, 73]. In Chapter 5, we use 3D modeling tools to understand how 
diffusion on the cell membrane is restricted during macropinocytosis.  
 
1.3 Methods 
1.3.1 Gene expression profiling techniques  
Gene expression profiling techniques allow us to extract correlations between 
CXCL12/CXCR4/CXCR7 gene level expression and patient outcomes. The rapid cost 
decrease of whole genome sequencing has produced an enormous amount of data to 
mine. In fact, not only are there thousands of publicly available datasets, but several 
websites that collect and allow facile search of this massive amount of data [74-76]. 
Microarray technology is the most common method of profiling gene expression. A DNA 
microarray organizes probes to specific DNA sequences on a solid surface (either chip or 
microscopic beads). The current standard microarray can probe for nearly 40,000 genes. 
These microarrays rely on the a priori knowledge of DNA sequence to develop the probes 
of the array. Therefore, current microarrays are not specific enough to detect small 
differences between proteins, such as the CXCL12 isoforms. RNAseq, a next-generation 
sequence method, alleviates this issue (Figure 1.2). Instead of relying on probes, RNAseq 
relies on a digital method to determine gene expression levels. In RNAseq, cDNA 
(converted by reverse transcriptase of patient mRNA) is digested into small pieces, or 
RNAseq “reads”. An algorithm aligns the reads to the genome, and the number of reads 
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specific to a particular isoform are counted to determine relative abundance of one 
isoform to another [77].  
1.3.2 In silico models of cancer 
Increasingly, mathematical and computational models are used to untangle the complex 
behaviors of biological systems. The major types of models for cancer can be classified 
as continuous models and discrete models. Continuous models use ordinary and partial 
differential equations (ODEs and PDEs, respectively) to describe the changes in cell 
density or tumor invasion [78-81]. These deterministic models tend to describe the tumor 
as a continuous medium and predict cell population dynamics without an emphasis on the 
underlying mechanisms [82, 83]. On the other hand, agent-based models (ABM) are 
discrete models where the biological system is described as a collection of individual 
agents in an environment. Typically, the agents in these models are the cells in the 
system, which reside on a lattice environment. Cell interactions with other cells and their 
environment are governed by a set of rules. Commonly, ABMs incorporate stochasticity 
by implementing probabilities for these interactions. ABMs focus on determining the 
effect of these individual interactions on the emergent behavior of the system [84, 85]. 
1.3.3 Multi-scale models 
We and others have constructed hybrid ABMs that combine the advantages of both 
continuous and discrete models in order to provide a mechanistic examination of 
processes occurring at multiple biological scales [83, 86-97]. In these multi-scale models, 
cellular behavior is typically modeled in an ABM framework and ODE/PDEs describe 
molecular processes. For example, on the tissue scale, cells may be able to move, grow, 
proliferate, change states and die. Each cell on the lattice can have a set of ODEs 
describing intracellular signaling pathways. When cells secrete or internalize chemokines 
and other molecules on the lattice, PDEs are used to calculate molecular diffusion and 
update the levels of molecules at each lattice space. These models have been successfully 
used to investigate the role of molecular scale processes on the overall dynamics of the 
tissue scale.  
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Most ABMs that include the role of chemotaxis for cellular migration base the direction 
of movement solely on the chemokine concentrations in the neighborhood, without any 
information about receptor dynamics [94, 98, 99]. Furthermore, many hybrid ABMs that 
do incorporate intracellular signaling pathways for chemotaxis do not incorporate the role 
of receptor dynamics. Yet, receptor desensitization is universal among chemokine 
receptors and required for cells to chemotax [100]. 
1.3.4 Uncertainty and sensitivity analysis 
In mathematical and computational models of biological systems, parameter values are 
often estimated from experiments under different conditions, extrapolated from literature 
and/or fit to the model itself. Due to this uncertainty in the accuracy of the inputs, 
uncertainty and sensitivity analyses (U/SA) are crucial to the examination of complex 
models. Uncertainty analysis explores the uncertainty in the model derived from the 
uncertainty in parameter inputs. Sensitivity analysis investigates the contribution of each 
individual parameter to the uncertainty of the model results [101, 102]. Several 
approaches have been developed to perform U/SA. Of particular interest is Latin 
hypercube sampling (LHS) coupled with partial rank correlation coefficients (PRCC), 
which has been used to carry out U/SA in both deterministic and stochastic models [80, 
88, 103]. 
 
LHS is a popular sampling technique because it can provide a large amount of 
uncertainty data with a relatively small sample size and is greater than one order of 
magnitude more efficient than random sampling methods [101, 103]. Rather than varying 
one parameter at a time, in LHS, all parameters are varied simultaneously, providing an 
unbiased examination of each parameter, regardless of which might turn out to be most 
important. LHS is a stratified non-replacement sampling strategy where each parameter 
range is divided into N equal probability intervals. Each probability interval is sampled 
only once and is repeated for each parameter. Simulations are then run using M 
combinations of parameter values and produces M model outputs [101-103]. PRCC can 
then be calculated to determine how well the variability of a parameter correlates to a 
selected model output. PRCC values are between -1 and 1, which are associated with a 
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perfectly negative or perfectly positive correlation between the parameter and model 
outcome.  
 
1.4 Thesis summary 
 
In this thesis, we focus on multiple scales of biology. In Chapter 2, we correlate CXCL12 
isoform gene expression levels to patient population outcomes. In Chapter 3, we link the 
molecular scale to the tissue scale to explain how events such as ligand-receptor binding 
and internalization shape gradients and affect cell movement within tumors. In Chapter 4, 
we model CXCR4/CXCR7 signaling in more depth to understand how targeting CXCR7 
in the context of mitigating CXCR4 signaling may result in unintended effects. In 
Chapter 5, we construct a 3D model of macropinocytosis to understand how plasma 
membrane bound molecules reorganize during such complex events. 
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1.5 Figures
 
Figure 1.1 Effects of CXCL12 gradients on cancer progression.  
(A) The primary breast tumor microenvironment. CXCR4+ and CXCR7+ cancer cells 
may respond to gradients of CXCL12 produced by carcinoma-associated fibroblasts. (B) 
Distant metastatic site. CXCL12 gradients produced by bone marrow stromal cells can 
provide a homing mechanism for cancer cells to metastasize.  
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Figure 1.2 Algorithm for calculating relative gene expression in RNAseq 
Contrary to microarrays, probing gene expression using RNAseq is not dependent on the 
a priori creation of probes specific to genes of interest. Instead, the RNAseq algorithm 
accepts randomly spliced parts of the patient’s genome, and aligns it to a map of the 
genome. Then, the algorithm counts regions specific to each protein of interest. In the 
case of CXCL12 isoforms, the C-terminus of CXCL12-β and -γ are unique to those 
isoforms, however the exon closest to the N-terminus is not. Therefore, RNAseq would 
count the total number of unique regions of CXCL12-β and -γ, and then deduce that the 
remaining counts of the shared exon is correlated to the expression of CXCL12-α. 
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Chapter 2  
A comprehensive analysis of CXCL12 isoforms in 
breast cancer 
 
2.1 Abstract 
 
CXCL12-CXCR4-CXCR7 signaling promotes tumor growth and metastasis in breast 
cancer.  Alternative splicing of CXCL12 produces isoforms with distinct structural and 
biochemical properties, but little is known about isoform-specific differences in breast 
cancer subtypes and patient outcomes. We investigated global expression profiles of the 
six CXCL12 isoforms, CXCR4, and CXCR7, in The Cancer Genome Atlas (TCGA) 
breast cancer cohort using next generation RNA sequencing in 948 breast cancer and 
benign samples, and seven breast cancer cell lines.  We compared expression levels with 
several clinical parameters, as well as metastasis, recurrence, and overall survival. 
CXCL12-α, β, and γ are highly co-expressed, with low expression correlating with more 
aggressive subtypes, higher stage disease, and worse clinical outcomes.  CXCL12-δ did 
not correlate with other isoforms, but was prognostic for overall survival and showed the 
same trend for metastasis and recurrence free survival. Effects of CXCL12-δ remained 
independently prognostic when taking into account expression of CXCL12, CXCR4, and 
CXCR7. These results were also reflected when comparing CXCL12-α, -β, and -γ in 
breast cancer cell lines. We summarized expression of all CXCL12 isoforms in an 
important chemokine signaling pathway in breast cancer in a large clinical cohort and 
common breast cancer cell lines, establishing differences among isoforms in multiple 
clinical, pathologic, and molecular subgroups.  We identified for the first time the clinical 
importance of a previously unstudied isoform, CXCL12-δ.  
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2.2 Introduction 
 
Nearly all human genes undergo alternative splicing, substantially increasing diversity in 
protein structure and function [1]. Genome-wide analyses of several different cancers 
demonstrate extensive perturbations in splicing during tumor initiation and metastasis 
[2,3]. Alternatively spliced proteins regulate fundamental processes in cancer, including 
apoptosis, metabolism, and metastasis, suggesting that dysregulated splicing is critical to 
malignancy [4-6]. As prominent examples of alternative splicing in cancer, a switch from 
pyruvate kinase M1 (PKM1) to the M2 isoform drives anabolic metabolism in malignant 
cells, and a novel splice variant of the transmembrane protein CD44 promotes metastasis 
[5,7-9]. Isoforms of these and other genes preferentially expressed in malignant versus 
normal tissues provide potential biomarkers for detection of cancer and may contribute to 
drug resistance of cancer cells. Identifying changes in protein isoform expression in 
cancer will improve understanding of key signaling pathways in tumorigenesis and point 
to novel therapeutic targets to improve cancer therapy [10,11].         
  
Chemokine CXCL12 and its chemokine receptors CXCR4 and CXCR7 (recently 
renamed as ACKR3) comprise a signaling axis strongly linked to tumor growth and 
metastasis in breast cancer and more than 20 other malignancies [12,13]. CXCL12 
binding to CXCR4 activates pathways including phosphatidylinositol-3 kinase and 
mitogen activated protein kinases (MAPK) to promote growth, survival, and chemotaxis 
of breast cancer cells. High levels of CXCL12 are expressed in common sites of breast 
cancer metastasis such as lung, liver, bone, and brain [14]. CXCR4 commonly is 
upregulated on breast cancer cells, and numerous studies have demonstrated both gene 
and protein overexpression of CXCR4 on cancer cells in primary breast tumors [15-18]. 
The anatomic distribution of CXCL12 and studies in mouse models of cancer suggest 
that gradients of this chemokine drive local invasion and subsequent homing of CXCR4+ 
breast cancer cells to secondary sites [18,19]. CXCR7 also is expressed by breast cancer 
cells and stromal cells, such as endothelium on tumor vasculature, in primary breast 
cancers [20]. CXCR7 functions as a scavenger receptor for CXCL12, functioning in part 
to decrease amounts of this chemokine in the extracellular space and establish 
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chemotactic gradients [21,22]. CXCR7 also promotes survival and invasion of malignant 
cells [23].  
 
Although six different isoforms of human CXCL12 (α, β, γ, δ, ε, and φ) have been 
described, most studies of CXCL12 focus only on the α isoform or do not distinguish 
among isoforms [24]. CXCL12 may be secreted by malignant cells in primary breast 
cancers in addition to carcinoma-associated fibroblasts and/or mesenchymal stem cells in 
the tumor microenvironment [17,25,26]. Fibroblasts isolated from primary breast tumors 
secrete CXCL12 at higher levels than fibroblasts from normal mammary tissue despite no 
genetic mutations in stroma [27,28]. These findings suggest that cancer cells stimulate 
adjacent fibroblasts to produce higher levels of total CXCL12 in breast tumors than 
normal mammary tissue [28]. However, while these data demonstrate that carcinoma-
associated fibroblasts are characterized by increased CXCL12, it remains unclear to what 
extent total CXCL12 in breast cancers differs from normal tissue and affects prognosis. 
Based on expression of CXCL12-α and -β in two different breast cancer microarray 
datasets and immunohistochemistry of primary breast tumors, Mirisola and colleagues 
reported that higher expression levels of CXCL12-α and -β correlate with better disease-
free survival [29]. However, a separate high throughput analysis of CXCL12 expression 
concluded that higher CXCL12 levels correlate with increased metastasis and local 
recurrence in breast cancer [17]. Determining effects of high versus low CXCL12 on 
prognosis and disease progression in breast cancer is essential to direct optimal use of 
therapeutic antibodies and other agents being developed for CXCL12-targeted cancer 
therapy [30]. 
 
Prior genetic analyses of mRNA for CXCL12 isoforms have used microarrays, which 
frequently lack probes to detect specific isoforms of these genes. However, next-
generation sequencing overcomes this limitation. Using bioinformatics analysis of 
publicly available data sets from The Cancer Genome Atlas (TCGA), we investigated 
expression of CXCL12 isoforms, as well as CXCR4 and CXCR7 in breast cancer. We 
then correlated patterns of expression with important molecular phenotypes, clinical 
parameters, and outcomes in these patients. These analyses revealed distinct differences 
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in expression for various isoforms of these genes. We show that low levels of expression 
of CXCL12 correlate with worse prognosis in breast cancer with isoform-specific 
differences among α, β, γ, and δ isoforms. These data demonstrate the impact of CXCL12 
isoforms in breast cancer and underscore the need to better understand functional 
differences among these molecules in disease progression and therapy.   
2.3 Methods 
2.3.1 Study Design and RNA Sequencing 
Publicly available RNA next-generation sequencing and clinical data (844 breast cancer 
and 104 benign breast samples) were retrieved from The Cancer Genome Atlas (TCGA) 
for breast cancer [31]. Additional clinical data such as PAM50 clustering and clinical 
follow-up for the TCGA were obtained from the UCSC Cancer Genomics Browser [32]. 
RNA sequencing data for seven breast cancer cell lines (two samples each) were obtained 
from the Illumina iDEA database (www.illumina.com). Three of these cell lines have 
been shown to have metastatic potential (BT20, MDA-MB-231, and MDA-MB-468), and 
four cell lines have been shown to have no metastatic potential (BT474, MCF7, T47D, 
and ZR-75-1) [33-35].  RNA sequencing reads were aligned to the genome with Tophat 
[36] using Genome Reference Consortium Human Build 37 (GRCh37 or hg19) 
(www.ncbi.nlm.nih.gov) as the reference genome.  
 
Seven hundred eighty-five of the cancer samples had clinical data from TCGA, and 832 
had data from UCSC Cancer Genome Browser. Her2 status was not included as a 
column, so we calculated it based on the immunohistochemistry (IHC) data column.  For 
cases with equivocal IHC, we then used the in-situ hybridization (ISH) data column.  
 
Normalization was performed using Fragments per Kilobase per Million (FPKM), and 
isoform expression values were generated using Cufflinks with Ensembl version 69 as the 
reference transcriptome [37]. Cufflinks calculates isoform expression levels using a 
statistical model in which the probability of observing a given fragment is a linear 
function of the transcript abundance. Gene level expression is the sum of transcript level 
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expression, as each read is assigned to a single transcript. Tophat was chosen because it is 
the standard sequence aligner used by Cufflinks [38].  
2.3.2 Statistical and Bioinformatics Analysis 
Correlation coefficients were generated using Spearman’s correlation. Hierarchical 
clustering was performed on the covariance matrices to generate heat maps. Expression 
levels of the isoforms and at the gene level were compared across clinical and pathologic 
groups such as cancer vs. normal, tumor stage, histology, hormone receptor status, and 
PAM50 cluster [39]. Means between groups were compared using Analysis of Variance 
(ANOVA). Expression was divided into high versus low expression using the median 
expression value. Kaplan Meier curves were generated for the high and low expression 
groups and compared using the Log-rank test for metastasis free survival (MFS), 
recurrence free survival (RFS), and overall survival (OS). Hazard ratios (HR) were 
generated using univariate Cox regression.  Multi-gene analysis was performed using 
Cox regression with expression of each gene/isoform as a covariate.  Comparison of 
expression between metastatic versus non-metastatic cell lines was performed using 
Student’s T-test. Statistics and plots were generated using the R statistical computing 
software and GraphPad Prism. 
2.4 Results 
2.4.1 Differential expression of CXCL12 isoforms, CXCR4, and CXCR7 in breast 
cancer versus normal breast tissue 
Studies of isoforms of CXCL12 in cancer and other diseases have been limited by the 
lack of isoform-specific probes on microarrays and antibodies for immunohistochemistry.  
As a result, studies have focused predominantly on only the α and β isoforms of 
CXCL12.  To overcome limitations of microarrays and antibodies, we investigated 
expression levels of all isoforms of CXCL12 and receptors CXCR4 and CXCR7 in breast 
cancer using the TCGA RNA sequencing dataset.  The clinical and pathologic 
characteristics of the tumor samples and patients in this dataset are shown in Table 1. 
 
The Cufflinks analysis program assigns each read to individual isoforms such that the 
sum of expression levels for a specific isoform is equal to the gene level of expression.  
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Based on this analysis, we determined that the most common isoform of CXCL12 in 
breast cancer is α (65%), followed by β (27%) > γ (5%) > δ (2%).  We detected only very 
low levels of expression for CXCL12-ε (0.1%) and –φ (0.2%), and therefore refrained 
from statistical inference using these isoforms.   
 
To establish for the first time correlations among CXCL12 isoforms, CXCR4, and 
CXCR7, we examined the Spearman’s covariance matrix with hierarchal clustering for 
breast cancer and normal tissue, respectively (Figure 2.1A, 2.1B).  In breast cancer, 
CXCL12 α and β were highly correlated (correlation coefficient of 0.91), and these two 
isoforms also correlated highly with gene-level expression of CXCL12 (correlation 
coefficients of 0.99 and 0.95 for CXCL12 α and β, respectively) (Figure 2.1A).   By 
comparison, the γ, ε, and φ isoforms of CXCL12 correlated moderately with expression 
of α, β, and gene-level expression (correlation coefficients of 0.44 to 0.59).  Interestingly, 
the δ isoform, which is not well characterized in the literature, correlated very poorly 
with the other CXCL12 isoforms (correlation coefficients of -0.11 to 0.27) and in cancer 
samples, clustered with CXCR4 and CXCR7 rather than with the other CXCL12 
isoforms.   CXCR4 and CXCR7 displayed a weak, positive correlation with gene-level 
expression of CXCL12 and its α and β isoforms, but did not correlate with each other. 
These same general correlations were present in normal samples (Figure 2.1B). However, 
in normal samples, CXCR7 tended to correlate inversely with CXCR4, and CXCR7 also 
exhibited modest to strong correlations with CXCL12-α, β, and overall gene-level 
expression of this chemokine.   
 
We next investigated levels of expression for various chemokine and receptor isoforms in 
cancer and normal tissues.  While previous publications report discordant results for 
CXCL12 in breast cancer versus normal breast, our analysis showed significant 
downregulation of CXCL12-α, β, and γ in cancer (Figure 2.1C).  Expression of CXCL12-
δ also decreased in cancer as compared with normal, although differences were not 
significant.  Similarly, CXCR7 was downregulated in cancer. CXCR4 demonstrated the 
opposite pattern with upregulation in cancer, consistent with prior literature [15,17,18].  
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2.4.2 Variations among CXCL12 isoforms, CXCR4, and CXCR7 with clinical and 
molecular staging parameters 
Within cancer samples, CXCL12-α, β, and γ varied significantly with tumor stage (Figure 
2.2A).  For these isoforms of CXCL12, lower stage tumors had higher levels of 
expression with the highest amounts of each isoform present in stage I primary breast 
tumors.  We observed a similar trend for gene-level expression of CXCL12.   We also 
compared differences in expression of various isoforms with histologic classifications of 
breast cancer. Invasive ductal and invasive lobular carcinomas comprise the majority of 
the TCGA data set, and most of the mixed histology samples contain features of both 
invasive ductal and lobular cancer. Gene-level expression of CXCL12, as well as α, β, 
and γ isoforms, showed significant variations across different histologic groups (Figure 
2.2B).  Amounts of total CXCL12 and these three isoforms were highest in invasive 
lobular cancer with a rank order of invasive lobular > mixed > invasive ductal carcinoma.  
We note that lowest levels of expression for CXCL12 and the α, β, and γ isoforms 
occurred in less common histologic types of breast cancer, medullary and mucinous.  
Other isoforms of CXCL12 did not vary significantly with tumor stage or histologic type, 
and we also did not identify significant correlations with gene-level CXCR4 or CXCR7.     
 
In clinical oncology, breast cancers are categorized based on hormone receptors (estrogen 
[ER] and progesterone [PR]) and amplification of the oncogene Her2.  These categories 
determine prognosis and treatment options [40].  We analyzed expression of CXCL12, 
CXCR4, and CXCR7 and individual isoforms in tumors positive for both ER and PR, 
Her2 only, and all three receptors (triple positive), as well as primary cancers lacking 
expression of these three receptors (triple negative).  Gene-level expression of CXCL12 
and the α and β isoforms each varied significantly across these subtypes with highest 
amounts in ER/PR positive and triple positive cancers (Figure 2.3A).  By comparison, 
levels of overall CXCL12, CXCL12-α, and CXCL12-β decreased in triple negative 
cancer and to an even greater extent in Her2 positive tumors.  Other isoforms of CXCL12 
did not vary significantly with receptor status.  CXCR7 varied with receptor status in a 
pattern comparable to CXCL12 (Figure 2.3A).  Levels of CXCR7 were highest in ER/PR 
positive and triple positive tumors with lower expression in triple negative and Her2 
 25 
positive cancers.  Interestingly, we identified a distinct pattern of expression for CXCR4, 
which was elevated in triple negative breast cancer relative to the other groups [41].   
 
More recently, breast cancers have been classified into intrinsic molecular subtypes 
(Normal-like, Luminal A, Luminal B, Her2-enriched, and Basal-like) defined by a 50 
gene panel referred to as PAM50.   Intrinsic subtypes add prognostic and predictive 
information to standard metrics used to categorize breast cancer.  When analyzed across 
intrinsic subtypes, CXCL12 and its α, β, and γ isoforms varied significantly (Figure 
2.3B). Expression was highest in the Normal-like cluster, which is consistent with our 
data in Figure 2.1A showing upregulation of these isoforms in normal samples. Luminal 
A had the next highest expression with Luminal B, Her2-enriched, and Basal clusters 
exhibiting lower expression.  We also identified significant variations of receptors with 
intrinsic subtypes of breast cancer.  CXCR4 showed differential expression among 
clusters with lowest levels in Luminal A and Luminal B subtypes and highest expression 
in Basal cancers.  By comparison, levels of CXCR7 were highest in Luminal A and 
Luminal B subtypes.   
 
CXCL12 and its α, β, and γ isoforms vary significantly with race. We identified higher 
expression in whites than Asians or African-Americans (Figure 2.7A). Gene-level 
CXCL12 and the α isoform also changed significantly by age group with levels peaking 
in the 50-60 year age group relative to younger or older patients (Figure 2.7B).  
CXCL12-β and -γ showed a similar pattern across age groups, although differences were 
not significant.  We did not identify significant correlations for race or age groups for 
CXCR4 or CXCR7.  
2.4.3 CXCL12 isoforms correlate with patient outcomes 
We next examined the correlation of gene and isoform expression with important clinical 
outcomes in breast cancer: metastasis, recurrence, and overall survival. Kaplan-Meier 
curves for high versus low expression of gene-level CXCL12 demonstrated that low-
expression of gene-level CXCL12 corresponded with a significantly worse MFS (p-value 
< 0.008, HR=2.2), but not RFS or OS (Figure 2.4A-C). Similarly, low expression of 
CXCL12-α corresponded with significantly worse MFS (p-value < 0.033, HR=1.9) but 
 26 
not RFS or OS (Figure 2.4D-F).  Unlike CXCL12-α, low levels of both CXCL12-β and -γ 
correlated with significantly worse MFS (β isoform p-value < 0.0015, HR=2.6; γ isoform 
p-value < 0.011, HR=2.2) and RFS (β isoform p-value < 0.028, HR=2.1; γ isoform p-
value < 0.024, HR=2.1), but not OS (Figure 2.4G-L).  
 
CXCL12-δ, the isoform that does not correlate with expression patterns of other isoforms 
in breast cancer or normal breast tissue, had a different association with outcomes.  Low 
expression of the δ isoform also showed trends for reduced MFS and RFS (Figure 
2.4M,N), although not statistically significant (MFS, p-value < 0.16, HR=1.5; RFS, p-
value < 0.077, HR=1.7). Notably, low CXCL12 δ was the only CXCL12 isoform 
correlated with worse OS (p-value < 0.0035, HR=1.8) (Figure 2.4O).  
 
CXCL12, CXCR4, and CXCR7 do not operate independently, but as important 
components in a complex network. We examined the expression levels of CXCL12- δ, 
the least understood isoform in the context of the expression of the other genes in the 
pathway. Low CXCL12- δ is independently prognostic for OS even after taking into 
account CXCL12, CXCR4, and CXCR7 expression (p-value < 0.004, HR=0.56), and 
shows the same trend in MFS and RFS (Figure 2.5A-C) multi-gene analysis.  
2.4.4 CXCL12 isoforms correlate with metastatic potential in breast cancer cell lines 
By nature, clinical samples such as the TCGA contain a mix of cell types, including 
tumor cells, normal breast tissue and vasculature, making it difficult to identify the cell 
type(s) producing each transcript.  To overcome this limitation, we examined RNAseq 
data in seven breast cancer cell lines for CXCL12 isoforms. Surprisingly, we find isoform 
expression shows a different trend than in the TCGA samples, with γ showing the highest 
expression proportion (42%), followed by α (33%) > β (24%).  We detected only very 
low levels of expression for CXCL12-δ (0.5%), ε (0.1%) and –φ (0.2%).  
 
We compared CXCL12 isoform expression levels between cell lines with metastatic 
potential and those without metastatic potential (Figure 2.6), and found that CXCL12 and 
its α, β isoforms were expressed significantly lower in samples with metastatic potential, 
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which is in agreement with the trends of isoform expression in clinical samples. The 
same trend was seen with CXCL12- γ, though not statistically significant. 
2.5 Discussion 
 
While alternative splicing formerly appeared to be limited to a small number of genes, 
studies now demonstrate that almost all human genes undergo alternative splicing to 
create protein diversity [42].  Variants generated by loss of splicing fidelity or regulated 
transitions between isoforms drive cancer and many other human diseases, generating a 
large number of novel transcripts and proteins expressed predominantly or uniquely in 
cancer.  For example, up to 36 different isoforms of the Wilms tumor gene 1 (WT1) have 
been identified with specific variants specifically upregulated in acute and chronic 
myeloid leukemias, suggesting key functions in cancer initiation and/or progression 
[43,44].  Similarly, isoforms of vascular endothelial growth factor (VEGF) exhibit 
distinct functional activities in tumor angiogenesis that vary based on anatomic site, 
emphasizing the importance of tumor environments on isoforms [45-47].  In addition to 
conferring unique functions to cancer cells and tumor environments, alternative splicing 
offers a rich source of potential prognostic and predictive biomarkers.  Biomarkers and 
targeted therapies based on alternative splicing may have a higher likelihood for success 
than conventional approaches centered on a whole gene or protein.  Collectively, these 
studies highlight the clinical relevance of identifying disease-associated changes in 
alternative splicing.   
 
Prior research has established central functions of CXCL12 in cancer growth and 
metastasis, but very few studies have investigated isoforms of CXCL12 in cancer.  In 
renal cell carcinoma, an analysis limited to CXCL12-α and -β revealed that only the β 
isoform correlated with tumor grade and infiltration of CD8 T cells [48].  CXCL12-β also 
was upregulated in bladder cancer, a disease in which expression of this isoform 
predicted metastasis and disease-specific mortality [49].  This study of bladder cancer 
also showed that amounts of CXCL12-α did not change between normal and malignant 
tissue, while CXCL12-γ was undetectable.  Neither these studies nor any others have 
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investigated the other three CXCL12 isoforms (δ, ε, or φ) in cancer due to the lack of 
antibodies against these isoforms and limitations in high throughput technology.   
 
Next-Gen sequencing allows our study to fill notable gaps in knowledge about the 
CXCL12/CXCR4/CXCR7 pathway by providing the first characterization of expression 
levels of all known alternative splicing variants of CXCL12 in breast cancer or any other 
malignancy.  We found that primary human breast cancers express four different 
isoforms of CXCL12 in rank order of α  > β > γ > δ, while ε and φ essentially were 
undetectable in the TCGA breast cancer samples.  Expression of CXCL12 isoforms 
varied significantly across many different clinical and molecular categories of breast 
cancer, including stage, histologic type, intrinsic molecular subtype, and hormone 
receptor status.  Changes in abundance of transcripts typically occurred in parallel for 
each CXCL12 isoform as would be expected for an mRNA regulated by the same 
common promoter elements.  We also discovered lower levels of CXCL12 transcripts in 
subtypes of breast cancer regarded as more aggressive, such as triple-negative and Her2 
amplified, and with progression to higher stage.  These findings corresponded with 
Kaplan-Meier analyses, where low expression of CXCL12 and specific isoforms was 
associated with worse outcomes.  We identified isoform-specific effects on MFS, RFS, 
and OS with low levels of CXCL12- α, -β and -γ significantly correlated with worse MFS 
and RFS.  Most notably, we note that low levels of CXCL12-δ associated with worse OS 
and showed the same trend for RFS and MFS, despite the fact that CXCL12- δ 
expression does not correlate with expression of the other isoforms.  This relationship is 
robust, and persists even after taking into account CXCL12, CXCR4, and CXCR7 
expression in multi-gene analysis, indicating the independent prognostic significance of 
CXCL12- δ.  These data provide the first evidence that CXCL12-δ is expressed in human 
cancer and correlate with a patient outcome.   
 
Expression levels of CXCL12 in breast cancer cell lines generally mirror conclusions 
from the clinical samples that lower levels of CXCL12 correlate with worse prognosis.  
We found that breast cancer cell lines without metastatic potential (in mouse models) had 
higher levels of CXCL12 expression than cell lines that metastasize more widely.  
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Studies of CXCL12 in breast cancer focus on secretion of this chemokine by stromal cells 
in primary and metastatic sites, frequently overlooking effects of CXCL12 produced by 
cancer cells.  However, epigenetic silencing of the CXCL12 promoter has been reported 
in breast cancer cells with greater metastatic potential, and re-expressing CXCL12 limits 
metastatic disease in mouse xenograft models [25]. Our analysis of cell lines may inform 
likely sources of various CXCL12 isoforms in tumor microenvironments.  Breast cancer 
cells express CXCL12-α, β, and γ with very minimal expression of δ, which could 
indicate that stromal cells are the predominant source of the δ isoform in primary breast 
cancers.  We also note that CXCL12-γ is higher than α and β in our panel of breast cancer 
cell lines, which is opposite the pattern in primary tumors.  Differences between data 
from cell lines versus tumors may reflect dynamic regulation of CXCL12 isoforms in 
vivo, greater contributions of stromal cells to overall expression of CXCL12-α and β in 
breast tumors, or simply genomic changes as the original cancer samples were 
transformed into immortalized cell lines. In addition, CXCL12 levels within the tumor 
microenvironment may be affected by post-translational modification, such as cleavage 
by CD26 or matrix-metalloproteinase-2.[50,51] 
 
Isoform-specific differences in expression and breast cancer outcomes suggest distinct 
functions of individual splice variants of CXCL12 on disease progression.  Recent studies 
have begun to identify unique biochemical properties of CXCL12 isoforms, particularly 
α, β, and γ.  While all isoforms share the same core structure, CXCL12-β, γ, δ, ε, and φ 
differ by inclusion of exons that add 4, 40, 51, 1 or 11 additional amino acids, 
respectively, to the carboxy-terminus of the molecule [24].  Particularly for CXCL12-γ, 
the added carboxy-terminal amino acids are enriched with basic residues that enhance 
binding to heparan sulfates and other negatively-charged extracellular matrix molecules 
[52].  By comparison, CXCL12-β and to a greater extent γ have reduced binding affinities 
for receptors CXCR4 and CXCR7.  Biochemical differences in binding to receptors and 
extracellular matrix molecules translate to different functional outcomes.  In mouse 
models, CXCL12-γ promotes chemotaxis of immune cells and endothelial progenitors to 
a significantly greater extent than other isoforms [53,54].  Greater binding to heparan 
sulfates and extracellular matrix molecules also limits proteolytic degradation of 
 30 
CXCL12 [55].  These studies highlight functional differences among CXCL12 isoforms 
in receptor binding, chemotaxis, and stability that could alter outcomes in breast cancer.  
Our data also support further studies analyzing functional differences among CXCL12 
isoforms, especially for CXCL12-δ.   
 
Correlation between gene transcript data and protein expression is dependent on the gene 
and tissue type. However, mRNA expression is generally a good proxy for protein 
expression and is frequently used as biomarkers.[56-58] Gene expression also forms the 
basis of the PAM50 molecular subtyping of breast cancer as well as Oncotype Dx, a 
widely used predictive model for chemotherapy response in breast cancer.[59-62] 
Specifically for CXCL12- α, β, and γ, mRNA levels as measured by quantitative RT-PCR 
correlate with protein levels as measured by ELISA.[63] We also recognize that this 
study has limitations based on the data publicly available through the TCGA.  While the 
data set contains transcript data for a large number of patients, the median follow-up time 
is relatively short, and therefore the number of metastasis and recurrence events is small, 
thus limiting our statistical power. This likely accounts for why the p-values for 
CXCL12- δ MFS and RFS do not reach significance.  We also do not know the full 
treatment history for all patients, such as exact chemotherapy and radiation regimens, and 
there is likely significant heterogeneity in treatments given the multi-institutional nature 
of the data.  Even with these limitations, we were able to identify significant differences 
in outcomes for isoforms of CXCL12.  
 
In summary, our data reveal new associations of CXCL12, CXCR4, and CXCR7 gene 
expression with molecular, histologic, and clinical categories of human breast cancer.  In 
addition, we have identified isoform-specific differences in CXCL12 for outcomes in 
breast cancer, suggesting distinct biochemical functions of isoforms in disease 
progression.  These compelling results establish the foundation for mechanistic pre-
clinical studies of these isoforms in breast cancer.  Additional studies also are warranted 
to elucidate the biological and functional differences between the CXCL12 isoforms and 
validate them as potential biomarkers.  
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2.6 Tables 
 
Table 2.1 Cancer patient characteristics compiled from TCGA 
Mean Age (Years) 58.0 ± 13.3 Median Follow-up (Months) 23.7 
Variable (n)   Variable (n)   
Estrogen Receptor  Node Stage  
  Positive 579   0 361 
  Negative 170   1+ 409 
Progesterone Receptor  Death  
  Positive 505   Positive 104 
  Negative 241   Negative 675 
Her2 Receptor  Recurrence  
  Positive 141   Positive 53 
  Negative 508   Negative 315 
PAM50 Status  Metastasis  
  Basal 138   Positive 48 
  Her2 66   Negative 324 
  Luminal A 414 Gender  
  Luminal B 190   Female 776 
  Normal 24   Male 9 
Overall Stage  Menopause  
  1 127   Pre- 181 
  2 127   Post- 493 
  3 171 Race  
  4 15   White 591 
Tumor Stage    Black or African American 55 
  1 207   Asian 51 
  2 467   American Indian 1 
  3 76     or Alaskan Native  
  4 32   
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2.7 Figures
 
Figure 2.1 Hierarchal clustering and expression levels of CXCL12 isoforms, 
CXCR4, and CXCR7 in cancer and normal tissue 
Spearman’s covariance matrix with hierarchal clustering of CXCL12 isoforms, CXCR4, 
and CXCR7 for (A) breast cancer and (B) normal tissue. (C) Expression levels of 
CXCL12 isoforms, CXCR4, and CXCR7 in breast cancer and normal tissue. Expression 
levels are mean ± sem. *: p<0.05, **: p<0.001 
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Figure 2.2 Expression levels of CXCL12 isoforms vary by tumor and histology 
Expression levels of CXCL12-", -! and –# vary significantly by (A) tumor and (B) 
histology. Expression levels are mean ± sem. *: p<0.05, **: p<0.001 
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Figure 2.3 Expression levels of CXCL12 isoforms vary with hormone receptor status 
and molecular subtype 
Expression levels of CXCL12 isoforms, CXCR4, and CXCR7 vary with hormone 
receptor status (A) and PAM50 molecular subtype (B). Expression levels are mean ± 
sem. *: p<0.05, **: p<0.001 
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Figure 2.4 Metastasis free, recurrence free and overall survival curves for CXCL12 
isoforms 
Higher levels of gene-level CXCL12 (A-C), CXCL12-" (D-F), -! (G-I), –# (J-L) 
generally correlate with improved metastasis free survival and recurrence free survival. 
Higher expression of CXCL12-$ (M-O) correlates with better overall survival.  
 
 36 
 
Figure 2.5 Multi-gene analysis for CXCL12-!, gene-level CXCL12, CXCR4 and 
CXCR7 
Multi-gene analysis reveals that expression of CXCL12-$ for MFS (A) and RFS (B) and 
OS (C) when accounting for gene-level CXCL12, CXCR4, and CXCR7. Error bars 
represent 95% confidence intervals.  
 
 
 
Figure 2.6 Expression of CXCL12 isoforms in breast cancer cell lines 
Expression of gene-level CXCL12 and CXCL12-" and –! isoforms are significantly 
higher in cell lines without metastatic potential, compared to cell lines with metastatic 
potential. Expression levels are mean ± sem. *: p<0.05 
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Figure 2.7 Expression of CXCL12 isoforms vary by race and age 
 (A) CXCL12 and its ", !, and # isoforms vary significantly with race. (B) Overall 
CXCL12 and CXCL12-" vary significantly with age. Expression levels are mean ± sem. 
*: p<0.05, **: p<0.001 
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Chapter 3 Cell, isoform, and environment 
factors shape gradients and modulate chemotaxis 
 
3.1 Abstract 
 
Chemokine gradient formation requires multiple processes that include ligand secretion 
and diffusion, receptor binding and internalization, and immobilization of ligand to 
surfaces. To understand how these events dynamically shape gradients and influence 
ensuing cell chemotaxis, we built a multi-scale hybrid agent-based model linking gradient 
formation, cell responses, and receptor-level information. The CXCL12/CXCR4/CXCR7 
signaling axis is highly implicated in metastasis of many cancers. We model CXCL12 
gradient formation as it is impacted by CXCR4 and CXCR7, with particular focus on the 
three most highly expressed isoforms of CXCL12. We trained and validated our model 
using data from an in vitro microfluidic source-sink device. Our simulations demonstrate 
how isoform differences on the molecular level affect gradient formation and cell 
responses. We determine that ligand properties specific to CXCL12 isoforms (binding to 
the migration surface and to CXCR4) significantly impact migration and explain 
differences in in vitro chemotaxis data. We extend our model to analyze CXCL12 
gradient formation in a tumor environment and find that short distance, steep gradients 
characteristic of the CXCL12-γ isoform are effective at driving chemotaxis. We highlight 
the importance of CXCL12-γ in cancer cell migration: its high effective affinity for both 
extracellular surface sites and CXCR4 strongly promote CXCR4+ cell migration. 
CXCL12-γ is also more difficult to inhibit, and we predict that co-inhibition of CXCR4 
and CXCR7 is necessary to effectively hinder CXCL12-γ-induced migration. These 
findings support the growing importance of understanding differences in protein 
isoforms, and in particular their implications for cancer treatment.  
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3.2 Introduction 
 
Chemotaxis is a critical physiological and pathological process. Although cells only 
discern local differences in chemokine concentration via receptor binding, 
chemoattractant gradients may be maintained over distances much greater than a cell 
length. These long distance gradients provide a roadmap for leukocytes to reach sites of 
inflammation or cancer cells to invade and metastasize to distant organs. The simplest 
notion of chemotactic gradient formation involves secretion of soluble chemokines and 
diffusion away from their source. In vivo gradient formation is fundamentally more 
complicated and dynamic, involving multiple cell types, chemokine removal by 
receptors, and interactions with the physical migration “terrain”. To therapeutically target 
gradient formation and chemotaxis, experimental and computational models are needed 
to facilitate observation, control, and prediction at all scales: molecular, cellular, and 
tissue.  
 
Due to the challenge of visualizing and manipulating in vivo gradients, many chemotaxis 
model systems have been developed. Such systems, including Boyden chambers and 
microfluidic generators, supply stable, defined gradients, but these exogenous, applied 
gradients may not provide physiologically-relevant gradient formation. To bridge this 
gap, we recently highlighted an in vitro microfluidic source-sink device that exploits cell-
generated gradients to drive chemotaxis [1,2] (Figure A.1). Here, we leverage these 
microfluidic device-based data to develop a computational model and predict which 
underlying molecular-scale events control in vivo gradient generation and ensuing 
chemotaxis.   
 
The CXCL12/CXCR4 signaling axis is a prime example of how cellular and 
environmental factors form complex chemoattractant gradients that guide cells to distant 
locations. This signaling pathway has been implicated as a major driver of metastasis in 
multiple malignancies [3-8]. In breast cancer, CXCL12 is secreted by both carcinoma-
associated fibroblasts and cancer cells in the primary tumor environment and is 
constitutively expressed in common sites of metastasis, such as bone, lung, and liver 
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[9,10]. CXCL12 has two known receptors, the G-protein coupled receptor CXCR4 and 
the atypical chemokine receptor CXCR7 (recently renamed ACKR3). CXCR4 binding to 
CXCL12 initiates survival, growth, and chemotaxis pathways [11]. Expression of the 
CXCR4 receptor, which is upregulated on cancer cells in both primary and metastatic 
tumors, mirrors that of CXCL12, suggesting that CXCR4-bearing cancer cells are 
actively guided by CXCL12 gradients to exit the primary tumor and metastasize to 
distant organs [12]. CXCR7 functions in part as a decoy receptor that scavenges and 
degrades ligand from the extracellular space [13]. CXCR7 is overexpressed on tumor-
associated vasculature as well as on subsets of cancer cells in the primary tumor 
environment, and this receptor has been shown to lower overall CXCL12 levels in tumors 
[14,15]. Collectively, these receptor-based interactions between CXCL12, CXCR4, and 
CXCR7 only partially define the dynamic and complex signaling environment that drives 
chemotaxis.  
 
Although receptor-based mechanisms of gradient formation and signaling are most well-
known, ligand-specific effects may also dictate gradient shape.  Much of the current 
knowledge on CXCL12/CXCR4 signaling focuses on the CXCL12-α isoform, as it is the 
most prevalent. However, other isoforms have been detected at lower expression levels. 
Studies of CXCL12 generally have overlooked the existence of six alternatively spliced 
isoforms (α, β, γ, δ, ε, and φ) that are comprised of an identical N-terminal core and vary 
by the addition of 1 to 41 largely basic amino acids at unstructured C-termini [16]. Both α 
and β isoforms have been detected in the primary tumor environment[10], and we 
recently identified CXCL12-γ in late stage cancer [1]. These isoforms have between 1 
and 4 putative basic heparan sulfate binding domains, which affect how well isoforms 
bind to the migration surface and receptors and may also influence gradient stability and 
local concentrations [17-20]. Whether or not isoform-specific effects enhance or hinder 
migration is unclear.  
 
To improve our understanding of how gradients are dynamically shaped and maintained 
and how cells interact with such gradients, we developed a multi-scale hybrid agent-
based model. Multi-scale models have been used to explain emergent properties on the 
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tissue-scale that arise from individual cell decisions informed by the molecular-scale for a 
wide range of biological phenomena [21-23]. We used in vitro data on breast cancer cells 
migrating in a microfluidic source-sink device to train and validate the model and to 
predict gradient characteristics. We then used the model to ask: How do active cell 
properties, such as binding and internalization, shape the gradient? What are the factors 
that can explain different isoform abilities to elicit chemotaxis? Given what can be 
discovered in the device, how might these results be used to make predictions for a tumor 
environment?  
 
Our simulations demonstrate that the decoy receptor CXCR7 dictates gradient magnitude 
and shape across the device environment due to its strong affinity for CXCL12. Despite a 
lower effective affinity of CXCL12 for CXCR4, CXCR4-expressing cells shape the local 
gradient at their leading edge and dynamically change the gradient as they move. In 
addition to these active-cell factors, simulations identify that properties of strong affinity 
for the migration surface and a high effective affinity for CXCR4 make the CXCL12-γ 
isoform a much stronger elicitor of chemotaxis than the α or β isoforms. Our model 
predicts that CXCR4+ cells move best in short distance, steep gradients that are 
characteristic of gradients of CXCL12-γ. Furthermore, we predict that blocking CXCR4 
and CXCR7 receptors is less effective at inhibiting CXCR4+ migration in gradients of 
CXCL12-γ compared to the other isoforms. Importantly, these emergent properties still 
hold true in simulations of a tumor environment, indicating the potential importance of 
CXCL12-γ in enhancing chemotaxis in cancer.   
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3.3 Methods 
3.3.1 Cell migration in a microfluidic source-sink device 
All in vitro experimental data, except those used for model validation, are taken from our 
previous report of chemotaxis in an in vitro microfluidic source-sink device [1]. Briefly, 
MDA-MB-231 breast cancer cells were individually transduced to express recombinant 
CXCL12 isoforms (α, β, or γ), CXCR4, or CXCR7. Three cell types, cells secreting one 
of the CXCL12 isoforms (CXCL12+, source cells), CXCR4-expressing cells (CXCR4+), 
and CXCR7-expressing (CXCR7+) cells, were patterned in the microfluidic source-sink 
device. This pattern consisted of one stripe of CXCR4+ cells patterned between one 
stripe each of CXCL12+ and CXCR7+ cells. Each stripe of cells is 200 µm wide with 
200 µm distance between each stripe [1,2] (Figure A.1). Chemotaxis was quantified by 
averaging the mean distance CXCR4+ cells moved towards the source cells after 24 hr 
compared to 0 hr. To manipulate ligand levels, portions of the CXCL12+ cells were 
replaced with non-secreting cells. These cell dilutions are represented as “Percentage of 
source cells secreting CXCL12.” Parameters obtained directly from the in vitro source-
sink device include dimensions of the microfluidic environment, cell density, cell 
patterning dimensions, and dilution of the number of secreting cells (Table A.1).  
 
For this work, we obtained additional data for model validation using the microfluidic 
source-sink device. For these experiments, we increased gaps between the cell stripes 
from 200 µm to 400 µm (Figure A.1). Total receptor numbers were quantified using flow 
cytometry as described in [24] and are shown in Table A.2.  
3.3.2 Multi-scale hybrid agent-based model overview 
We constructed two variants of a multi-scale hybrid agent-based model of CXCR4+ 
chemotaxis in cell-generated CXCL12 gradients (Figure 3.1). We represent our 
microfluidic source-sink device environment (Figure A.1; [1]) with a 3D lattice. 
CXCL12+, CXCR4+, CXCR7+ cells are represented as discrete agents within the model 
and move in 2D on the bottom layer of the lattice, the “migration surface” (Figure 3.1A). 
We represent the in vivo tissue environment with a 2D grid. For both model variants, 
CXCL12 is secreted into the environment, diffuses and degrades in the extracellular 
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space, and binds to the migration surface and to CXCR4 and CXCR7 receptors. 
Receptor-mediated uptake of CXCL12 by CXCR4 and CXCR7 further shapes the 
gradient by removing ligand from the environment. Movement on the cellular-scale is 
dependent on gradient formation on the tissue-scale and receptor dynamics on the 
molecular-scale. These three scales are linked by a chemotaxis algorithm that governs 
CXCR4+ cell movement.  
3.3.3 Model implementation 
The model consists of two different layers: an environment layer and an agent layer. The 
environment is a grid that holds the information for all of the extracellular molecules 
(soluble and device-bound CXCL12). The agent layer contains the position and 
molecular-scale information (Table A.1b for all molecular species) for each agent. When 
an agent interacts with its environment (ie. ligand uptake), the extracellular ligand 
concentration is the value in the corresponding gridspace of the environment layer. 
3.3.4 Model geometry 
The chamber of the experimental microfluidic source-sink device is 20 mm x 2 mm x 0.1 
mm (length x width x height) [1] (Figure A.1). In order to model gradient generation and 
cell movement within the microfluidic source-sink device while minimizing 
computational cost, we assume symmetry and model a 0.25 mm x 2 mm x 0.1 mm space 
using a 25 x 200 x 10 grid. The lattice spacing is 10 µm, approximately the size of a 
single cell, and thus only one cell is allowed to occupy each lattice space at any time. For 
CXCL12 diffusion, we implement no flux boundary conditions on the four sides that 
represent the top, bottom, left, and right edges of the device and periodic boundary 
condition on the front and back edges. Agents reside on the migration surface and move 
in 2D. For agent movement, we implement no flux boundary conditions on left and right 
edges, and periodic boundary conditions on the front and back edges. Implementation of 
these boundary conditions approximate both gradient generation and agent movement in 
the long microfluidic channel despite the shortened grid (Figure A.2).  
 
For tumor-environment simulations, we use the same lattice framework, but with a 100 x 
100 2D grid. We assume that the simulated tumor environment neighbors a similar 
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environment by implementing no flux boundary conditions on all four sides for diffusion 
and periodic boundary conditions on all sides for agent movement. To assess if gradient 
predictions in the 2D grid can be extrapolated to those in 3D gradients, we performed 
some pseudo-tumor simulations with a 100 x 100 x 5 grid, with no flux boundary 
conditions for diffusion on all sides.  
3.3.5 Secretion and diffusion of soluble CXCL12 
We assume a constant and uniform secretion rate per cell (rate constant: CXCL12sec); 
secreted ligands are deposited into the cell-containing compartment. To compare to 
experimental data, in some simulations we allow only a fraction of CXCL12 cells to 
secrete CXCL12. The overall secretion rate is the product of the number of secreting cells 
and the secretion rate constant.  Diffusion of soluble CXCL12 (L) is described by the 
diffusion equation.      
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3.3.6 Binding of CXCL12 to migration surface 
CXCL12 isoforms have different affinities for glycosaminoglycans (γ > β > α), and we 
assume that the affinity of isoforms to the device surface is in the same order [19,20]. We 
use mass action kinetics and assume reversible binding of ligand (L) to sites on the 
migration surface (S) to calculate the concentration of ligand bound to the migration 
surface ( L ⋅S ): 
d[L ⋅S]
dt = k f ,L,S ([L][S]−KD,L,S[L ⋅S])       (3.2) 
where kf,L,S is the forward rate constant for ligand binding to the surface site and KD,L,S is 
the equilibrium dissociation constant for the same (Figure 3.1B). We assume that ligand 
cannot bind surface sites that are currently occupied by a cell.  
3.3.7 Extracellular degradation of CXCL12 
CXCL12 undergoes protease-mediated degradation in cell media and in extracellular 
space[25,26]. For simplicity, we assume that extracellular degradation of soluble and 
surface-bound CXCL12 occurs with the same first-order kinetics (rate constant kdeg):  
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d[L]
dt = −kdeg[L]          (3.3) 
d[L ⋅S]
dt = −kdeg[L ⋅S]         (3.4) 
 
3.3.8 Receptor-mediated ligand uptake and dynamics 
Receptor internalization and desensitization impacts chemotactic responses as well as 
gradient shaping, which are both influenced by receptor interactions with β-arrestin [27-
31]. To focus on the effects of cell-based gradient shaping, we implement ordinary 
differential equations (ODEs) based on mass action to describe molecular-scale events 
for CXCR4+ (Figure 3.1C) and CXCR7+ cells (Figure 3.1D). These equations describe 
ligand binding to receptor, receptor binding to β-arrestin, internalization of β-arrestin-
bound complexes, receptor and β-arrestin recycling, and receptor and ligand degradation. 
The ODEs that describe these events were constructed and validated in previous work 
([32] and Tables A.1b-f). We consider the effective affinity of ligand for receptor to 
account for binding affinities for the receptor itself and glycosaminoglycans on the cell 
surface. There are two key differences between CXCR4 and CXCR7 dynamics: (1) β-
arrestin binds transiently to CXCR4, whereas it binds tightly to CXCR7, and (2) CXCR4 
degradation is ligand-induced, whereas CXCR7 is constitutively recycled (Figure 3.1C-
D). Prior to simulation, these CXCR4 and CXCR7 ODEs are solved in the absence of 
ligand to determine the number of unbound β-arrestin and surface and internalized 
receptors per cell at steady state, and cells with these quantities are placed on the grid. 
We did not incorporate other aspects of CXCL12/CXCR4/CXCR7 signaling, such as 
ligand dimerization and receptor homo- and heterodimers, as there is very limited 
information on the kinetics of these processes and our previous work showed that they 
are not required to adequately describe ligand binding and internalization [32]. Dimer 
formation occurs at a much smaller time scale than ligand-receptor dynamics and dimers 
are relatively stable over the experimental time frame [33-36], indicating that including 
kinetics of dimer formation in the model may not be necessary. We did not include 
CXCR7 signaling, as the migrating cells do not express CXCR7 [2]. Our focus on the 
model is on the effects of cell-generated gradients, and prior studies also show that 
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chemokine scavenging by CXCR7 on sink cells is sufficient for gradient formation [37-
39].  
 
3.3.9 Random cell movement              
Cells move in 2D on the surface of the device or in the tissue environment. At each 
movement time step, we calculate the next location for each agent. An agent can move to 
any of the eight lattice spaces in its Moore neighborhood or stay in its current space. To 
implement random movement for CXCL12+ and CXCR7+ cells, each of the nine lattice 
spaces is assigned an equal probability for movement. From these individual 
probabilities, we calculate a cumulative probability distribution that sums to 1. A random 
number between 0 and 1 is chosen, and the agent moves into the lattice space 
corresponding to that probability, if the chosen lattice space is empty. Otherwise it 
remains in its current lattice space. This type of simple random movement algorithm has 
been employed in numerous models (e.g. [40-43]). 
3.3.10 Chemotaxis algorithm 
To replicate experimental in vitro data, we needed to capture the motion of hundreds of 
individual cells over a 24 hr time period in response to a changing chemokine gradient. 
Specifically, we wanted to understand the role of receptor binding and internalization in 
that process. For computational tractability we chose a coarse-grained representation 
where chemotaxis is implemented as a movement probability defined by receptor 
occupancy and the number of CXCR4 surface receptors.  
 
We build on previous models by assuming that cells sense gradients by comparing 
differences in receptor occupancy across their length [44-50] and implement this 
assumption on the discretized environment by calculating the projected receptor 
occupancy (RO) [50,51] for each lattice space in the Moore neighborhood of a CXCR4+ 
cell (including its current space):  
RO = [C][C]+KD,R4,L12
* (surfaceCXCR4)9 ,      (3.5) 
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where [C] is the sum of soluble and surface-bound ligand concentration in that lattice 
space [52-55], KD,R4,L12 is the equilibrium dissociation constant for ligand binding to 
CXCR4, and surfaceCXCR4 is the total number of CXCR4 receptors on the cell surface 
of the agent. We assume a uniform distribution of receptors on the cell surface, and thus 
1/9 of the total surface receptors are available to sense concentrations in any of the 9 
lattice spaces [56].  
 
To translate differences in receptor occupancy to probability intervals, we first calculate  
dROi =
ROi −min+ s
ROi −min+ si=1
9
∑
,       (3.6) 
where ROi is the projected receptor occupancy of the ith lattice space, min is the minimum 
RO of the neighborhood and s is a chemotaxis sensitivity factor, representing the 
difference in RO to which a cell is sensitive. The sensitivity factor allows cells to respond 
to absolute differences in receptor occupancy, as opposed to relative differences in 
receptor occupancy. Similar to the procedure for CXCL12+ and CXCR7+ cells, the dROi 
values are normalized to 1, the cumulative probability distribution is created, and the 
agent moves into the lattice space corresponding to a random number chosen from 0 and 
1 if the chosen lattice space is empty. If KD,R4,L12 >>[C], or if KD,R4,L12 << [C] then the 
calculated receptor occupancy values are similar and cells move essentially randomly.  
 
The inclusion of the chemotaxis sensitivity factor s implements the assumption that 
chemotaxis is dependent on the number of cell surface receptors present at the time of 
movement [50,56-58]. We implement s as a decreasing linear function of the number of 
available surface chemokine receptors: 
s =m× surfaceCXCR4+ b ,       (3.7) 
where m is the slope, b is the y-intercept, and surfaceCXCR4 is as described above. These 
sensitivity parameters are fit to experimental data. While s is not limited to this form, 
model variants without this simple dependence on receptor number were unable to 
capture cell migration behavior in device experiments. When the number of available 
surface chemokine receptors is small, s is much greater than the difference in receptor 
occupancy, and the resulting probability intervals are similar and movement is random. 
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As the number of available surface chemokine receptors increases and s approaches zero, 
chemotaxing cells move based on differences in receptor occupancy alone.  
3.3.11 Initial cell positions 
The simulation grid is initialized with CXCL12+, CXCR4+, and CXCR7+ cells. For 
device simulations, cells are positioned randomly in stripes, with space in between where 
no cells are seeded (Figure A.1, Figure 3.1, Figure 3.2A) with a density of 2500 
cells/mm2, as they are experimentally. For tumor-like simulations, we base cell patterns 
on histological data from primary breast tumors. Both CXCR4+ cancer cells and 
CXCL12+ stromal cells typically are in clusters of 4-5 cells [10,14]. CXCR7+ cells in the 
tumor environment appear more randomly placed [15]. We determined cell densities by 
counting the number of CXCL12+, CXCR4+ or CXCR7+ cells in an image frame and 
divided by the total number of cells within the same frame. In accordance with these 
images, we initialized tumor-like simulations by randomly placing clusters of CXCL12+ 
and CXCR4+ cells and individual CXCR7+ cells on the grid. While limited to 
representative examples of primary breast cancers, these data provide qualitative insights 
into cell arrangements in human tumors. 
3.3.12 Numerical solution 
The overall algorithm of the simulation is depicted in Figure A.3. We use the principle of 
operator splitting to solve the simultaneous events of diffusion, degradation, and 
reactions [59-64]. Briefly, this method reduces the diffusion, extracellular binding and 
degradation, and molecular-scale reaction events to a partial differential equation, linear 
first order ordinary differential equations, and sets of ordinary differential equations for 
each lattice space and agent as described above. Within the model workflow, we simulate 
cell movement using a six minute movement time step over the 24 hr experimental set up, 
for a total of 240 timesteps. The six minute movement time step was determined by 
fitting the spread of randomly moving cells to experimental data of CXCR4+ cells 
moving in the absence of ligand (Figure A.4). Ligand secretion, diffusion, degradation 
and ligand binding to the migration surface are calculated using 0.1 second timesteps. 
ODEs depicting receptor-ligand dynamics are solved for each agent using a fourth-order 
Runge Kutta numerical solver with 0.01 second timesteps. The diffusion and ODE time 
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steps are the maximum time step allowable for solver stability. We use the alternating-
direction explicit (ADE) method to solve diffusion as described in previous work [60,61]. 
3.3.13 Uncertainty and sensitivity analysis 
We use Latin Hypercube Sampling (LHS) and Partial Rank Correlation Coefficients 
(PRCC) to identify parameters that have a significant effect on model output. LHS is a 
stratified non-replacement sampling strategy where all parameters are varied 
simultaneously [65,66]. PRCC values are calculated to determine how well the variability 
of a parameter correlates to a selected model output. PRCC values are between -1 and 1, 
which are associated with a perfectly negative or perfectly positive correlation between 
the parameter and model outcome. 
 
To determine how molecular scale events dictate CXCR4+ chemotaxis, we performed 
sensitivity analyses by varying CXCR4 and CXCR7 kinetic parameters. We used LHS to 
generate 100 parameter sets, where each parameter was ranged over its known literature 
values (Tables A.1c-d). Each set was replicated 10 times to get an average value to 
perform PRCC analysis.  
3.3.14 Parameter estimation, model fitting and validation 
When possible, we use experimental data to determine model parameters. Kinetic and 
equilibrium parameters for CXCR4 and CXCR7 ODEs are the same as previously 
published, unless otherwise noted [32] (Tables A.1c-d). When unavailable, we estimate 
parameters with values restricted within ranges reported from literature. To determine the 
isoform-specific effective equilibrium dissociation constant to CXCR4, the equilibrium 
dissociation constant for binding to the migration surface, secretion rate constant, and m 
and b that define the chemotaxis sensitivity factor, we fit the model to experiments 
measuring CXCR4+ cell migration for each of three CXCL12 isoforms and for several 
different rates of ligand secretion. The initial estimate for the effective equilibrium 
dissociation constant to CXCR4 of CXCL12-α was set to the value used in our previously 
published ODE model; and we assumed that CXCL12 isoforms with higher numbers of 
heparan sulfate binding domains [17-20] would have higher affinities. The initial 
estimates for equilibrium dissociation constant for binding to the migration surface of 
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each CXCL12 isoform to the migration surface are based on their reported affinities to 
heparan sulfate [19]. The initial estimates for isoform-specific secretion rates are based 
on previously reported experiments using ELISA and bioluminescence-based 
measurements [1]. We used LHS to generate 100 random parameter sets, ran each 
parameter set for 20 replications, and chose the parameter set that minimized the squared 
error between model and experimental data. To validate these isoform-specific fitted 
parameters, we ran the model for the case where CXCL12+ and CXCR7+ cells are 
spaced further from the CXCR4+ cells.  
3.3.15 Statistics 
All plots and statistical comparisons were created with GraphPad Prism (La Jolla, CA). 
We plot simulation data as the mean of 30 replications with standard deviation. 
Additional replications beyond 30 did not significantly change the mean or standard 
deviation.  
3.4 Results 
3.4.1 Multi-scale hybrid agent-based model tracks ligand concentration, cell locations, 
and molecular-scale information 
Using an in vitro microfluidic source-sink device dependent on cell-generated gradients 
to prompt chemotaxis, we previously determined that the strength of CXCR4-mediated 
chemotaxis is differentially impacted by CXCL12 isoforms and is increased when in the 
presence of its scavenger receptor, CXCR7 [1,2]. We hypothesized that this is due to 
gradient shaping mechanisms that are impacted by isoform-specific secretion rates, 
ligand binding to surfaces and the rate of ligand scavenging by CXCR7. To quantify 
these underlying molecular events and how they control gradient shaping and cell 
responses to chemotaxis, we developed a hybrid agent-based model that links molecular 
scale interactions to cell population (or tissue) scale outcomes. The model calculates the 
chemokine concentration gradient over time and position as it is influenced by cell 
secretion, diffusion and external degradation, receptor-ligand dynamics on moving cells, 
and binding to the migration surface. Here we present model outputs using the 
physiological parameters noted in Table A.1.   
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At the start of simulation, CXCL12+, CXCR4+ and CXCR7+ cells are placed in an 
environment that lacks ligand (Figure 3.2A). The model allows us to analyze which 
molecular-scale events dominate over time. At early times, diffusion and surface binding 
control the CXCL12 gradient (Figure A.5, panels A-C). At later times, ligand removal by 
CXCR4 and CXCR7 dynamics are crucial to controlling gradient magnitude and shape; 
however, they control the gradient at different length scales. CXCR7 is an effective 
scavenger that binds to CXCL12 with a much greater affinity than CXCR4 [67]. This 
high affinity for CXCL12 allows CXCR7 to significantly reduce the overall magnitude of 
CXCL12 concentration in the device and can alter the gradient over distances on the 
order of millimeters. In contrast, CXCR4 also depletes CXCL12 levels, but primarily in 
the region where CXCR4+ cells are located (Figure A.5, panels D-F). Sensitivity analysis 
identified that ligand binding and internalization by CXCR4 and CXCR7 have significant 
impact on CXCR4+ migration and overall CXCL12 concentration (Table A.3). The 
contribution of soluble and surface-bound CXCL12 to the total gradient can also be 
assessed. Most ligand is bound to the migration surface, despite the fact that the affinity 
of ligand to surface is relatively low (100nM), because there are many surface sites 
(Figure 3.2B).  
 
As cells move on the grid, the model dynamically updates molecular scale information. 
As CXCR4+ cells spend more time in rising CXCL12 levels, ligand binding induces 
receptor internalization and degradation, resulting in decreasing receptor number over 
time and position within the device (Figure 3.2C). Simulations predict that significant 
losses of surface receptors can occur even at low ligand concentrations. In this 
representative example, the CXCR4+ cells at the furthermost left and right edges of the 
device have a difference of ~99,000 surface receptors (a 20% decrease between the 
rightmost and leftmost cells) at the end of simulation. Much of chemotaxis literature 
demonstrates chemotaxis in gradients of which cells move, but do not modify, yet we 
predict that cells actively shape their gradient as they move.  As CXCR4+ cells advance 
towards the source cells, ligand binding, internalization and degradation result in gradient 
shifting along with the CXCR4+ cells (Figure 3.2D). Thus, our model captures 
experimentally observed phenomena and gives mechanistic and molecular insight into 
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chemotaxis. Furthermore, the model offers insight on the differences in contributions of 
CXCR4 and CXCR7 to the ligand gradient across position and time.  
3.4.2 Migration in cell-generated gradients is dependent on isoform-specific properties 
CXCL12 isoforms have different abilities to generate chemotaxis within the source-sink 
device. Our experimental data measuring CXCR4+ migration towards the source cells [1] 
are reproduced in Figure 3.3A-C. Notice that with 100% of source cells secreting, 
gradients of CXCL12-γ can elicit greater migration than gradients of CXCL12-β and 
CXCL12-α (CXCR4+ migration at 100% secretion, CXCL12-α: 39.6 µm ± 24.3; 
CXCL12-β: 46.1 µm ± 26.6; CXCL12–γ: 65.7 µm ± 35.5, ordinary one-way ANOVA P-
value < 0.0001). CXCL12 isoforms also differ in their migration curves. CXCR4+ 
migration in gradients of CXCL12-α does not significantly change even when the 
percentage of secreting cells is decreased by two orders of magnitude, but presents a bell-
shaped curve for CXCL12-β and significantly decreases when secretion is diluted to 1% 
for CXCL12-γ. We hypothesized that four isoform-specific parameters impact migration 
– secretion rate, affinity for the migration surface, effective affinity for CXCR4, and the 
chemotaxis sensitivity factor (s) – and fit these model isoform-specific parameters to data 
on CXCR4+ migration for each of the CXCL12 isoforms across the different secretion 
rates (Figure 3.3A-C).  
 
It has been previously noted that CXCL12-γ has a markedly lower secretion rate than the 
α and β isoforms and a much higher affinity to cell surfaces (due to strong binding to 
glycosaminoglycans) [1,19,20]. As expected, the fit parameters have secretion rates in the 
order of α>β>>γ and affinities to the migration surface of γ>>β>α (Table 1). Initially, we 
refrained from varying the effective ligand affinity for CXCR4 and the chemotaxis 
sensitivity factor parameters, as differences among isoforms are not well established. 
However, a reasonable fit for CXCL12-γ data was not possible without increasing the 
effective affinity of CXCL12-γ to CXCR4 as well as slightly decreasing the slope (m) of 
the chemotaxis sensitivity factor (resulting in more sensitive migration) for the CXCL12–
γ isoform. Although measurements of CXCL12 isoform binding determined that the 
affinity of CXCL12-γ to CXCR4 is lower than the other isoforms [20], it has been 
suggested that the high affinity by which CXCL12–γ binds to cell-surface heparan 
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sulfates may confer a higher effective affinity to CXCR4 than the other isoforms [17]. 
Limited data show differences in signaling between isoforms, and indicate that binding of 
the γ isoform to CXCR4 elicits more β-arrestin signaling than the other isoforms 
[1,17,68]. The fitted values for ligand affinity to the migration surface and secretion rate 
constants between isoforms are in accordance with experimental data [1,17,19].  
 
Next, we predicted the effect of increasing the distance between the initial cell positions 
for all three CXCL12 isoforms on CXCR4+ migration (Figure 3.3D). Compared to 
migration using 200 µm spacing, CXCR4+ migration using 400 µm spacing is reduced 
for all isoforms. We then used the in vitro source-sink device under these conditions to 
measure the average CXCR4+ migration and found that the model predictions agree well 
with experimental data. Thus, our model accurately describes migration in our 
microfluidic source-sink device based on isoform-specific differences, placement of cells, 
and a broad range of CXCL12 secretion. In addition, the fitted parameters support that 
isoforms differ in their binding to the surface, binding to CXCR4, secretion rates, and 
sensitivity to movement, with the CXCL12–γ in particular displaying a much higher 
affinity to the migration surface and effective affinity to CXCR4 compared to the other 
isoforms.  
3.4.3 Non-specific and receptor binding are both critical to migration 
Because our computational model suggested that isoforms differ in binding to the 
migration surface and to CXCR4, we varied these two parameters to explore how ligand 
properties affect the chemokine gradient and subsequent chemotaxis. Increasing ligand 
affinity to the migration surface (decreasing KD,L,S) creates steeper gradients and results in 
an upward shift of the chemotaxis curve (Figure 3.3E). Increased affinity to the migration 
surface can explain why CXCR4+ cells move furthest in gradients of CXCL12-γ, 
followed by –β, then –α at 100% secretion. Examination of the CXCL12 gradients 
reveals that despite lower secretion rates, gradients of CXCL12-β and –γ have higher 
overall concentrations and steeper gradients due to enhanced binding to the migration 
surface (Figure A.6). Increasing the ligand effective affinity to CXCR4 results in an 
upward shift of the chemotaxis curve (Figure 3.3F). As ligand effective affinity to 
CXCR4 increases (decreasing KD,R4,L12), cells chemotax more efficiently in lower 
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concentrations. However, at higher concentrations, surface receptors are downregulated, 
reducing migration. Together with secretion rate, effective affinity for CXCR4 can 
explain the isoform-specific chemotaxis curve shapes. CXCL12-α has a low effective 
affinity to CXCR4 and mid-level secretion rate constant (20 molecules/cell-s) resulting in 
a relatively flat chemotaxis curve. We could not reproduce the steep bell-shaped curve for 
CXCL12-β, but note the large error bars for the 10% condition. (A lower secretion rate 
combined with a high affinity to CXCR4 - outside current literature ranges - would 
achieve a bell-shaped curve.) Finally, CXCL12-γ is secreted at a low rate and has a high 
effective affinity for CXCR4. The significant decrease at 1% secretion compared to 
100% is due to its high effective affinity for CXCR4 resulting in maximal chemotaxis of 
the CXCL12-γ at 100%, and then a drop off at 1% due to low levels of ligand. These 
findings confirm that isoform-specific differences in binding to both the migration 
surface and to CXCR4 significantly control CXCR4+ migration. 
3.4.4 Migration is sensitive to the number of CXCR4 receptors, and less sensitive to 
CXCR7 
Potential therapeutic strategies for reducing chemotaxis include blocking CXCR4 or 
CXCR7 [57,69]. Using CXCL12-α-like parameters listed in Table A.1a (and determined 
above), we find that migration is sensitive to the number of CXCR4 and less so to the 
number of CXCR7 receptors. Blocking as few as 25% of CXCR4 receptors is sufficient 
to completely inhibit migration at low secretion rates, but is less effective at inhibiting 
migration at higher secretion rates (Figure 3.4A). Stronger inhibition of migration across 
all secretion rates requires blocking more than 50% of CXCR4 receptors. In contrast, 
nearly all CXCR7 receptors (90-99%) must be blocked to effectively reduce CXCR4+ 
cell migration at high secretion rates (Figure 3.4B). Note that due to the high starting 
numbers of receptors in the transfected cells modeled in the simulation, 50% blocking of 
CXCR4 and 90% blocking of CXCR7 correspond to ~105 available receptors per cell 
(3.55x105 and 2x105 receptors per cell for CXCR4 and CXCR7, respectively). Cancer 
cells have on the order of 103 – 105 receptors per cell [70,71]. Clearly strong inhibition of 
migration is difficult with receptor numbers on the higher end of the range, but may 
require a smaller percentage of receptors to be blocked to effectively reduce migration on 
the lower end of the range. Blocking CXCR7 has a greater effect on CXCR4+ migration 
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at high secretion rates and a smaller effect on CXCR4+ migration at lower secretion 
rates, which is consistent with our in vitro data using CXCR7+ cells unable to internalize 
CXCL12-CXCR7 complexes [1]. At lower secretion rates, the gradient is primarily 
controlled by diffusion and ligand binding to the migration surface and CXCR7 has little 
effect. At high secretion rates, CXCR7 plays a significant role in diminishing the overall 
concentration in the device and limiting CXCR4 internalization (Figure A.7). By 
blocking both CXCR4 and CXCR7, migration can be inhibited across all secretion rates 
(Figure 3.4C), suggesting that a combination of CXCR4 and CXCR7 blocking may work 
as a treatment strategy to effectively hinder migration.  
3.4.5 Inhibition of CXCR4+ migration is isoform-specific  
Next, we examined if inhibition of CXCR4+ cell migration by blocking CXCR4 or 
CXCR7 is isoform-specific. We already established that high ligand affinity to the 
migration surface or to CXCR4, which is characteristic of the γ isoform, elicits higher 
CXCR4+ cell migration (Figure 3.3). Blocking 50% of CXCR4 receptors is effective at 
reducing migration across secretion rates for ligand with higher affinity to the migration 
surface as well as higher affinity to CXCR4 (Figure 3.4D), but not as well as with lower 
affinities to the surface or to CXCR4 (CXCL12-α-like). Furthermore, model simulations 
blocking CXCR7 with isoforms having elevated affinities to the migration surface and to 
CXCR4 reveal that the role of CXCR7 in modulating migration may also be isoform-
specific (Figure 3.4E). Although blocking 90% of CXCR7 markedly decreases migration 
for the CXCL12-α-like parameters, it has much less of an effect in modulating migration 
for ligand with higher affinities to the migration surface and to CXCR4, further 
highlighting the potential importance of understanding the role of high affinity ligands 
like CXCL12-γ within the tumor environment. Two questions arise from these in vitro 
and in silico studies: do isoform gradients form in the tumor environment and what is the 
effect on CXCR4+ cell migration? 
3.4.6 Gradients produced by tumor-like cell arrangements   
We have focused up to this point on cell migration observed in our microfluidic source-
sink device, where cells are initially arranged in stripes. We next wanted to explore the 
implications of our findings for gradient formation and cell migration in a more tumor-
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like environment. To do this, we patterned cells to mimic the disorganization of 
CXCL12+, CXCR4+, and CXCR7+ cells observed in invasive breast cancer. We 
arranged CXCL12+, CXCR4+ and CXCR7+ cells on the simulation grid based on 
histological data (Figure 3.5A) [10,14,15].  For our initial set of simulations, all cells 
were immobile and we focused on generation of chemokine gradients within a 24 hr time 
period.   
 
We first examine gradients using the same parameter values and receptor numbers as in 
the device (Table A.1).  Predicted gradients at 24 hr are shown in Figure 3.5B-D for the 
three isoforms. Similarly to the microfluidic source-sink device (Figure A.6), gradients of 
CXCL12-β (Figure 3.5C) and -γ (Figure 3.5D) are steeper and have higher maximum 
concentrations than gradients of CXCL12-α. When CXCR7 is removed from the grid 
(Figure 3.5E-G), gradients for all isoforms become more diffuse, but have the most 
change for CXCL12-α and CXCL12-β. As CXCR7 has the most influence in gradient 
shaping when the ligand affinity for the extracellular space is low and when secretion 
rates are high, CXCR7 is more necessary to shape gradients of CXCL12-α and CXCL12-
β than that of CXCL12-γ.  
 
The simulations in Figure 3.5B-G used receptor numbers characteristic of the transfected 
cell lines used in our microfluidic source-sink device experiments (CXCR4, 7.1x105; 
CXCR7, 2x106). Next, we ran simulations to predict gradients for lower receptor levels 
(5x103 receptors/cell) that represent the lower range of receptor overexpression in cancer 
(Figure 3.5H-J) [70,71]. Gradients predicted for receptor numbers in this pathological 
range are similar to gradients predicted for environments that lack CXCR7. We note that 
CXCR4+ and CXCR7+ cells are able to produce microgradients, as they internalize 
ligand in the lattice space where they are placed (highlighted by the Inset of Panel I). 
These model predictions show that qualitative differences between gradients of CXCL12 
isoforms determined in the microfluidic source-sink device hold true in the more 
disorganized cell arrangements found in tumors, and that secretion rates and ligand 
binding to the migration surface controls gradient shape and scope.  
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3.4.7 Steep short-distance gradients provide better homing than shallow long-distance 
gradients 
Continuing with the parameters relevant to receptor overexpression in cancer (as in 
Figure 3.5H-J), we allowed CXCR4+ cells to move (Figure 3.6). We quantified 
chemotaxis by normalizing the number of CXCR4+ cells within 30 µm of a CXCL12 
cluster at 24 hr to the number at the start of simulation. Similarly to the microfluidic 
source-sink device, we find that CXCR4+ cells move best in gradients of CXCL12-γ, 
followed by CXCL12-β, and CXCL12-α. The shallow long-range gradients of CXCL12-
α do not promote migration in this cell arrangement and for these low receptor numbers; 
however, using a higher number of total receptors results in increased migration of 
CXCR4+ cells in CXCL12-α gradients (Figure A.8), indicating that gradients formed 
with CXCL12-α-like properties can induce chemotaxis when combined with increased 
receptor signaling. We also explored which isoform-specific parameters are most 
responsible for increased migration in gradients of CXCL12-β and –γ by systematically 
replacing one of the ligand-related parameters of CXCL12-α for that of γ (Figure A.8). 
Similarly to the device simulations, we found that increased effective affinity for CXCR4 
and for the migration surface promotes CXCR4+ chemotaxis towards CXCL12 
producing cells. Higher migration in gradients of CXCL12-γ and -β also mirror higher 
levels of surface CXCR4. The average number of CXCR4 surface receptors per cell is 10 
times higher in gradients of CXCL12-γ than in CXCL12-α (850 compared to 86 CXCR4 
surface receptors per cell).  
 
Inhibition of either CXCR4 or CXCR7 results in a significant decrease in CXCR4+ 
migration in gradients of CXCL12-β. Given that single inhibition of CXCR4 or CXCR7 
was relatively ineffective at limiting chemotaxis in CXCL12-γ gradients, we performed 
co-inhibition of CXCR4 and CXCR7, resulting in complete suppression of CXCR4+ 
movement (P-value = 0.52 at 24 hr compared to at 0 hr). To understand how these results 
on the 2D grid apply to the 3D environment, we performed additional simulations with 
the same parameters (as in Figure 3.5H-J), but with a 3D dimension for diffusion, using a 
grid size of 100x100x5 instead of 100x100x1. The gradient trends remain the same: 
CXCL12-γ and -β promote shorter and steeper gradients than CXCL12-α. When 
CXCR4+ cells within this expanded grid were allowed to move, we found that the 2D 
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migration trends hold true in 3D (Figure A.9).  Taken together, these results demonstrate 
that CXCL12 isoforms form gradients that differ in shape, magnitude and scope even 
within the disorganized pattern of cancer cells present in some tumors. Moreover, we call 
attention to the importance of CXCL12-γ within the tumor environment, as its high 
ligand binding properties elicits higher CXCR4+ migration and requires interventions 
such as co-inhibition of CXCR4 and CXCR7 to significantly reduce migration.  
3.5 Discussion 
 
Chemotaxis plays a critical role at major stages of cancer progression. Angiogenesis 
required to supply the tumor with nutrients is directed by external gradients of cytokines 
such as vascular endothelial growth factor [72-75]. Tumor-promoting macrophages are 
recruited from blood to tumor sites by CCL2 and CCL5 [76]. Expression of chemokines 
and their receptors, such as CXCL12/CXCR4 and CCL21/CCR7, in both primary and 
metastatic tumors suggest that chemokine receptor-bearing cells actively enter the 
circulation and home to metastatic sites [12]. While it is well established that cells move 
in a directed manner towards chemoattractants, little is known about the shape and 
magnitude of chemoattractant gradients in tissue. Understanding gradient dynamics and 
cell responses to these gradients is imperative to targeting cancer metastasis.  
 
Our multi-scale hybrid agent-based model calculates gradient formation as it is shaped by 
molecular-scale events and cellular behavior. We trained and validated the model on an 
in vitro microfluidic source-sink device that capitalizes on gradients formed by actively 
secreting CXCL12+ cells, migrating CXCR4+ cells, and scavenging CXCR7+ cells. We 
used the model to gain insight on why CXCL12 isoforms have differential effects on 
migration. Recent data suggest that different isoforms of CXCL12 may have distinct 
outcomes for cancer [1,20,77]. Our simulations demonstrate that ligand affinity for the 
migration surface and for CXCR4 significantly impact migration. Gradients of CXCL12-
γ prompt greater migration of CXCR4+ cells than CXCL12-α in both the microfluidic 
source-sink device and the pseudo-tumor simulations and can in part be explained by 
high affinity for both the migration surface and receptor. High affinity for the surface 
results in steeper gradients for cells to navigate, and the high effective affinity for the 
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receptor results in a shift of the chemotaxis curve that allows higher migration even at 
lower secretion rates. In addition, cells in gradients of CXCL12-γ maintain higher levels 
of cell surface CXCR4 than when in gradients of the other CXCL12 isoforms. This is 
analogous to reports of enhanced chemotaxis with higher cell surface CXCR4 in the 
pathological setting of WHIM syndrome (warts, hypogammaglobulinemia, infections, 
and myelokathexis). The cytoplasmic tail of CXCR4 is truncated in WHIM syndrome, 
resulting in reduced internalization,higher number of CXCR4 surface receptors, and 
enhanced chemotaxis of leukocytes in response to CXCL12 [3,78]. These factors may 
explain why CXCL12-γ is better at eliciting chemotaxis of immune cells and endothelial 
progenitors compared to other isoforms [20,79].  
 
The properties that make CXCL12-γ better at eliciting chemotaxis also make it harder to 
inhibit. Blocking CXCR4 or CXCR7 is less effective at inhibiting CXCR4+ migration 
when the ligand (like CXCL12-γ) has a high affinity for the migration surface or for 
CXCR4. Our pseudo-tumor simulations demonstrate that blocking both CXCR4 and 
CXCR7 receptors may be a potential method to inhibit migration in such gradients. In 
addition to having a higher affinity for the migration surface and CXCR4, CXCL12-γ is 
present at lower levels within the tumor environment [77], and lower levels of CXCL12 
correlate with increased metastasis in mouse models and worse prognosis in breast cancer 
[14,15,77,80,81]. The combined effects of low expression and high binding 
characteristics make CXCL12-γ a worthwhile target for study in cancer metastasis.  
 
More broadly, our simulations highlight the importance of non-specific ligand binding to 
extracellular space. We predict that the majority of the chemokine presented to cells is 
surface-immobilized, even for ligands with ostensibly lower affinities to surface-sites as 
CXCL12-α. These findings are consistent with in vivo findings of stable and functional 
haptotactic gradients [82]. Many extracellular matrix proteins, such as heparan sulfate 
and collagens, have been shown to be elevated in cancer [83], but much of the research 
focus is on their mechanical properties. Our simulations indicate that the high presence of 
extracellular matrix proteins in cancer may support the steep, short-distance gradients that 
more efficiently regulate chemotaxis.  
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One surprising result is that cells shape their own gradient as they move. Largely due to 
the difficulty of visualizing gradients, most reports of CXCR4+ chemotaxis overlook the 
participation of CXCR4-bearing cells in shaping their own gradient. Here we use our 
agent-based model to observe and confirm that cell clusters of CXCR4 actively shape 
their own gradients. In the in vitro microfluidic source-sink device, the collective 
migrating cells maintain gradient steepness locally at the leading edge. In the pseudo-
tumor simulations, we find that individual CXCR4+ cells deplete ligand in their local 
environment. There is currently little literature on the potential for cells to shape their 
own gradient [38,84]; this may be one mechanism by which migrating cells can promote 
migration of follower cells [85]. 
 
While the receptor-ligand binding and internalization dynamics were constructed and 
validated on quantitative experimental data [32], we recognize that the model uses a 
simplified view of the complex interactions among CXCL12, CXCR4 and CXCR7. All 
of these proteins exist in both monomer and dimer forms that may have further 
implications on the strength of chemotaxis response or switches to other biological 
responses [33-35,86,87]. The presence of heparan sulfate, which was incorporated in the 
model with device surface-sites as well as the increased effective affinity of CXCL12 to 
CXCR4, further complicates the picture by inducing CXCL12 dimers and may alter 
CXCR4 recognition of the ligand [88,89]. As we gain more knowledge as to how these 
complicated interactions affect cell responses, we will be able to model more complicated 
behaviors of migrating cells within CXCL12 gradients.  
 
Ultimately, we are interested in what gradients may look like in the tumor environment. 
Gradients form even with disorganized tissue architecture present in cancers. We find 
that short-distance, steep gradients promote greater chemotaxis towards chemokine-
secreting cells than shallow gradients maintained over longer distances. Only a few 
reports have successfully visualized in vivo gradients [82,90,91], but characteristics such 
as gradient shape and magnitude have not been quantified. As imaging techniques such as 
intravital microscopy improve, we should be able to gain more information on gradient 
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formation over time and position in living tissues. To improve our understanding of the 
factors that modulate chemotaxis in tumors, it will be important to gather more 
histological data on the numbers and patterning of secreting and receptor-bearing cells in 
the tumor environment. Improvements to the model should capture matrix interactions in 
a packed cell environment, the mechanics of cell movement in a dense tissue 
environment, possible gradients of glycosaminoglycans, and isoform-specific protection 
from degradation. The integration of computational and experimental work to understand 
in vivo gradient formation will also provide insights to allow modulation of gradients for 
therapeutic purposes.  
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3.6 Tables  
 
Table 3.1 Isoform-specific fitted parameters  
Parameter  Definition CXCL12-α CXCL12-β CXCL12-γ 
KD,L,S (nM) Equilibrium dissociation 
constant for surface site 
binding 
100 20 5 
CXCL12sec (#/cell-s) Secretion rate constant 20 15 5 
KD,R4,L12 (nM) Effective equilibrium 
dissociation constant for 
CXCR4 binding 
40 40 10 
m Chemotaxis sensitivity 
factor slope 
-6.73x10-3 -6.73x10-3 -6.25x10-3 
b Chemotaxis sensitivity 
factor y-intercept 
3.5x103 3.5x103 3.5x103 
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3.7 Figures 
 
 
Figure 3.1 Multi-scale hybrid agent-based model 
Model simulates CXCR4+ cell movement in response to CXCL12 gradients. (A) Three 
types of agents (cells) move in a discrete manner on the surface of a 2D or 3D lattice: 
CXCL12+, CXCR4+ cells and CXCR7+ cells. CXCL12 gradients are formed and shaped 
by diffusion and degradation binding to the migration surface (B), and receptor-mediated 
uptake by CXCR4 (C) and CXCR7 (D). We assume that both soluble CXCL12 and 
CXCL12 bound to the migration surface are able to bind CXCR4 or CXCR7. Molecule-
scale dynamics shown in C and D are described by experiments and model in [32]. 
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Figure 3.2 Multi-scale model predicts cell movement, molecular-scale information, 
and gradient formation within the microfluidic source-sink device 
 (A) Heat maps depict CXCL12 concentration in the agent layer and are overlaid with 
agent positions. Initial patterning of CXCL12+, CXCR4+ and CXCR7+ cells is shown at 
0 hr. CXCL12+ and CXCR7+ cells, which move randomly, are not shown at later time 
points for clarity. Concentration values are averaged from 30 simulations. Cell positions 
shown are from one representative simulation. (B) Contribution of surface-bound (blue) 
and soluble (red) CXCL12 on total CXCL12 (black) concentration. At 0 hr, all 
concentrations are 0 nM. Concentration values are averaged from 30 simulations. (C) 
Number of CXCR4 surface receptors (sum of free, ligand-bound and β-arrestin-bound 
CXCR4) per individual CXCR4+ cell is plotted at the cell’s position across the width of 
the device. Data are shown for one representative simulation, the same simulation used 
for cell positions in (A). (D) Heat maps depicting CXCL12 concentration when 
CXCL12-CXCR4 binding and internalization ODEs are turned off at 8 hrs. All 
simulations depicted here were run with parameters from Table A.1. Normalized position 
of 0 to 1 corresponds to the device width of 0.5mm to 1.5mm. 
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Figure 3.3 CXCL12 isoform-specific effects on CXCR4+ cell migration 
 (A-C) Experimental data show isoform-specific differences in average CXCR4+ cell 
migration as a function of the percentage of source cells secreting CXCL12 in our source-
sink device (data from [1]).  We fit our model to these data by varying four isoform-
specific parameters (chemotaxis sensitivity factor parameter m, CXCL12 isoform affinity 
to the migration surface, CXCL12 isoform effective affinity for CXCR4, and CXCL12 
isoform secretion rate). (D) Using the model, we predicted the average migration of 
CXCR4+ cells within the same source-sink device for when 100% of source cells are 
secreting and when the distance between the cells stripes is increased from 200 µm to 400 
µm. Compared to panels A-C, migration for all isoforms is reduced. We measured the 
average migration using the source-sink device and find that that it matches model 
predictions. (E,F) The model predicts CXCR4+ average migration for different secretion 
rate constants of CXCL12+ cells as (E) ligand affinity to migration surface (Mid affinity 
KD,L,S = 5nM; High affinity KD,L,S  = 1nM) and (F) ligand affinity to CXCR4 (Mid affinity 
KD,R4,L12 = 5nM; High affinity KD,R4,L12  = 1nM) are increased. The low affinity case for 
both E and F uses the CXCL12-α parameters listed in Table A.1. Model data are 
expressed as mean of 30 replications +/- standard deviation. For experiments only: * P < 
0.05; ** P < 0.005; *** P < 0.0005. 
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Figure 3.4 Blocking migration to high affinity ligands is more difficult than to low 
affinity ligands 
Average migration of CXCR4+ cells for different secretion rate constants of CXCL12-
secreting cells as (A) CXCR4, (B) CXCR7 or (C) both CXCR4 and CXCR7 are blocked. 
Blocking 50% of CXCR4 receptors (D) or 90% of CXCR7 receptors (E) is not as 
effective at reducing CXCR4+ migration when the ligand has a high affinity for CXCR4 
(KD,R4,L12  = 1nM) and when the ligand has a high affinity for the migration surface (KD,L,S  
= 1nM). Data are expressed as mean of 30 replications +/- standard deviation.  
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Figure 3.5 Gradients form even in disorganized cell structures representative of 
tumors 
(A) Positions of CXCL12+ (red), CXCR4+ (white) and CXCR7+ (green) cells in 
simulation, based on histological data from literature [10,14,15]. We predicted 
chemokine gradients using same parameters as used in the device (Table A.1) for 
CXCL12-α (B), CXCL12-β (C) and CXCL12-γ (D). Gradients when CXCR7+ cells are 
replaced with non-receptor bearing cells for CXCL12-α (E), CXCL12-β (F) and 
CXCL12-γ (G). Gradients using a reduced number of CXCR4 and CXCR7 receptors 
(5x103 per cell) for CXCL12-α (H), CXCL12-β (I) and CXCL12-γ (J). Gradients shown 
are at 24 hr; cells were immobile throughout the entire time period. Data are expressed as 
mean concentration using 30 replications.   
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Figure 3.6 CXCL12-γ enhances migration in tumor-like simulations 
Model predictions of directed CXCR4+ migration in a tumor-like environment. Number 
of CXCR4+ cells within 30 µm of a CXCL12 cluster at 24 hr represented as fold change 
(in comparison to number at 0 hr). Each simulation had a randomly generated pattern. 
CXCL12 and CXCR7+ cells remained static throughout the entire time period, whereas 
CXCR4+ cells were allowed to move. All parameters are the same as those used for 
gradient predictions in Figure 3.5H-J, with reduced numbers of CXCR4 and CXCR7 
(5x103 per cell), except that the chemotaxis sensitivity factors (for all isoforms: m=-
6.85x10-3, b=25) were altered to increase sensitivity to migration. Control simulation 
lacks CXCL12 on the grid. Data are expressed as mean of 30 replications +/- standard 
error of the mean. Arrows represent statistics using Student’s T-test, brackets represent 
statistics using ANOVA. * P < 0.05, ** P < 0.0005, *** P < 0.0005 
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Chapter 4  
Regulation of G-protein coupled receptor 
signaling by competition control points 
 
4.1 Abstract 
 
Signaling pathways are highly connected networks with multiple shared components. 
Perturbations in one signaling pathway may result in unintended changes in another. In 
this chapter, we examine the role of competition in CXCL12/CXCR4/CXCR7 signaling 
pathway. These receptors share not only a ligand, CXCL12, but also intracellular 
signaling components such as β-arrestin and ERK. Both receptors are highly implicated 
in numerous cancers. To determine how targeting one receptor may result in unintended 
consequences due to the sharing of common components, we constructed a mechanistic 
model of CXCR4 and CXCR7 receptor dynamics and signaling. We find that CXCR7 has 
been overlooked in its role as a scavenger when co-expressed with CXCR4. Its high 
affinity for both CXCL12 and β-arrestin limit both aspects of CXCR4 signaling. The 
model also predicts that changes in β-arrestin can increase, decrease, or have no impact 
on CXCR4 G-protein signaling depending on receptor recycling and relative rates of 
phosphorylation to ligand binding. Furthermore, to determine if co-expression of CXCR7 
affects patient outcomes, we trained and validated a Cox proportional hazards model 
incorporating CXCL12, CXCR4, and CXCR7. When taking into account these three 
genes, CXCR7 is the most significantly associated with clinical outcome. 
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4.2 Motivation 
 
Signaling pathways are not isolated sets of intracellular reactions, but are connected 
networks that regulate and can be regulated by one another. Competition for shared 
components within signaling pathways plays a crucial role in determining cell responses 
and behavior. For example, competition is a means to ultrasensitivity, a mechanism to 
amplify signaling responses. Both intermolecular (multiple molecules competing for a 
substrate) and intramolecular (two sites on a single molecule competing for a substrate) 
competition are mechanisms by which graded responses are converted to switch-like 
responses [1-4]. As another example, G-protein coupled receptors (GPCRs), the most 
common receptor target for therapeutics, can operate through classical G-protein 
pathways as well as β-arrestins [5]. For the angiotensin II type 1A receptor, competition 
between the G-protein coupled receptor kinases GRK2 and GRK5/6 controls whether 
signaling occurs primarily through G-proteins or through β-arrestins, resulting in distinct 
dynamics of phosphorylated ERK [6]. Identifying key parameters controlling competition 
is critical to the design of therapeutics that limit off-target effects.  
 
The CXCL12/CXCR4/CXCR7 signaling axis offers a unique opportunity to look at 
competition. While the majority of chemokine receptors have at least three ligands as 
binding partners [7], CXCL12 is the only known ligand for CXCR4, and has just one 
other receptor, CXCR7 (recently renamed as ACKR3) [8]. The CXCL12/CXCR4 
signaling pathway is a requirement for immune cell homing and plays a key role in 
metastasis of many cancers [7,9-15]. Upon binding CXCL12, CXCR4 elicits G-protein 
activation, a rise in intracellular free calcium, cAMP inhibition, and signaling via Akt, 
ERK, and β-arrestin [16-21]. CXCR7 is an atypical chemokine receptor that signals 
primarily via β-arrestins and can also promote ERK signaling [5,22]. Therefore, CXCR4 
and CXCR7 share a ligand, and many intracellular components, raising the potential for 
crosstalk between pathways.  
 
While it appears that CXCR4 and CXCR7 co-expression results in signaling and cell 
behavior distinct from cells expressing only one of the receptors [23-27], consequences 
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of co-expression are still poorly understood. Since β-arrestin binds to CXCR7 with an 
order of magnitude higher affinity than to CXCR4 [28], one hypothesis is that CXCR7 
co-expression would sequester β-arrestin and thus promote CXCR4-mediated G-protein 
signaling [24]. However, CXCR7 is also a high affinity receptor for CXCL12, and binds 
with an affinity 10 times higher than that of CXCR4 to CXCL12 [29]. It is difficult to 
extract patterns from literature because studies examining CXCR4 and CXCR7 co-
expression use different cell lines, levels of receptor expression, ligand concentrations, 
and various assays to analyze signaling and behavioral outputs [23-27,30]. Even if 
experimental systems were made completely consistent, complexity still remains because 
competition occurs in the context of multiple simultaneous kinetic events. Therefore, 
computational modeling is an essential tool to understand and manipulate pathway 
outcomes.  
 
To understand how competition modulates intracellular signaling pathways, we 
constructed a mechanistic model using ordinary differential equations that incorporate 
ligand-receptor dynamics, G-protein and β-arrestin signaling. We use this model to ask 
the following questions: To what extent does CXCR7 control CXCR4 signaling? Can we 
alleviate the effects of CXCR7 on CXCR4 signaling by adjusting levels of shared 
components or targeting a kinetic event? How does affecting the levels of the shared 
component, β-arrestin, or inhibiting CXCR7 affect CXCR4 signaling? To address these 
questions, we use a model system containing (?) G-protein-mediated phosphorylated 
ERK as our output of CXCR4 G-protein signaling. To understand how CXCR7 affects 
ERK signaling, we performed time course Westerns blots and found that the addition of 
CXCR7 reduces overall ERK signaling in MDA-MB-231 and mouse embryonic cell 
lines. Using our mechanistic model, we find that CXCR7 co-expression can reduce 
CXCR4-mediated G-protein signaling due to its high affinity for CXCL12, while 
simultaneously scavenging β-arrestin. Furthermore, adding a competitive inhibitor to 
CXCR7 can disrupt its effects on CXCL12/CXCR4 signaling, but only at high CXCL12 
concentration when CXCL12 is not limiting. We also determined that targeting CXCR4 
recycling or CXCR4 rates of ligand binding relative to phosphorylation are two potential 
methods to mediate CXCL12/CXCR4 signaling. Lastly, we evaluated the clinical 
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relevance of CXCL12/CXCR4/CXCR7 by creating a Cox proportional hazards model 
using publicly available clinical data. We found that out of the three genes, CXCR7 is 
most significantly associated with metastasis free survival, when taking into account all 
three proteins of the CXCL12/CXCR4/CXCR7 axis. 
4.3 Methods 
4.3.1 Model overview 
The seven-transmembrane receptors CXCR4 and CXCR7 share at least three signaling 
components: CXCL12, β-arrestin, and ERK. We constructed a mass action kinetic model 
using ordinary differential equations to examine the role of competition between CXCR4 
and CXCR7 as detailed in Figure 4.1 and Tables 4.1 - 4.4. We used our previously 
published and validated model of ligand and β-arrestin dynamics to CXCR4 and CXCR7 
as the base of our model [28]. To examine CXCL12/CXCR4 signaling, we incorporated 
G-protein activation. To understand integrated signaling responses, we added ERK 
phosphorylation by both G-protein and β-arrestin pathways.  
4.3.2 Ligand and β-arrestin binding to receptors 
We assume that CXCL12 binds to CXCR4 and CXCR7 with a 1:1 stoichiometric ratio 
[31]. Although CXCL12 and its receptors exist as both monomers and dimers 
[16,23,30,32-35], we do not incorporate dynamics of dimer formation in the model, as 
previous reports show that the number of CXCR4 and CXCR7 homo- and heterodimers 
is not a function of CXCL12 or CXCL11 levels at physiological concentrations and 
remains relatively stable for ~ 60 minutes [30].  
 
We include the presence of a CXCR7 inhibitor in the model to understand how inhibiting 
CXCR7 may shift CXCR4 signaling. We assume that the CXCR7 inhibitor is comparable 
to a current molecule in development, CCX733 (ChemoCentryx). We assume that the 
CXCR7 inhibitor competes with CXCL12 at the same binding site, activates β-arrestin 
recruitment to CXCR7, and trafficks similarly to CXCL12 with CXCR7 [36]. 
 
β-arrestin can bind to both ligand and non-ligand bound phosphorylated receptors. Our 
first generation model of CXCR4/CXCR7 dynamics did not include receptor 
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phosphorylation prior to β-arrestin binding [28]. The model in this work adds 
phosphorylation of free and ligand-bound receptors to simulate receptor phosphorylation 
by GRKs [37,38]. We assume that the concentration of GRK is not limiting, and 
therefore do not track it as a separate species in the model [6]. We found the addition of 
receptor phosphorylation to be needed to give appropriate phosphoERK dynamics (as 
discussed in more detail below.)  
4.3.3 Receptor trafficking, degradation and recycling 
CXCR4 is a class A G-protein coupled receptor that has a transient association with β-
arrestin. CXCR7 is a biased receptor that has a more persistent interaction with β-arrestin 
[39]. In the model, this is incorporated by modeling the trafficking of internalized 
CXCR7 through a late endosome before recycling to the cell membrane. Ligand-bound 
CXCR4 is degraded, whereas non-ligand bound CXCR4 is recycled as free receptor to 
the surface. All CXCR7 is recycled and all ligands (CXCL12 and drug) are degraded.  
4.3.4 G-protein and ERK signaling 
We assume that ligand-bound CXCR4 can bind reversibly to G-proteins. Upon binding, 
the G-protein can be promoted to its activated state and detach from the receptor 
complex. We also incorporate constitutive activation and deactivation of G proteins [40-
42]. G-protein-mediated ERK phosphorylation (gpERK) is a function of both activated G 
protein and ERK concentrations. G-protein-phosphorylated ERK can translocate to the 
nucleus [43]. ERK can also be phosphorylated via the CXCL12/CXCR7 β-arrestin 
pathway. CXCL12-bound CXCR7 residing in the endosome can induce phosphorylation 
of ERK (bpERK), which is calculated in a separate pool than G-protein-phosphorylated 
ERK. We assume the same rate constant for constitutive dephosphorylation of both 
bpERK and gpERK. Class A receptors such as CXCR4 result in transient activation of 
phosphorylated ERK that peaks between 2 and 10 minutes [32,44]. In order to achieve 
such a pattern, the model required the addition of the phosphorylated receptor species that 
is unable to interact with G-proteins.   
 
 81 
4.3.5 Differences from the first generation model 
There are four major differences from our first generation model. The first is the addition 
of receptor phosphorylation prior to β-arrestin binding. We fit the forward and reverse 
rate constants of the phosphorylation step to match measurements of CXCR4 and 
CXCR7-β-arrestin interaction (described in results)[28]. Second, we added equations for 
CXCR4-mediated G-protein signaling, including constitutive G-protein activation and 
deactivation, G-protein binding to CXCL12-bound CXCR4, activation of the CXCR4-G-
protein complex, detachment of activated G-protein from the receptor-complex and 
activation of gpERK. Parameter ranges for these kinetic events were based on literature 
(Tables 4.1 - 4.4), and parameter values were adjusted within literature ranges to produce 
patterns of gpERK activation consistent with literature. Third, we added ERK 
phosphorylation from the β-arrestin pathway. Parameters of bpERK activation were taken 
from literature. Lastly, we adjusted the dissociation constant (KdL12R4) from its 
previous value of 40nM to 8nM, which is within the range of values reported in literature 
[32,45]. All baseline parameters, initial conditions, and equations can be found in Tables 
4.1 - 4.4.  
4.3.6 Measurement of phosphorylated ERK in MDA-MB-468 and MEFs 
We cultured MDA-MB-468 and mouse embryonic fibroblasts in DMEM (Life 
Technologies) with 10% serum, 1% glutamine, and 0.1% penicillin/streptomycin. To 
induce increased CXCR7 expression, we transduced cells as described previously [28]. 
Cells were harvested and SDS-PAGE was performed using a 10% gel (Biorad). We 
analyzed endogenous phosphoERK1/2 and total ERK1/2 in total cell lysates by Western 
blotting with a rabbit mAb (Cell Signaling) and an anti-rabbit secondary antibody 
conjugated with horse radish peroxidase (Cell Signaling).  Primary and secondary 
antibody dilutions for phosphoERK1/2 and total ERK1/2 were 1:1500 and 1:4000; and 
1:4000 and 1:6000, respectively. We detected bound antibody complexes with Pierce 
ECL Western Blotting Substrate (Thermo Scientific).  We used IVIS Spectrum 
instrument (Caliper, Hopkinton, MA, USA) to quantify light emitted from Western blots 
as photon flux. 
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4.3.7 Cox proportional hazards model 
We used three publicly available breast cancer clinical cohorts and their associated 
clinical and normalized gene expression data. We divided these cohorts into a training 
cohort (Wang et al.), and two validation cohorts (Kao et al., van de Vijver et al). The 
clinical characteristics of the cohorts have been described previously. Briefly, the cohort 
by Wang et al. was comprised of 286 tumor samples from lymph node-negative patients 
from the Netherlands who were treated from 1980-95 and who did not receive systemic 
adjuvant or neoadjuvant therapy. The median age was 52 years, the median follow-up 
time was 8.4 years for the patients who survived, 97% were T1-2, and the majority (87%) 
received radiation therapy [46]. The first validation cohort was from Kao et al. and 
consisted of 327 frozen tumor samples from every third patient treated between 1991 and 
2004 at the Koo Foundation Sun-Yat-Sen Cancer Center in Taiwan [47]. The median age 
was 46, median follow-up was 8.1 years, and the patients were heterogeneous in stage, 
grade, hormone receptor status and treatment modality [47]. The second validation cohort 
was from van de Vijver et al. and comprised 295 consecutive tumor samples from 
patients from the Netherlands who were treated from 1984-95, and who were diagnosed 
at age 52 or younger with a tumor less than 5cm in diameter. The median age was 44 and 
the median follow-up was 7.2 years [48].  
 
The MIAME compliant datasets were downloaded from the Gene Expression Omnibus 
(GEO) database with series number GSE20685 (Kao) and GSE2034 (Wang). Data for the 
van de Vijver cohort was obtained from http://microarray-
pubs.stanford.edu/wound_NKI/explore.html (also available from 
http://www.oncomine.org). Expression levels were log transformed, median centered and 
scaled. Wang was chosen to be the training cohort because the patients were node 
negative and had not received any adjuvant or neo-adjuvant systemic therapy and thus 
best captured true metastatic potential. We used the Cox proportional hazards function in 
R to create a gene signature incorporate CXCL12, CXCR4 and CXCR7. This model was 
fit to metastasis free survival in the training cohort with CXCL12, CXCR4 and CXCR7 
as covariates. Then the model was used to make predictions in the validation cohorts. 
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Performance was evaluated by comparing the outcomes in the top quartile of the 
signature predictions, versus the rest, using the log-rank test in all three clinical cohorts.  
4.4 Results 
4.4.1 Model validation 
In this work, we built upon our previously published and validated model of CXCR4 and 
CXCR7 ligand, receptor and β-arrestin dynamics to further understand how competition 
for shared components affect signaling [28]. To examine CXCL12/CXCR4 signaling, we 
added equations for G-protein activation, including G-protein binding to CXCL12-bound 
CXCR4, G protein activation and detachment (Figure 4.1). Both activated G-proteins and 
ligand-bound CXCR7 promote ERK phosphorylation. It has been well established that 
ERK phosphorylation by G-proteins (gpERK) is more transient, with a peak between 2-
10 minutes, whereas β-arrestins promote a steady increase of ERK phosphorylation 
(bpERK) [32, 39, 44]. In order to produce gpERK temporal patterns consistent with 
literature, we implemented receptor phosphorylation as a requirement for β-arrestin 
association[38, 49] and to fit phosphorylation rate constants (kpR4, kpL12R4, kpR7, 
kpC7) of β-arrestin mediated pathways to ERK with the restriction that phosphorylation 
of ligand-bound receptors occurs with a faster rate constant than phosphorylation of free 
receptors (Table 4.1) [50, 51].  
 
The addition of receptor phosphorylation did not significantly alter dynamics of β-
arrestin interaction with the receptors. Fold change interaction of CXCR4 (Figure 4.2A) 
and CXCR7 (Figure 4.2B) to β-arrestin is still consistent with the first generation model, 
as well as experimental data measuring receptor-β -arrestin interaction using a 
bioluminescence complementation assay (Figure 4.2C,D) [28]. Due to a stronger 
interaction with β-arrestin, in the absence of ligand, CXCR7 is found mostly inside the 
cell, whereas a weaker interaction with β-arrestin results in primarily cell-surface 
CXCR4. Our model is also consistent with the observation that truncated CXCR4 unable 
to bind β-arrestin result in an increase of surface CXCR4, as in WHIM syndrome [37, 
52] (Figure 4.2E).  
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4.4.2 Increasing CXCR7 results in reduced total ERK phosphorylation in MDA-MB-
468 and mouse embryonic fibroblast cell lines 
Previous reports of CXCR4 and CXCR7 co-expression use a variety of cell lines to probe 
combined CXCR4/CXCR7 signaling. The goal was to use cell lines that did not have 
detectable endogenous CXCR7, so we could look at the effects when adding CXCR7. 
This way, we could determine initial conditions of phosphorylated ERK and if the 
temporal patterns change. We administered 100ng/ml of CXCL12 to both normal (mouse 
embryonic fibroblasts) and cancer (MDA-MB-468 breast cancer cells) cells and 
performed Western blots for phosphorylated ERK. In both cell types, we found that 
overall levels of pERK decrease by 20-50% in the presence of increased CXCR7. We 
used this experimental data to inform the model for initial pERK levels (about 10% of 
total ERK).  
 
4.4.3 Increasing CXCR7 results in reduced CXCR4-mediated G-protein signaling 
CXCR7 has been hypothesized to promote CXCR4-mediated G-protein signaling by 
scavenging β-arrestin from CXCR4 [24]. To understand the effects of CXCR7 on 
CXCR4 signaling, we varied levels of CXCR7 in relation to CXCR4 expression from 0 
to 50 times the number of CXCR4 receptors/cell. We also varied CXCL12 ligand 
concentration from 0.01 to 1000nM. All other parameters remained as in Table 4.1. We 
use G-protein phosphorylated ERK (gpERK) as our output of CXCR4 signaling.  
 
The model predicts that CXCR7 co-expression results in a reduction of CXCR4-mediated 
G-protein signaling (Figure 4.4A). This trend remains with increasing or decreasing total 
CXCR4 (data not shown). While CXCR7 is a high affinity receptor for β-arrestin, it is 
also a high affinity partner for CXCL12. As CXCR7 levels increase, it scavenges both β
-arrestin and CXCL12 from CXCR4 (Figure 4.4B). Reducing CXCR7 affinity to 
CXCL12 (Figure 4.4C) and reducing CXCR7 binding to β-arrestin can alleviate its 
effect on CXCR4 signaling (Figure C.1). Therefore, CXCR7 scavenges both CXCL12 
and β-arrestin from CXCR4 (Figure 4.4E).  
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4.4.4 CXCR4 recycling and rapid phosphorylation enhances CXCR4-mediated G 
protein signaling  
Following receptor phosphorylation by GRKs, β-arrestin scaffolds with CXCR4 or 
CXCR7 to internalize the receptor complexes. We hypothesized that increasing β-
arrestin would result in decreased G-protein signaling due to increased competition 
between G proteins and β-arrestin for CXCR4. However, the model predicts the 
opposite: increasing β-arrestin results in a small increase (< 10%) of CXCR4-mediated 
G-protein signaling (Figure 4.5A). Despite increased G-protein signaling, the proportion 
of internalized and degraded receptors increases with β-arrestin levels. How can 
increased receptor internalization and increased G-protein signaling occur at the same 
time? By systematically turning off kinetic events in the model, we determined that this 
phenomenon is due to a combination of the following: (1) internalized CXCR4 recycles 
to the surface and (2) ligand binding is faster than phosphorylation. By eliminating 
CXCR4 recycling, G-protein signaling no longer increases with β-arrestin levels (Figure 
4.5B), but instead decreases due to increased CXCR4 degradation. In addition, increasing 
the forward rate of binding of CXCL12 to CXCR4 while decreasing the phosphorylation 
rate of CXCR4 reduces the dependence on β-arrestin levels (Figure 4.5C). Thus, 
depending on the trafficking patterns of CXCR4 and the relative rates of ligand binding 
to receptor phosphorylation, increasing β-arrestin levels can provide two types of effects 
(Figure 4.5D).    
 
4.4.5 High CXCR7 inhibitor concentrations can alleviate CXCL12 scavenging, but 
sequesters β-arrestin and promotes bpERK at high CXCL12 concentrations.  
The role of CXCR7 in cancer has spurred the development of inhibitors against CXCR7 
[53, 54]. Since CXCR7 shares many signaling components with CXCR4, we include the 
presence of a CXCR7 inhibitor in the model to understand how inhibiting CXCR7 may 
shift CXCR4 signaling. An inhibitor of CXCR7 might be expected to increase CXCR4-
mediated G-protein signaling, due to a higher availability of CXCL12. Indeed, the model 
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predicts that at low CXCL12 concentrations, CXCR4-mediated G-protein signaling does 
increase with increasing CXCL11 (Figure 4.6A). Closer examination on where CXCL12 
and ERK is being distributed reveals three distinct regions. At low CXCL12 and inhibitor 
concentrations, the majority of CXCL12 bound to any receptor preferentially binds to 
CXCR7 (Figure 4.6B). At low CXCL12 and high inhibitor concentrations, CXCL12 now 
preferentially binds to CXCR4. However at high CXCL12 concentration, CXCL12 is no 
longer limiting. Therefore, CXCL12/CXCR7 binding increases. The model also predicts 
that the G-protein and β-arrestin pathways compete for ERK. As gpERK decreases, 
bpERK increases (Figure 4.6C).  
 
4.4.6 CXCR7 is most significantly associated with clinical outcomes within the 
signaling trio 
The model has demonstrated how co-expression of CXCR7 with CXCR4 can 
dramatically shift CXCR4 signaling by affecting at least three control points: CXCL12, 
β-arrestin, and ERK. To investigate if the co-expression of CXCR7 is correlated with 
patient outcomes, we used publicly available clinical data to examine CXCL12, CXCR4, 
CXCR7 expression to create a three-gene Cox proportional hazards model. First, we 
evaluated the relationship between gene expression of CXCL12, CXCR4, and CXCR7 
with metastasis free survival in the Wang clinical cohort. In this model, we found that 
low CXCL12 and high CXCR7 expression both confer significantly increased risk, which 
is consistent with previous reports (Figure 4.7A) [55, 56]. However, CXCR4 expression 
does not significantly affect metastasis risk after taking into account CXCL12 and 
CXCR7 expression. The gene signature is able to risk stratify patients in our training data 
(p=0.0002, HR=12.07). To validate the gene signature, we used the parameters from the 
Cox proportional hazards model in two addition clinical cohorts. We find that a high 
signature confers increased risk of metastasis in both cohorts (Kao: p=0.008, HR=1.81, 
Van de Vijver: p=0.002, HR=1.9), validating the prognostic ability of the model and 
confirming that the inter-relationship and relative gene expression of CXCL12, CXCR4, 
and CXCR7 are clinically important (Figure 4.7B). 
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4.5 Discussion 
 
Despite the identification of countless oncogenes as major drivers of cancer, cancer drug 
development has a poor rate of clinical success [57]. Part of the difficulty in targeting the 
CXCL12/CXCR4 pathway is that it is essential for many homeostatic functions [58]. The 
second receptor to CXCL12, CXCR7, has also been implicated in cancer and inhibition 
of CXCR7 has been suggested as a strategy that may also mitigate the malignant effects 
of CXCR4 signaling [53, 54]. Considering that CXCR4 and CXCR7 share multiple 
components within their pathways, modulating one pathway may have undesired 
consequences for the other. To understand such consequences, we developed a 
mechanistic model of CXCL12/CXCR4/CXCR7 receptor dynamics and signaling with an 
emphasis on the shared components in the pathways.  
 
Our model predicts that increasing CXCR7 results in a decrease in CXCR4-mediated G 
protein signaling across a large range of CXCL12 concentrations (Figure 4.4). This is 
supported by studies using cAMP inhibition, Ca2+ signaling and GTP-gS binding as 
metrics of G-protein activity [23, 24]. While other studies focus on the importance of 
CXCR7 in controlling extracellular ligand concentration and gradients [59-62], our 
model highlights the importance of CXCR7 in scavenging CXCL12 from CXCR4 
receptors on the same cell. Due to its higher affinity for both ligand and β-arrestin, 
CXCR7 can significantly hamper CXCR4 signaling. Targeting CXCR7 with a 
competitive inhibitor can reverse these effects, but our model shows that if CXCL12 
levels are not limiting, then the inhibitor has little effect (Figure 4.6). Thus, the model 
points to the importance of determining CXCL12 levels within tissue.  
 
Receptor-ligand dynamics shifts the direction in which a shared molecule controls 
signaling. The model shows that increasing levels of β-arrestin can increase, decrease, 
or have no effect on CXCR4-mediated G-protein signaling, depending on recycling of 
internalized receptor and relative rates of ligand binding compared to receptor 
phosphorylation (Figure 4.5). This suggests one reason for the lack of consensus in 
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literature regarding how CXCR7 shapes CXCR4 signaling [23-27]. The direction in how 
a shift in β-arrestin levels affect CXCR4 signaling is sensitive to overall rates of 
recycling, receptor phosphorylation, and ligand binding. It is difficult to compare across 
experiments that use various cell types because controlling for all of these important 
events in receptor-ligand dynamics is not currently possible.  
 
Once we established that co-expression of CXCR7 can regulate CXCR4 signaling, we 
investigated if patient outcomes are also dependent on the co-expression of CXCR4 and 
CXCR7. Previous studies have identified that CXCR4 and CXCL12 are independently 
correlated with patient outcomes [9, 15, 55, 56, 63, 64]. However, the expression of these 
three genes in the integrated CXCL12/CXCR4/CXCR7 signaling axis have never been 
evaluated in the context of one another. We created a Cox proportional hazards model 
that evaluates CXCL12, CXCR4, and CXCR7 expression in three breast cancer clinical 
cohorts. This model calculates that CXCR7 is most significantly correlated with patient 
outcome compared to CXCL12 and CXCR4. In addition, the hazard ratio of CXCR7 
(1.186) suggests that higher levels of CXCR7 confer with worse patient prognosis.  
 
One future direction is to predict which downstream pathway of CXCR4 is the one 
related to malignancy. While our Cox proportional hazards model suggests that 
increasing CXCR7 is related to worse outcomes, our mechanistic model is unable to 
pinpoint if it is due to altered CXCR4-mediatd G-protein or β-arrestin signaling, as 
increasing CXCR7 limits both G-protein and β-arrestin pathways. Furthermore, while 
we detailed receptor-ligand dynamics in this model, our model did not detail potential 
signaling differences when CXCR4 and CXCR7 create heterodimers, which may have 
signaling effects unique to the heterodimer structure. Lastly, a major limitation with the 
clinical data used in the Cox proportional hazards model is the inability to determine if 
cells co-express CXCR4 and CXCR7, or if they are expressed on separate populations of 
cells.  
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4.6 Tables 
 
Table 4.1 Initial quantities 
Parameter Units Description Totals* Steady-state value 
R4 #/cell Free surface CXCR4 105 [1] 2.0x104 
R4p #/cell Phosphorylated R4 0 5.8x104 
R4B #/cell β-arrestin-bound R4  0 6.5x102 
L12R4 #/cell CXCL12-bound R4 0 0 
L12R4p #/cell Phosphorylated L12R4 0 0 
L12R4B #/cell β-arrestin-bound L12R4  0 0 
L12R4G #/cell G-protein-bound L12R4 0 0 
L12R4Ga #/cell Ga-bound L12R4 0 0 
R4Bi #/cell Internalized R4 (B is removed) 0 2.2x104 
L12R4Bi #/cell Internalized L12R4B 0 0 
L12R4Bii #/cell L12R4Bi after B removal 0 0 
degR4 #/cell Degraded R4 0 0 
R7 #/cell Free surface CXCR7 105 [1] 9.3x101 
R7p #/cell Phosphorylated R7 0 8.2x104 
R7B #/cell β-arrestin-bound R7  0 2.9x103 
L12R7 #/cell CXCL12-bound R7 0 0 
L12R7p #/cell Phosphorylated L12R7 0 0 
L12R7B #/cell β-arrestin-bound L12R7  0 0 
R7Bi #/cell Internalized R7B 0 4.5x103 
R7Bii #/cell R7Bi after B removal 0 1.0x104 
L12R7Bi #/cell Internalized L12R7Bi 0 0 
L12R7Bii #/cell L12R7Bi trafficked to late endosome 0 0 
XR7 #/cell Inhibitor-bound R7 0 0 
XR7p #/cell Phosphorylated XR7 0 0 
XR7B #/cell β-arrestin-bound XR7  0 0 
XR7Bi #/cell Internalized XR7Bi 0 0 
XR7Bii #/cell XR7Bi trafficked to late endosome 0 0 
B #/cell Free β-arrestin 105 [1] 9.2x104 
G #/cell Unactivated G protein 105 [2,3] 9.9x104 
Ga #/cell Activated G protein 104 1.0x101 
L12 nM Extracellular CXCL12 0 0 
X nM Extracellular inhibitor 0 0 
ERK #/cell Free ERK 105 [3,4] 8.0x104 
gpERK #/cell ERK phosphorylated by Ga 0 1.0x104 
bpERK #/cell ERK phosphorylated by L12R7Bi 0 1.0x104 
nucERK #/cell gpERK translocated to the nucleus 0 0 
* In order to determine the distribution of receptors bound to β-arrestin prior to ligand binding, equations 
are solved in the absence of ligand to steady-state conditions. 
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Table 4.2 Rate constants 
Description Parameter Value Units  
Ligand binding     
Forward rate constant of L12 binding to R4, R4p 
and R4B 
kfL12,R4 2.1x10-3 nM-1s-1 [1] 
Forward rate constant of L12 binding to R7, R7p 
and R7B 
kfL12,R7 1.4x10-3 nM-1s-1 [1] 
Dissociation constant of L12 from R4 KDL12,R4 8.0 nM [1] 
Dissociation constant of L12 from R4p and R4B KDL12,R4B (KDL12,R4 KDB,L12R4)/ 
KDB,R4 
nM [1] 
Dissociation constant of L12 from R7 KDL12,R7 8.0x10-1 nM [1] 
Dissociation constant of L12 from R7p and R7B KDL12,R7B (KDL12,R7 KDB,L12R7)/ 
KDB,R7 
nM [1] 
β-arrestin binding     
Forward rate constant of B binding to R4p and 
L12R4p 
kfB,R4 8.5x10-9 cell/#/s [1] 
Forward rate constant of B binding to R7p and 
L12R7p 
kfB,R7  1.4x10-8 cell/#/s [1] 
Dissociation constant of B from R4p KDB,R4 7.8x106 cell/#/s [1] 
Dissociation constant of B from L12R4p KDB,L12R4 5.1x106 cell/#/s [1] 
Dissociation constant of B from R7p KDB,R7 2.3x106  cell/#/s [1] 
Dissociation constant of B from L12R7p KDB,L12R7 6.5x105  cell/#/s [1] 
Internalization and trafficking     
Rate constant for internalization of R4B  keR4B 2.3x10-3  s-1 [1] 
Rate constant for internalization of L12R4B  keL12R4B 4.7x10-3 s-1 [1] 
Rate constant for recycling of R4Bi to cell surface krecR4Bi 6.9x10-5  
 
s-1 [1] 
Dissociation rate constant of B from L12R4i koffB,L12R4i 7.4x10-4 cell/#/s [1] 
Rate constant for degradation of R4 kdegR4 1.0x10-4 s-1 [1] 
Rate constant for internalization of R7B  keR7B 3.9x10-3 s-1 [1] 
Rate constant for internalization of L12R7B keL12R7B 2.1x10-3 s-1 [1] 
Rate constant for trafficking of L12R7B  ktrL12R7Bi 5.5x10-4 s-1 [1] 
Rate constant for recycling of L12R7B  krecL12R7Bi 2.8x10-4 s-1 [1] 
Dissociation rate constant of B from R7Bi koffB,R7 2.5x10-3   cell/#/s [1] 
Rate constant for degradation of L12  kdegL12 1.0x10-4 s-1 [1] 
Equations for CXCR7 inhibitor, X     
Forward rate of X binding to R7 kfX,R7 kfL12,R7 nM-1s-1  
Dissociation constant of B from XR7  KDB,XR7 KDB,L12R7 cell/#/s  
Forward rate of B binding to XR7 kfB,XR7 kfB,R7 nM-1s-1  
Dissociation constant of X from R7  KDX,R7 2 nM  
Dissociation constant of X binding to R7p and R7B KDX,R7B KDX,R7 KDB,XR7 / KDB,R7 nM [5] 
Internalization of XR7B keXR7B keL12R7B s-1  
Rate constant for trafficking of XR7B ktrXR7Bi ktrL12R7Bi s-1  
Rate constant for recycling of XR7B krecXR7Bi krecL12R7Bi s-1  
Degradation of X kdegX kdegL12 s-1  
G-protein parameters     
Constitutive activation rate constant of G kact,G 1x10-6 cell/#/s [3] 
Forward rate constant of L12R4 binding to G kfb,G,L12R4 1x10-3  cell/#/s  
Reverse rate constant of L12R4 and G binding krb,G,L12 1 s-1 [2] 
Activation rate constant of L12R4G to L12R4Ga kact,L12R4G 1x10-3 s-1 [2] 
Detachment rate of Ga from L`14 kdetach,Ga 1x101 s-1 [2] 
Constitutive deactivation of Ga to G kdeact,Ga 1x10-4 s-1 [2] 
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Table 4.2 continued     
Receptor phosphorylation      
Forward rate constant of phosphorylation of R4 by 
GRKs 
 
kpR4 1x10-3 
 
s-1 ^ 
Reverse phosphorylation rate constant of R4p 
 
kpL12R4 1x10-5 s-1 ^ 
Forward rate constant of phosphorylation of L12R4 
by GRKs 
 
kpL12R4 1x10-2 s-1 ^ 
Reverse phosphorylation rate constant of L12R4p 
 
kpL12R4p 1x10-4 s-1 ^ 
Forward rate constant of phosphorylation of R7 by 
GRKs 
kpR7 1 s-1 ^ 
Reverse phosphorylation rate constant of R7p kpL12R7p 1x10-3 s-1 ^ 
Forward rate constant of phosphorylation of L12R7 
by GRKs 
kpL12R7 1 s-1 ^ 
Reverse phosphorylation rate constant of L12R7p kdepL12R7 1x10-3 s-1 ^ 
ERK signaling     
Constitutive activation of gpERK vact,gpERK  1x10-4 s-1 [3] 
Activation of gpERK by G protein kpgpERK 1x10-4 cell/#/s [3] 
Dephosphorylation of gpERK kdephos,gpERK 2x10-3 s-1 [3] 
Translocation of gpERK to the nucleus kegpERK 1x10-3 s-1 [3] 
Constitutive activation of bpERK 
 
kact,bpERK 1x10-4 s-1 [3] 
Activation of bpERK by β-arrestins kpbpERK 1x10-4 cell/#/s [3] 
Dephosphorylation of bpERK kdephos,bpERK 1x10-1 s-1 [3] 
^ Denotes parameters determined in this work 
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Table 4.3 Event Rates 
Ligand binding  
CXCL12 binding to R4 
vb,L12,R4 = kfL12R4(R4L12 - 
KDL12R4L12R4) 
CXCL12 binding to R7 
vb,L12,R7 = kfL12R7(R7L12 - 
KDL12R7L12R7) 
CXCR7 inhibitor binding to R7 
vb,X,R7 = kfXR7(R7X - 
KDXR7XR7) 
CXCL12 binding to R4p 
vb,L12,R4p = kfL12R4(R4pL12 - 
KDL12R4BL12R4p) 
CXCL12 binding to R7p 
vb,L12,R7p = kfL12R7(R7pL12 
- KDL12R7BL12R7p) 
CXCR7 inhibitor binding to R7p 
vb,X,R7p = kfXR7(R7pX - 
KDXR7BXR7p) 
CXCL12 binding to R4B 
vb,L12,R4B = kfL12R4(R4BL12 - 
KDL12R4BL12R4B) 
CXCL12 binding to R7B 
vb,L12.R7B = 
kfL12R7(R7BL12 - 
KDL12R7BL12R7B) 
CXCR7 inhibitor binding to R7B 
vb,X.R7B = kfXR7(R7BX - 
KDXR7BXR7B) 
Receptor phosphorylation by GRKs 
Phosphorylation of R4 
vp,R4 = kpR4R4 
Phosphorylation of R7 
vp,R7 = kpR7R7 
 
Phosphorylation of L12R4 
vp,L12R4 = kpL12R4L12R4 
Phosphorylation of L12R7 
vp,L12R7 = kpL12R7L12R7 
Phosphorylation of XR7 
vp,XR7 = kpXR7XR7 
β-arrestin binding  
B binding to R4p 
vb,B,R4p = kfBR4(R4pB - KDBR4R4B) 
B binding to R7p 
vb,B,R7p = kfBR7(R7pB - 
KDBR7R7B) 
 
B binding to L12R4p 
vb,B,L12R4p = kfBR4(L12R4pB - 
KDBL12R4L12R4B) 
B binding to L12R7p 
vb,B,L12R7p = 
kfBR7(L12R7pB - 
KDBL12R7L12R7B) 
B binding to XR7p 
vb,B,XR7p = kfBR7(XR7pB - 
KDXR7BXR7B) 
Receptor internalization 
Internalization of R4B 
vi,R4B= keR4BR4B 
Internalization of R7B 
vi,R7B = keR7BR7B 
 
Internalization of L12R4B 
vi,L12R4B= keL12R4BL12R4B 
Internalization of L12R7B 
vi,L12R7B = keL12R7BL12R7B 
Internalization of XR7B 
vi,XR7B = keXR7BXR7B 
β-arrestin dissociation 
Dissociation of B from L12R4Bi 
voff,L12R4Bi = koffBR4L12R4Bi 
Dissociation of B from 
R7Bi 
voff,R7Bi = koffBR7R7Bi 
 
Trafficking, recycling, and degradation  
 Trafficking of L12R7Bi to 
late endosomes 
vtr,L12R7Bi = 
keL12R7BiL12R7Bi 
Trafficking of XR7Bi to late 
endosomes 
vtr,XR7Bi = keXR7BiXR7Bi 
Recycling of R4Bi 
vrec,R4Bi = krecR4BiR4Bi 
Recycling of R7Bii 
vrec,R7Bii = krecR7BiR7Bii 
 
Degradation of L12R4Bii 
vdeg,L12R4Bi = kdegL12R4BiL12R4Bii 
Recycling of L12R7Bii 
vrec,L12R7Bii = 
krecL12R7BiiL12R7Bii 
Recycling of XR7Bii 
vrec,XR7Bii = krecXR7BiiXR7Bii 
Degradation of CXCL12i 
vdeg,L12i = kdegL12L12i 
 Degradation of CXCR7 inhibitor 
vdeg,Xi = kdegXXi 
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Table 4.3 continued   
G protein signaling G protein-mediated ERK 
signaling 
β-arrestin-mediated ERK 
signaling 
Constitutive activation of G protein 
vact,G = kact,GG 
Phosphorylation of ERK by 
G proteins 
vp,gpERK = kpgpERKGaERK 
Phosphorylation of ERK by 
L12R7Bi 
vp,bpERK,7 = 
kpgpERK,7L12R7BiERK 
Binding of L12R4 to G 
vb,G,L12R4 = kfb,G,L12R4GL12R4-
krb,G,L12L12R4G 
Dephosphorylation of 
gpERK 
vdephos,gpERK = 
kdephos,gpERKGaERK 
Dephosphorylation of bpERK 
vdephos,bpERK = kdephos,bpERKbpERK 
Activation of receptor-bound G 
protein 
vact,L12R4G = kact,L12R4GL12R4G 
Translocation of gpERK to 
the nucleus 
vtr,gpERK = kegpERKgpERK 
Constitutive activation of bpERK 
vact,bpERK = kact,bpERKERK 
Detachment of Ga from L2R4 
vdetach,Ga = kdetach,GaL12R4Ga 
Constitutive activation of 
gpERK 
vact,gpERK = kact,gpERKERK 
 
Deactivation of activated G protein 
vdeact,Ga = kdeact,GaGa 
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Table 4.4 Differential Equations 
Extracellular ligand 
dL12/dt = ( - vb,L12,R4 - vb,L12,R4p - vb,L12,R4B - vb,L12,R7 - vb,L12,R7p - vb,L12,R7B)  (n  109 / (NavV)) 
dX/dt = (-vb,X,R7 - vb,X,R7p - vb,X.R7B)  (n  109 / (NavV)) 
CXCR4 and CXCR7 
dR4/dt = - vb,L12,R4 - vp,R4 + vrec,R4Bi dR7/dt = - vb,L12,R7 - vp,R7 + vrec,R7Bii  + vrec,L12R7Bii - vb,X,R7 + 
vrec,XR7Bii 
dR4B/dt = - vb,L12,R4B + vb,B,R4p - vi,R4B dR7B/dt = - vb,L12.R7B + vb,B,R7p - vi,R7B 
dL12R4/dt = vb,L12,R4 - vb,G,L12R4 - vp,L12R4 + vdetach,Ga dL12R7/dt = vb,L12,R7 - vp,L12R7 
dL12R4B/dt = vb,L12,R4B + vb,B,L12R4p - vi,L12R4B dL12R7B/dt = vb,L12.R7B + vb,B,L12R7p - vi,L12R7B 
dR4p/dt = vp,R4 - vb,B,R4p - vb,L12,R4p   dR7p/dt = vp,R7 - vb,B,R7p - vb,L12,R7p - vb,X,R7p   
dL12R4p/dt = vp,L12R4 + vb,L12,R4p  - vb,B,L12R4p dL12R7p/dt = vp,L12R7 + vb,L12,R7p - vb,B,L12R7p 
dL12R4G/dt = vb,G,L12R4 - vact,L12R4G  
dL12R4Ga/dt = vact,L12R4G - vdetach,Ga  
dR4Bi/dt = vi,R4B - vrec,R4Bi dR7Bi/dt = vi,R7B - voff,R7Bi 
 dR7Bii/dt = voff,R7Bi - vrec,R7Bii 
dL12R4Bi/dt = vi,L12R4B - voff,L12R4Bi dL12R7Bi/dt = vi,L12R7B - vtr,L12R7Bi 
dL12R4Bii/dt = voff,L12R4Bi - vrec,R4Bi dL12R7Bii/dt = vtr,L12R7Bi - vrec,L12R7Bii 
 dXR7/dt = vb,X,R7 -  vp,XR7 
 dXR7B/dt = vb,B,XR7p + vb,X.R7B - vi,XR7B 
 dXR7p/dt = vp,XR7 + vb,X,R7p  - vb,B,XR7p 
 dXR7Bi/dt = vi,XR7B - vtr,XR7Bi 
 dXR7Bii /dt = voff,XR7Bi - vrec,XR7Bii 
β-arrestin, G protein and ERK 
dB/dt = - vb,B,R4p - vb,B,L12R4p  + vi,R4B + voff,L12R4Bi - vb,B,R7p  - vb,B,L12R7p + voff,R7Bi + vrec,R7Bii - vb,B,XR7p +vrec,XR7Bii     
dG/dt = - vb,G,L12R4 + vdeact,Ga - vact,G dERK/dt = - vact,gpERK - vact,bpERK - vp,gpERK - vp,bpERK,7 + 
vdephos,gpERK + vdephos,bpERK 
dGa/dt = vdetach,Ga + vact,G - vdeact,Ga dgpERK/dt = vact,gpERK + vp,gpERK - vdephos,gpERK - vtr,gpERK 
dL12R4G/dt = vb,G,L12R4 - vact,L12R4G dbpERK/dt = vact,ERK + vp,bpERK,7 - vdephos,bpERK 
dL12R4Ga/dt = vact,L12R4G - vdetach,Ga dnucERK/dt = vtr,gpERK 
1. Coggins NL, Trakimas D, Chang SL, Ehrlich A, Ray P, et al. (2014) CXCR7 Controls Competition for 
Recruitment of beta-Arrestin 2 in Cells Expressing Both CXCR4 and CXCR7. PLoS One 9: e98328. 
2. Kinzer-Ursem TL, Linderman JJ (2007) Both ligand- and cell-specific parameters control ligand 
agonism in a kinetic model of g protein-coupled receptor signaling. PLoS Comput Biol 3: e6. 
3. Heitzler D, Durand G, Gallay N, Rizk A, Ahn S, et al. (2012) Competing G protein-coupled receptor 
kinases balance G protein and beta-arrestin signaling. Molecular Systems Biology 8: 590. 
4. Sasagawa S, Ozaki Y, Fujita K, Kuroda S (2005) Prediction and validation of the distinct dynamics of 
transient and sustained ERK activation. Nat Cell Biol 7: 365-373. 
5. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, et al. (2010) CXCR7 functions as a 
scavenger for CXCL12 and CXCL11. PLoS One 5: e9175. 	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4.7 Figures 
 
 
 
Figure 4.1 Competition within the CXCL12/CXCR4/CXCR7 pathway 
Model of competition control points within the CXCL12/CXCR4/CXCR7 signaling 
pathway. CXCR4 and CXCR7 ligand binding, β-arrestin binding, internalization and 
signaling to ERK via the G protein and beta-arrestin pathways are modeled using 
ordinary differential equations based on mass action kinetics.  
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Figure 4.2 Model validation 
Fold change of CXCR4 (A) and CXCR7 (B) interaction with β-arrestin as calculated by 
the first generation model (colored solid lines) and the model in this work (black dotted 
lines superimposed on the first generation model lines). Receptor phosphorylation 
parameters were fit to match β-arrestin interaction data. Note that for the 0 nM 
concentration, the data from both models overlap with a fold change of 1. Experimental 
data of CXCR4 (C) and CXCR7 (D) interaction with β-arrestin (dots with error bars, as 
reported in [28]) to the model in this work (solid lines) shows that the model is in 
agreement with experimental measurements of β -arrestin dynamics. All initial conditions 
and rate constants are identical with those described in [28]. (E) Consistent with 
experimental observations, CXCR4 remains primarily on the surface and CXCR7 is 
primarily intracellular after ligand addition (10nM). Simulation of WHIM syndrome 
(kfB,R4p and kfB,C4p = 0) results in increased CXCR4 surface expression.  
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Figure 4.3 Co-expression of CXCR7 reduces overall pERK levels in MDA-MB-468 
and MEFs 
Western time courses with 100ng/ml of CXCL12 for (A) MDA-MB-468 and (B) mouse 
embryonic fibroblasts characterized by film and IVIS. 
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Figure 4.4 Co-expression of CXCR7 decreases G-protein signaling by sequestering 
CXCL12 
(A) G-protein-mediated phosphorylated ERK (integrated over the first 30 minutes after 
ligand addition) decreases with increased CXCR7 expression with CXCR4. (B) As 
CXCR7 expression increases, an increasing proportion of receptor-bound CXCL12 is 
bound to CXCR7. (C) Reducing the affinity of CXCL12 to CXCR7 by two orders of 
magnitude (KdL12,R7 increased to 80 from 0.8) alleviates the strong dependence on 
CXCR7 expression. (D) Similarly, reducing the affinity of !-arrestin to CXCR7 (kfb,B,R7 
decreased and KDB,R7 increased by two orders of magnitude) reduces strong dependence 
on CXCR7 expression. (E) CXCR7 scavenges both CXCL12 and !-arrestin from 
CXCR4. Panels outlined in dark black indicate the baseline CXCL12 and CXCR7 
parameters as listed in Tables 4.1 - 4.4. Colorbars for gpERK are % change from baseline 
parameters.  
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Figure 4.5 CXCR4 recycling and rapid phosphorylation enhances CXCR4-mediated 
G protein signaling 
(A) G-protein-mediated phosphorylated ERK (integrated over the first 30 minutes after 
ligand addition) increased with increasing !-arrestin. (B) Eliminating recycling of 
CXCR4 (krecR4Bi = 0) shifts the pattern and gpERK decreases with increasing !-arrestin. 
(C) Biasing CXCR4 to ligand binding over phosphorylation (kfL12R4 = 0.01, kpR4 =10-4, kpC4 
= 10-6) removes the dependence on !-arrestin levels. (D) CXCR4 recycling and rapid 
phosphorylation drive !-arrestin-dependent effects on CXCR4 signaling. Panels outlined 
in dark black indicate the baseline CXCL12 and !-arrestin parameters. Colorbars for 
gpERK are % change from baseline parameters.  
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Figure 4.6 Addition of CXCR7 inhibitor  
(A) Increasing CXCR7 inhibitor concentration increasing G-protein signaling at low 
CXCL12 concentrations, but at higher CXCL12 concentrations, CXCL12 is no longer 
limiting and CXCR7 sequesters both CXCL12 and ERK. (B) Plotting the percent of 
receptor-bound CXCL12 bound to CXCR4 vs. CXCR7 reveals three regions. At low 
CXCL12 and low inhibitor concentrations, CXCR7 sequesters CXCL12. At low 
CXCL12 and high inhibitor concentrations, CXCR4 no longer competes with CXCR7 
and binds CXCL12. At high CXCL12 concentrations, CXCL12 is no longer limiting. (C) 
In addition, at high CXCL12 concentrations, ERK available to be phosphorylated by the 
G-protein pathway is sequestered by CXCR7.  
Panels outlined in dark black indicate the baseline CXCL12 and !-arrestin parameters. 
Colorbars for gpERK are % change from baseline parameters. 
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Figure 4.7 Cox proportional hazards model of CXCL12, CXCR4, CXCR7 
expression in cancer 
The three-gene Cox proportional hazards model was fit to publicly available data from 
Wang (A) and independently validated in two clinical cohorts (B).  
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Chapter 5  
Ruffles restrict diffusion in the plasma membrane 
during macropinosome formation 
 
5.1 Abstract 
 
In murine macrophages stimulated with Macrophage-Colony-stimulating Factor (M-
CSF), signals essential to macropinosome formation are restricted to the domain of 
plasma membrane enclosed within cup-shaped, circular ruffles. Consistent with a role for 
these actin-rich structures in signal amplification, microscopic measures of Rac1 activity 
determined that disruption of actin polymerization by latrunculin B inhibited ruffling and 
the localized activation of Rac1 in response to M-CSF. To test the hypothesis that 
circular ruffles restrict the lateral diffusion of membrane proteins that are essential for 
signaling, we monitored diffusion of membrane-tethered, photoactivatable green 
fluorescent protein (PAGFP-MEM) in ruffling and non-ruffling regions of cells. 
Although diffusion within macropinocytic cups was not inhibited, circular ruffles 
retained photoactivated PAGFP-MEM inside cup domains. Confinement of membrane 
molecules by circular ruffles could explain how actin facilitates positive feedback 
amplification of Rac1 in these relatively large domains of plasma membrane, thereby 
organizing the contractile activities that close macropinosomes. 
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5.2 Introduction 
 
In response to stimulation by growth factors, many cells extend actin-rich, circular ruffles 
that close into endocytic vacuoles called macropinosomes. Macropinocytosis begins with 
deformation of the plasma membrane by actin-based motile activities, first into linear or 
curved ruffles, then into cup shaped circular ruffles at the cell surface [1]. This ruffle 
closure is followed by cup closure, in which the circular ruffle constricts at its distal 
margin and separates from the plasma membrane as a macropinosome inside the cell [2]. 
 
Previous studies identified molecules that regulate macropinocytosis, including 
phosphatidylinositol 3’-kinase (PI3K) and Rac1 [2-4]. Activated growth factor receptors 
recruit and activate type I PI3K, which generates phosphatidylinositol 3,4,5-trisphosphate 
(PIP3) in the inner leaflet of the plasma membrane. Inhibitors of PI3K allow ruffle 
closure but inhibit cup closure [3,5], indicating that PIP3 directs the late stage of 
macropinosome formation. Rac1 is requisite in the macrophage ruffling response to 
macrophage colony-stimulating factor (M-CSF) [6,7]. 
 
How are the movements of the actin cytoskeleton organized to close cup-shaped 
extensions into intracellular vesicles? Concentrated PIP3 or Rac1 in the macropinocytic 
cup could regulate actin-myosin-based contractions that close the cup. Imaging of 
signaling in response to M-CSF showed that PIP3 generation and Rac1 activation closely 
follow ruffle closure and are confined within circular ruffles [4]. This indicates that 
circular ruffles create domains of plasma membrane that facilitate signal amplification 
and the contractile activities of cup closure. We hypothesize that molecules necessary for 
Rac1 signal amplification are confined to circular ruffles by an actin-based diffusion 
barrier in the cup. We therefore conducted experiments to probe the existence and 
location of diffusion barriers in the inner leaflet of ruffling plasma membrane. 
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5.3 Methods 
5.3.1 Cell culture  
Bone marrow-derived macrophages (BMM) were generated as previously described 
[5,8]. Bone marrow exudate was obtained from femurs of C57BL/6J mice. Marrow was 
cultured in medium (DMEM with 20% FBS and 30% L cell-conditioned medium) 
promoting the differentiation of macrophages. Bone marrow cultures were differentiated 
for 1 week with additions of fresh differentiation medium at Days 3 and 6. Following 
differentiation, macrophages were transfected and plated onto 25-mm circular coverslips. 
Cultures were incubated overnight in medium lacking M-CSF (RPMI 1640 with 20% 
heat-inactivated FBS). All experiments were performed the day after plating. 
5.3.2 Constructs and cell transfection  
Fluorophores were localized to the inner leaflet of the plasma membrane using the 
membrane localization domain from neuromodulin (MEM), a protein that associates with 
membrane via prenylation [9]. BMMs were transfected with plasmids encoding PAGFP-
MEM and mCherry-MEM via Amaxa Nucleofector II, using automated protocol Y-01. 
The conditions and reagents for macropinocytosis observation were 200 ng/mL MCSF 
(R&D Systems) in Ringer’s Buffer (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 2 mM NaH2PO4, 10 mM glucose and 10 mM HEPES at pH 7.2). In some 
experiments, Latrunculin B (5 µM) was added to cells five minutes before addition of M-
CSF. All imaging experiments were temperature controlled at 37°C. 
5.3.3 XYT photoactivation experiments  
Cells were imaged using an Olympus FV-500 Confocal microscope fitted with a 60x 1.45 
NA oil immersion objective. The microscope was equipped with diode-pulse (for 
photoactivation), argon (for GFP imaging), and HeNe green (for mCherry imaging) 
lasers. Image collection used Fluoview FV500 imaging software. Images were acquired 
at 1 frame/second using line sequential scanning. Three pre-activation images were 
collected for each experiment: these images were averaged to provide a fluorescence 
baseline reading. 
 
Photoactivation of PAGFP-MEM required one image scan with the diode laser set to 
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100% intensity. Photoactivation in defined regions of the cell membrane created patches 
of GFP fluorescence, whose fluorescence intensity decreased quickly by molecule 
diffusion in the membrane. 
 
Fluorescence intensities and PAGFP/mCherry ratiometric images were quantified using 
the “region mean intensity” measurement function in MetaMorph (Molecular Dynamics, 
Sunnyvale, CA). The averaged pre-activation images established a baseline fluorescence 
that was subtracted from all post-activation images. A normalized fluorescence for each 
post-activation image was calculated by dividing its fluorescence by the initial post-
activation timepoint fluorescence. 
5.3.4 Computer modeling experiments  
Three-dimensional models of the flat and cupped membranes were constructed using the 
transient diffusion module of COMSOL Multiphysics 3.4 (COMSOL Inc., Burlington, 
MA). The flat membrane (Figure 5.6A) was represented by two disks of 5.0 µm radius, 
ro, and 0.05 µm thickness, t, representing the top and bottom layers of the membrane, 
respectively. The outer radius, ro, was chosen to ensure that no molecules reached the 
outer edge of the model geometry during the time simulated. The cupped membrane 
(Figure 5.6B) was represented by a top layer geometry of an inner radius, ri, of 1.1 µm; 
distance between inner and outer cup walls, w, of 150 nm; and cup height, h, variable 
from 0.5 µm to 5.0 µm. The membrane thickness, t, was 0.05 µm and the outer radius, ro, 
was 5 µm. The bottom layer of the cupped membrane was represented by the same 
geometry as the flat membrane. COMSOL required specifying a membrane thickness to 
solve the cupped membrane, and this small value (0.05 µm) allowed us to mimic 
diffusion on the membrane surface. The software employs a finite element analysis to 
follow the time course of diffusion (solving ∂c
∂t +D∇
2c = 0
, 
where c is concentration and D is 
the diffusion coefficient) and to calculate the concentration of molecules at each point 
within the model geometry as a function of time. The initial condition for each model was 
equal to 2000 molecules uniformly distributed within the activation spot (ra = 1 µm), 
1000 molecules each in the top and bottom membrane layers. To compare simulation 
results with the experimental data (normalized fluorescence ratio), the number of 
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molecules within the activation spot was calculated at each time 
point and the computational ratio, R, was calculated as: R = top(t)+ bottom(t)top(0)+ bottom(0)
, where top(t) 
and bottom(t) are the number of molecules within the activation spot at time t on the top 
and bottom membrane layers, respectively. Simulation results from a flat membrane were 
fit to experimental data and used to determine a diffusion coefficient, D, of 1.1 x 10-9 
cm2/s. D was then used in simulations with the cupped membrane. 
5.3.5 XYZT photoactivation experiments  
Three-dimensional reconstructions of membrane dynamics (XYZT) used the same 
microscope and software as the XYT experiments. Image Z-stacks used a step size of 250 
nm between planes. Images were collected continuously in line sequential scanning 
mode. Collection of each Z-stack required approximately seven seconds. Image stacks 
were deconvolved using Huygens Essential software and the deconvolved stacks were 
visualized using the 4D viewer and linescan function in MetaMorph. 
5.3.6 FRET Microscopy  
Fluorescence images were collected using a Nikon Eclipse TE-300 inverted microscope 
with a 60x numerical aperture 1.4, oil-immersion PlanApo objective lens (Nikon, Tokyo, 
Japan) and a Lambda LS xenon arc lamp for epifluorescence illumination (Sutter 
Instruments, Novato, CA). Fluorescence excitation and emission wavelengths were 
selected using a JP4v2 filter set (Chroma Technology, Rockingham, VT) and a Lambda 
10-2 filter wheel controller (Shutter Instruments) equipped with a shutter for 
epifluorescence illumination control. Images were recorded with a Photometrics 
CoolSnap HQ cooled CCD camera (Roper Scientific, Tucson, AZ). Image acquisition 
and processing were performed using MetaMorph v6.3 (Molecular Devices, Sunnyvale, 
CA). Additional processing was performed using MATLAB v7.8.0 (The MathWorks, 
Inc., Natick, MA) and the equations of FRET stoichiometry [10]. 
 
FRET microscopy of macrophages expressing Citrine-Rac1 and Cerulean-PBD was 
carried out as previously described [4,10]. Briefly, collected images were background-
subtracted and shading-corrected. EA, ED, and Ratio images were then calculated using 
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published FRET stoichiometry equations [10,11]. G* images were calculated as 
previously described, using the coefficient values obtained from cells expressing Citrine-
Rac1(L61) and Cerulean-PBD [12]. G* values account for varying levels of donor and 
acceptor in a population of cells, and can therefore be used to accurately measure the 
fraction of active Citrine-Rac1 in cells that express variable relative amounts of Cerulean-
PBD and Citrine-Rac1. A paired two-tailed Student's t-test was used to compare average 
G* values from macropinocytic cups and entire cells. 
5.4 Results 
 
The relationship between actin-rich membrane ruffles and Rac1 signal amplification was 
examined by measuring the effect of the actin-depolymerizing agent latrunculin B on 
Rac1 activity. Quantitative Förster resonance energy transfer (FRET) microscopy was 
used to observe bone marrow-derived macrophages (BMM) expressing Citrine-Rac1 and 
Cerulean-PBD. PBD, derived from Pak1, binds the active (GTP-bound) form of Rac1 
[13]. The citrine and cerulean chimeras produce significant FRET interactions in regions 
of the cell where Rac1 is active. FRET stoichiometry was used to determine G*, which is 
the fraction of activated Citrine- Rac1 in any given region of the image [12]. G* values in 
forming macropinosomes were higher than in the surrounding cytoplasm, indicating that 
Rac1 amplification was restricted to the cup domain (Figure 5.1A, C, and F). After M-
CSF addition, cells treated with latrunculin B did not ruffle (Figure 5.1D) and the small 
increase of Rac1 activity was delocalized (Figure 5.1B and E). This indicated that Rac1 
signal amplification in cups was actin-dependent. 
 
To test the hypothesis that ruffles create barriers to diffusion in the inner leaflet of the 
plasma membrane, we measured the redistribution of plasma membrane-localized, 
photoactivatable green fluorescent protein (PAGFP-MEM), whose fluorescence 
following photoactivation increases 100-fold [14]. We first investigated whether ruffles 
could retain PAGFP-MEM near an initial region of photoactivation. Coexpression and 
imaging of monomeric Cherry (mCherry)-MEM chimeras provided a reference 
fluorescence that reported plasma membrane distribution. Ratiometric images, generated 
by dividing pixel values in the PAGFP-MEM images by the corresponding values in the 
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mCherry-MEM images, normalized PAGFP-MEM distribution in the various ruffling 
morphologies. We activated small patches of PAGFP-MEM molecules and measured the 
rates at which fluorescence intensity decreased by diffusion in the plasma membrane 
(Figure 5.2A). Curve-fitting analyses of fluorescence loss in flat regions of cells obtained 
a diffusion coefficient for PAGFP-MEM of 1.1x10-9 cm2/sec (Figure 5.2B, Figure 5.6A 
and B). Near linear ruffles, diffusion of the activated molecules was slightly inhibited 
(Figure 5.2C). However, PAGFP-MEM activated inside circular ruffles was retained 
much more than PAGFP-MEM in flat or ruffled membrane (Figure 5.2D), indicating that 
ruffled surfaces created effective barriers to diffusion of PAGFP-MEM. 
 
Quantitative measurements of the fluorescence depletion supported this observation 
(Figure 5.2E). The retention pattern for membrane cups leveled off approximately 15 
seconds after activation, suggesting that activated molecules were retained in the 
activation region. The steep initial decline in fluorescence retention in all of the 
membrane structures could be explained by the fact that PAGFP-MEM molecules were 
photoactivated in both the top and bottom (i.e., substrate-adherent) membranes of the 
cells. Accordingly, plots of fluorescence depletion reflect the dynamics of PAGFP-MEM 
in both membranes, including the unrestricted diffusion in the flat, bottom membrane. 
 
The apparent retention of PAGFP-MEM in the cup could be a consequence of its 
topography. Diffusion of PAGFP-MEM molecules activated inside membrane cups 
entails travel up the inner cup wall and down the outer cup wall. Apparent retention of 
activated PAGFP-MEM could simply reflect diffusion in the z-axis. However, 
simulations of diffusion in macropinocytic cups of various heights indicated that, in the 
absence of some type of barrier, diffusion in the z-axis would increase the retention of 
molecules in the activation spot only slightly (Figure 5.2F and 5.6C). The observed 
retention of PAGFP-MEM in cups could only be simulated by inclusion of a diffusion 
barrier (i.e., a region with a 10-100x lower diffusion coefficient) in the cup structure. 
 
To verify that the circular structures we analyzed were not closed pinosomes, we 
visualized photoactivated PAGFP-MEM using through-focus image acquisition and 3D 
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reconstruction by image deconvolution. These experiments showed directly that open 
macropinocytic cups retained PAGFP-MEM. Activated PAGFP-MEM molecules were 
visible in macropinocytic cups at least 19.5 seconds after activation (Figs. 5.3A-C). 
Comparable 3D reconstructions of activated PAGFP-MEM in flat membrane regions 
showed rapid and complete loss of fluorescence. 
 
Diffusion inside cups was further characterized using fluorescence intensity linescans of 
widefield microscopic images. Cherry-MEM linescans showed membrane contours. For 
open macropinocytic cups, the pixel intensities for Cherry-MEM were roughly equivalent 
inside and outside the cup, as fluorescence in each region derived from two layers of 
membrane (Figure 5.4A and B). In contrast, Cherry-MEM fluorescence from closed 
macropinosomes should include four layers of membrane: the top and bottom membranes 
of the cell plus the top and bottom membranes of the macropinosome. Accordingly, the 
Cherry-MEM pixel intensities measured from closed macropinosomes were 2.15 times 
the intensities of the surrounding area. This allowed us to use fluorescence linescans of 
Cherry-MEM images to confirm that all of the circular structures included in the 
quantification for Figure 5.2E were unclosed cups. 
 
Fluorescence linescans also allowed us to measure the extent to which different 
membrane structures inhibited lateral diffusion of activated PAGFP-MEM. The initial 
fluorescence profiles for patches of activated PAGFP-MEM showed Gaussian 
distributions. In flat membrane, the intensity decreased rapidly to that of the surrounding 
plasma membrane (Figure 5.4D-F), suggesting that the activated molecules diffused out 
of the activation region. For circular ruffles, the intensity profiles in the activation region 
remained elevated (Figure 5.4C), indicating retention of the photoactivated PAGFP-
MEM in the cup region. 
 
Retention of activated PAGFP-MEM in macropinocytic cups could be explained either 
by decreased diffusivity throughout the entire cup or by barriers localized to the circular 
ruffles. To determine if diffusion in the base of the cup resembles diffusion outside of the 
cup, we activated PAGFP-MEM in subregions of the cup structures and observed 
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fluorescence redistribution within the cup. Imaging (Figure 5.5A) and intensity linescans 
(Figure 5.5B, C) of ratio fluorescence revealed that the initially asymmetrical activation 
profiles rapidly leveled off inside the cup. Modeling simulated PAGFP-MEM 
redistribution by creating an initially hemispherical cohort of activated molecules which 
redistributed with the diffusion coefficients of flat membrane (10-9 cm2/sec) or barriers 
(10-11 cm2/sec or 0 cm2/sec) (Figure 5.5E, F). Diffusion barriers were assigned to 
different regions of the cup structure: the base, the inner wall, the distal rim, and 
combinations of those regions. The model most resembled the experimental data when 
the walls and rim of circular ruffles were assigned a barrier function and the base of the 
cup resembled flat membrane (Figure 5.5G, I). In contrast, simulations which assigned 
low diffusion coefficients to the base, walls and rim yielded did not resemble the 
observations (Figure 5.5 H, J). This is consistent with a mechanism in which proteins 
diffuse freely in the membrane of the base of the cup but encounter barriers in the ruffles. 
5.5 Discussion 
 
This study demonstrates that circular ruffles create barriers to protein diffusion in 
membranes. Unlike the diffusion barriers previously described for cleavage furrows [15] 
and the leading edge of cellular protrusions [16], the diffusion barriers of circular ruffles 
are capable of organizing microdomains for focused signal amplification. 
 
The molecular basis of the barrier remains unknown. Diffusion of membrane proteins or 
phospholipids could be restricted at the distal margins of ruffles, either by specific fence-
like structures that constrain the lateral movements of membrane-associated molecules or 
by physical constraints imposed by the high membrane curvature at the ruffle edge. In 
lipid rafts, tight packing of phospholipids reduces diffusivity [17]; raft-like structures at 
the distal margins of the macropinocytic cups could create effective barriers. 
Alternatively, the underlying actin meshwork could limit diffusion in the plasma 
membrane. The slight slowing of PAGFP-MEM diffusion observed in linear ruffles, 
relative to flat membrane (Figs. 2C, E), suggests that the barrier is intrinsic to ruffle 
structure. Actin or actin-associated proteins in ruffles could create effective barriers 
simply by slowing lateral diffusion of molecules along the broad face of the ruffle. 
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Regardless of its physical basis, the constraint on diffusion created by actin-rich ruffles 
could provide a mechanism for biasing signal amplification in self-organizing systems, 
leading to actin-dependent amplification of signals in ruffle-rich regions of the cell. 
 
The efficacy of the barrier for signal amplification is maximized in the circular ruffle, 
where diffusion is inhibited in all directions. Functionally, as a patch of plasma 
membrane with amplified activity of signaling proteins [4], circular ruffle represents a 
novel signaling domain. Activated receptors recruit and activate lipid-modifying 
enzymes, such as PI3K, which recruit other enzymatic proteins to the membrane domain 
through the formation of lipid or phospholipid species. Absent barriers, diffusion in the 
membrane could dissipate receptor-generated signals to subthreshold levels and the initial 
activation signal would be unable to reach concentrations needed to activate later signals. 
Barriers could allow concentrations of lipids or activated GTPases to remain high, 
thereby allowing the cell to recruit or activate the molecules that actuate the late stages of 
signaling. Accordingly, the actin-dependent amplification of Rac1 within circular ruffles 
indicates a positive feedback amplification mechanism in which restricted movement of 
diffusible signaling intermediates allows their concentration in the plasma membrane to 
exceed some transition threshold. Similarly, transient increases of PIP3 that follow 
immediately after ruffle closure could locally activate guanine nucleotide exchange 
factors for Rac1 or other GTPases [4]. Conversely, by stimulating actin polymerization 
necessary for circular ruffle formation, Rac1 could amplify PI3K activity through an 
actin-dependent mechanism. 
 
This mechanism of localizing signal amplification would be distinct from processes such 
as chemotaxis or phagocytosis, because it is independent of external orienting factors. 
Moreover, this focal signal amplification through restricted diffusion could provide a 
mechanism for cells to respond to lower concentrations of growth factor. 
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5.6 Figures 
 
Figure 5.1 Focal activation of Rac1 during macropinocytosis 
 (A–D) FRET interactions of Cerulean-PBD and Citrine–Rac1 in control (A,C) and 
latrunculin B-treated BMM (B,D) in response to M-CSF. (A,B) Left: Phase contrast; 
right: G*. Scale bars: 4 µm. (C,D) Time series for subregions of the cells shown in A and 
B, highlighting a forming macropinosome (C), and a comparable region of a latrunculin 
B-treated cell (D). Top row: Phase contrast; bottom row: G*. Scale bars: 1 µm. All color 
bars indicate G* values. (E) Quantification of total Citrine-Rac1 activity in control and 
latrunculin B- or wiskostatin-treated BMM (n=5 for all conditions). Dotted line indicates 
when M-CSF was added. (F) To quantify GTPase activation, the average G* in a forming 
macropinosome was divided by the average G* in the entire cell at each time point (n=10 
for each). The resulting ratio indicates the relative change in GTPase activity in the 
forming macropinosomes, with numbers greater than 1.0 indicating localized increases in 
activity. Sequences were aligned by the timing of ruffle closure (t=60 seconds). Ratios 
for Rac1 were significantly higher than cytoplasm values (*P<0.001) from 80 to 100 
seconds following the beginning of macropinosome formation. Ratios for Cdc42 did not 
significantly change during macropinosome formation. Error bars indicate s.d. 
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Figure 5.2 Selective photoactivation of PAGFP-MEM in plasma membranes 
(A) Schematic of experimental protocol for XYT experiments. PAGFP-MEM was 
photoactivated in regions of flat (a), ruffled (b) or cupped membrane (c). Fluorescence 
intensities were collected in these activation regions over time. Loss of fluorescence 
indicated diffusion of activated PAGFP-MEM out of the activation region; conversely, 
retention of activated PAGFP-MEM indicated restricted diffusion. (B–D) Images of 
different macropinocytic structures. Top row, mCherry–MEM; middle row: PAGFP-
MEM; bottom row, PAGFP:mCherry ratio. From left to right: 1 second pre-activation, 1 
second post-activation, 10 seconds post-activation, 20 seconds post-activation. Scale 
bars: 1 µm. Color bars indicate relative fluorescence intensities of ratio images. (B) 
Photoactivation in flat membrane. (C) Photoactivation in ruffle membrane. (D) 
Photoactivation in a macropinocytic cup. (E) Quantification of the fluorescence decrease 
in plasma membrane (n=5 for each condition). Membrane ruffles and cups demonstrate 
significant retention of photoactivated PAGFP-MEM. (F) Modeling of the effects of cup 
height on probe retention. Increasing cup height without adding a barrier or decreasing 
the diffusion coefficient did not affect molecule retention and could not account for the 
experimental values. Error bars indicate s.d. 
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Figure 5.3 4D reconstruction of activated PAGFP-MEM in an open macropinocytic 
cup 
Through-focus z-stacks were collected of PAGFP-MEM and mCherry at regular intervals 
after photoactivation of PAGFP-MEM in a cup. (A,B) Projections of a macropinocytic 
cup. Top row: mCherry–MEM; bottom row: PAGFP:mCherry ratio. From left to right: 
6.5, 13.0 and 19.5 seconds after activation of PAGFP-MEM. (A) XY projection of a 
macropinocytic cup and surrounding cellular region. Yellow boxes delineate the 
macropinocytic cup. (B) XZ projections of the macropinocytic cup (side view). Fields 
correspond to the regions marked by the yellow boxes in A. (C) Cross-sections of 
macropinocytic cups showing distribution of mCherry–MEM (red) and PAGFP:mCherry 
ratio (pseudocolor) at 13 seconds after photoactivation of PAGFP-MEM. Green line 
shows region of cross-section. Color bars indicate relative fluorescence intensities of ratio 
images. Scale bars: 1.0 µm. 
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Figure 5.4 Fluorescence intensity linescans of cupped or flat membrane 
(A,D) Representative linescans (yellow lines) in cupped and flat membrane, respectively. 
From left to right: mCherry–MEM image 1 second prior to activation, PAGFP:mCherry 
ratio image 1 second after activation, ratio image 10 seconds after activation, ratio image 
20 seconds after activation. Scale bars: 1.0 µm. Color bars indicate relative fluorescence 
intensities of ratio images. (B,E) Linescans of mCherry–MEM fluorescence intensities in 
cupped and flat membrane, respectively. (C,F) Linescans of PAGFP/mCherry 
fluorescence ratios in cupped and flat membrane, respectively, at 1, 10 and 20 seconds 
after photoactivation. Green lines indicate the perimeter of the activation region. Similar 
fluorescence patterns were seen for seven macropinocytic cups and for ten regions of flat 
membrane. 
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Figure 5.5 Diffusion dynamics within membrane cups indicate that the barrier 
localizes to the cup walls 
(A–C) Fluorescence redistribution following asymmetric activation of PAGFP-MEM in 
macropinocytic cups. (A) Representative images. From left to right: mCherry–Mem 
image 1 second prior to activation, PAGFP:mCherry ratio images 1, 10 and 20 seconds 
after activation. Yellow lines indicate position of linescans. Green boxes indicate the 
perimeter of the activation region. Scale bar: 1.0 µm. Color bars indicate relative 
fluorescence intensities of ratio images. (B) Linescan measurements of mCherry–MEM 
pixel intensities. (C) Linescan measurements of PAGFP:mCherry ratio values at 1, 10, 
and 20 seconds after photoactivation. Similar fluorescence patterns were seen in five 
macropinocytic cups. Paired vertical lines indicate the location of the cup wall. Green 
lines indicate the edge of the activation region. (D) Fluorescence measurements of 
activated and non-activated regions in the base of the cup over time, n=5. (E–J) Modeling 
of diffusion within cups. (E,F) Diagrams of activation patterns used to model diffusion 
inside the cup, showing views from above (C) and in sagital section (F). (G,H) 
Distributions of molecules along the diameter of the base of the cup normal to the 
activation boundary, measured at 1, 10 and 20 seconds after activation. (G) When the 
diffusion coefficient in the walls is 10−11 cm2/second (i.e., a barrier) and in the base of the 
cup is 10−9 cm2/second, fluorophore redistribution resembles the experimental data in C. 
(H) When the diffusion coefficients of the walls and base are both set to 
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10−11 cm2/second, fluorophore redistribution does not resemble the experimental data. 
(I,J) Modeling of the time course of fluorophore decrease from the activated region 
(triangles) and increase in the non-activated region (circles) when diffusion coefficients 
are set as in G (I) and H (J). The model resembles the experimental observations in D 
when the base of the cup has the same diffusion coefficient as membrane outside the cup 
(I). 
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Figure 5.6 Construction of flat and cupped membrane models 
(A) Flat membranes were modeled as three dimensional disks with an distinct region in 
the center to represent the membrane that is initially photoactivated. (B) By fitting the 
computational ratio to experimental flat membrane data, we determined that the 
diffusivity coefficient of plasma membrane-bound molecules is 1.1x10-9 cm2/s. (C) 
Cupped membrane geometry.   
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Chapter 6 Conclusions 
6.1 Summary of research findings 
The CXCL12/CXCR4 signaling axis is instrumental to the metastasis of many cancers, 
yet preclinical studies suggest that blocking the pathway alone is not sufficient to inhibit 
its malignant effects [1]. As cancer arises from a complex network of interdependent 
biological events, eliminating cancer cannot be understood by studying only one gene or 
protein at a time. In this thesis, we took three approaches to examine complexity in the 
CXCL12/CXCR4/CXCR7 signaling axis. In Chapters 2 and 4, we used a bioinformatics 
approach to study CXCL12 isoforms and to understand CXCR7 in the context of CXCR4 
signaling. In Chapter 3, we built a model integrating multiple biological scales to 
understand how molecular level behavior influences migration in the tissue scale. In 
Chapter 4, we developed a mechanistic model to understand how competition within the 
signaling pathway affects strategies targeting these receptors. Here, we summarize key 
conclusions from the thesis and discuss future directions of this work.  
6.1.1 CXCL12 isoforms matter in breast cancer 
In Chapter 2, we performed the first study to investigate the role of all six CXCL12 
isoforms in breast cancer. The Cancer Genome Atlas (TCGA) is a data platform 
providing free access to genomic data collected by the National Cancer Institute 
(cancergenome.nih.gov). Currently, all TCGA breast cancer data is available without 
limitations and is the only publicly available clinical database using RNAseq. This 
allowed us to differentiate between CXCL12 isoforms and correlate isoform expression 
to important clinical and survival metrics. While CXCL12-ε and -ϕ expression levels are 
undistinguishable from noise, four of the six isoforms; CXCL12-α, -β, -γ and -δ, are 
expressed at detectable levels in primary breast tumors. Lower levels of these isoforms 
correlate with cancer (as compared to normal tissue), higher tumor stage, and worse 
survival outcomes [2].  
 126 
 
While the bioinformatics analysis (Chapter 2) demonstrated clinical relevance of 
CXCL12 isoforms, the multi-scale model (Chapter 3) used a mechanistic approach to 
understand how isoforms can result in different migration outcomes. Previous studies 
have shown that CXCL12-γ is more effective than the α and β isoforms at promoting 
CXCR4+ chemotaxis, yet, due to experimental limitations, could only hypothesize that 
gradient differences among isoforms could explain this phenomena [3-6]. In our model, 
we showed that the characteristics of high affinity to CXCR4 and to the surface upon 
which cells are migrating make CXCL12-γ the most potent at promoting CXCR4+ 
migration. Our multi-scale model incorporated ligand diffusion, degradation, receptor-
mediated internalization, and surface binding to calculate gradient shape over position 
and time. Unlike experiments, the model was able to switch on and off individual 
molecular events. This allowed us to demonstrate that high affinity to surfaces results in 
steeper gradients and that high affinity to CXCR4 allows better directed movement of 
CXCR4+ cells. In addition to interpreting CXCR4+ migration in the in vitro microfluidic 
source-sink device, the model predicted that gradients will form in the disorganized cell 
structures representative of primary breast tumors, and that CXCL12 isoforms can also 
differentially regulate migration in those structures. While experimental models have 
focused on CXCL12 gradient formation due to the positioning of a bulk mass of 
CXCR7+ cells near CXCL12-secreting and CXCR4+ cells [4,7-9], our model was able to 
show gradient formation and consequent cell migration when cell patterns are more 
random in nature. In particular, we predict that CXCL12-γ is still more effective at 
driving CXCR4+ migration in tumor-like cell formations than CXCL12-α and –β [10].  
6.1.2 Low levels of CXCL12 can result in worse cancer outcomes 
A surprising result in the CXCL12 isoform bioinformatics analysis (Chapter 2) is that 
lower levels of CXCL12 confer worse prognosis than higher levels of CXCL12. 
Considering that CXCL12 was first identified as a potential malignant marker due to its 
expression in carcinoma-associated fibroblasts [11], we initially anticipated the opposite 
trend. A broad analysis of CXCL12 expression in Oncomine, a cancer microarray 
database that allows facile search of publicly available clinical data [12], reveals that the 
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majority of other publicly available breast cancer datasets correlate with lower levels of 
CXCL12 (Figure 6.1) [12]. 
 
The multi-scale model (Chapter 3) offers one explanation as to why higher levels of 
CXCL12 might correlate with better patient outcomes. The model demonstrates that high 
levels of CXCL12 promote significant receptor desensitization, resulting in reduced 
migration. In addition, at high CXCL12 levels, internalization by CXCR4 and CXCR7 
are insufficient to produce steep gradients that direct migration [10]. Other studies 
propose ways by which low levels of CXCL12 may confer worse patient outcomes. Pre-
treating CXCR4+ cells with a low concentration of CXCL12 prior to stimulation with a 
higher CXCL12 concentration suggests that low levels of CXCL12 pre-sensitize 
CXCR4+ cells to further activation [13].  Another study demonstrated that low plasma 
CXCL12 correlates with distant metastasis in breast cancer, proposing that low CXCL12 
in the blood do not desensitize CXCR4 on circulating tumor cells and allow for 
extravasation to the metastatic site [14,15].  
6.1.3 Targeting undesired CXCR4 activity in cancer  
Blocking the CXCR4 receptor has not been a clinically successful strategy to inhibit 
cancer progression [1]. Our multi-scale model highlighted simultaneous targeting of 
CXCR4 and CXCR7 as a strategy to halt CXCL12/CXCR4-mediated cancer progression. 
As CXCR7 is a high affinity receptor for both CXCL12 and β-arrestin, it controls both 
gradient scope and magnitude. Gradients of CXCL12-γ are particularly difficult to target, 
as its high affinity for glycosaminoglycans promotes steep gradients. Yet we find that 
simultaneous blocking of CXCR4 and CXCR7 activity results in a greater reduction of 
migration than the sum of blocking each receptor individually. This synergistic effect 
suggests targeting CXCR7 together with CXCR4 can boost efficacy without resorting to 
toxic levels of a CXCR4 inhibitor. Others have proposed co-targeting of CXCR7 with 
CXCR4 as a potential method to block undesired CXCR4 signaling [16].  
 
An alternative targeting strategy is to develop a biased therapeutic that can preserve 
beneficial CXCR4 function while inhibiting signaling pathways that result in pathological 
effects [17-20]. Biased therapeutics designed to correct the pathological signaling 
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pathway, rather than a complete inhibition of the receptor response, could provide 
improved therapy while mitigating toxicity. Also called permissive antagonists, these 
biased ligands may allow some agonist signaling. For example, while the CXCR7 
antagonist AMD3100 competes with CXCL12 at the ligand binding site (thus affecting 
all pathways downstream of CXCR4), ATI-2341 is a pepducin that favors Gαi activation 
over Gα13 and does not result in β-arrestin recruitment [19]. Identifying which parts of 
the signaling network to target will allow us to more precisely treat disease. 
 
In Chapter 4, we constructed a model to examine potential unintended consequences of 
inhibiting CXCR7 due to the fact that CXCR4/CXCR7 share many signaling 
components. CXCR7 is best known for its ability to scavenge extracellular CXCL12 and 
for being a seven-transmembrane receptor without G-protein activity [21-24]. Often 
overlooked is that CXCR7 can be co-expressed with CXCR4 on populations of tumor 
cells [25], which may have important implications when targeting the CXCL12/CXCR4 
pathway. Our mechanistic model of CXCR4/CXCR7 receptor dynamics and signaling 
shows that CXCR7 scavenges both CXCL12 and β-arrestin from CXCR4. Therefore, 
instead of increasing G-protein signaling, CXCR7 decreases G-protein signaling while 
simultaneously decreasing the availability of β-arrestin. The model also identified other 
potential targets that can shift the direction of G-protein mediated ERK signaling. We 
find that depending on the rates of CXCR4 recycling and the relative rate of receptor 
phosphorylation compared to ligand binding, increasing β-arrestin can have a positive, 
negative, or no impact on G-protein signaling. This suggests that altering recycling rates 
(potentially by targeting endosomes) or targeting G-protein receptor kinases may also be 
effective strategies to alter CXCR4 signaling.  
 
After screening 30,000 candidates, Castaldo et al. identified 41 compounds that can bind 
to CXCR4 [17]. These compounds belong to one of the five following classes: functional 
antagonists, G protein dependent antagonists, full antagonists, antagonists for both G 
protein and β-arrestin, and antagonists that affect internalization. As we gain more 
knowledge about which downstream pathways are responsible for specific cell behavior, 
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employing thorough screening strategies could identify currently available drugs that 
block specific pathways.  
6.2 Limitations and future directions 
6.2.1 Monomers and dimers of CXCL12, CXCR4, and CXCR7  
The role of CXCL12 in cancer cell migration is made even more complicated because it 
can signal in its monomer or dimer form [26-28]. The two forms exist in equilibrium 
[27,28] and monomers and dimers signal via different pathways [28-30]. Which 
pathways are promoted by monomers or dimers is still unclear. Using preferentially 
monomeric or constitutively dimeric CXCL12 produced from bacterial cultures, Drury et 
al. showed that the monomeric form primarily signals via β-arrestins and leads to 
persistant activation of pERK and chemotaxis, whereas the dimer form signals through G 
proteins and does not lead to chemotaxis. These conclusions were supported with 
transwell migration assays using human colorectal carcinoma cells (HCT116) as well as 
ERK time course studies [29]. Ray et al. isolated CXCL12 monomers and dimers 
secreted from human embryonic kidney (HEK)-295T cells using column chromatography 
and employed bioluminescence complementation techniques to verify the roles of 
monomers and dimers. They reported the opposite: CXCL12 monomers seemed to signal 
through G proteins more than dimers, whereas dimers resulted in higher association with 
β-arrestins and chemotaxis [30]. These data suggest that monomeric and dimeric 
CXCL12 are biased agonists. Whether or not monomeric and dimeric CXCL12 are 
indeed biased agonists, and how each CXCL12 isoform may differ in favoring monomer 
or dimer form, have additional implications on how the CXCL12/CXCR4 pathway can 
be targeted. These biological effects were not taken into account in our computational 
model. The present level of detail in the model focused on ligand binding and 
internalization and was sufficient for our model show how receptor-bearing cells and 
CXCL12 isoforms affect gradient shape. In our ordinary differential equation models 
representing ligand-receptor dynamics, we assumed that CXCL12 and CXCR4 interact 
with a stoichiometric ratio of 1:1, which is supported by functional and computational 
experiments[31]. Our ODE submodel was constructed and validated on quantitative 
binding and internalization experimental data using many CXCL12 concentrations and 
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over multiple time points in the same cell types used in the source-sink device 
experiments [32].  
 
CXCR4 and CXCR7 can also exist in dimer form – as homodimers, or as heterodimers 
with each other. Heterodimerization is not only limited to CXCR4 and CXCR7. CXCR4 
can dimerize with CCR2, CCR5 and CXCR3 [33].  
 
It is still unclear whether dimerization shifts signaling to one pathway versus another, or 
if it can elicit activation of pathways that either receptor cannot activate on its own [34-
37]. Modeling may be able to help uncouple these effects (Figure 6.2). By building a 
model that provides accurate predictions of CXCR4 signaling in cells lacking CXCR7, 
and vice versa, the model may be able to predict what behavior is expected if 
dimerization simply favors one pathway over another, or if signaling is distinctly due to a 
unique property of a heterodimer.  
6.2.2 Bioinformatics limitations  
Although patient tumor databases provide a wealth of information and a link to clinical 
relevance, one major limitation is that gene expression analysis profiles all cells in the 
tumor environment without regard for the type of cell. Considering that the tumor 
microenvironment plays a strong role in cancer progression, it would be advantageous to 
identify which cells (ie. fibroblasts, cancer cells, and others) express which receptors, and 
if some receptors are expressed together or individually. One high throughput method to 
separate cell types is serial analysis of gene expression (SAGE). This method separates 
cell types by first mincing and digesting tissue, and then subjecting the digested tissue 
through sequential filtration or single cell suspension with specific antigens to identify 
cell types such as leukocytes, myofibroblasts, endothelial, epithelial, and myoepithelial 
cells [38].  
6.2.3 Gradient directionality 
We have established that CXCR4 cells can move in the disorganized structures like the 
tumor environment, and that movement is affected by ligand type and presence of 
CXCR7. However, the model does not incorporate directionality. Why do CXCL12 
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gradients matter in the primary tumor environment? This question is left unanswered in 
current literature. One hypothesis is that CXCL12-expressing stroma residing on the 
tumor edge may promote local invasion of cancer cells [39]. Alternatively, CXCL12 may 
serve to keep CXCR4+ cancer cells in protective niches within the primary tumor [40]. It 
has also been demonstrated in mouse models that CXCL12 gradients promote 
angiogenesis by recruiting endothelial progenitor cells to the primary tumor site [11]. By 
incorporating a more realistic tumor environment (ie. vascular sources, a boundary 
between normal and malignant tissue), these hypotheses may be addressed in a future 
version of the multi-scale agent based model. 
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6.3 Figures  
 
Figure 6.1 Lower CXCL12 gene expression correlates with many types of cancers 
We used Oncomine [12] to look at the number of cancer datasets that show a correlation 
between low gene expression of CXCL12 and cancer tissue. The first column shows 
cancer types with available data in Oncomine. The numbers in the colored boxes 
represent the number of clinical data sets per cancer type that have a correlation between 
high CXCL12 and cancer (red) or low CXCL12 and cancer (blue). Note that for breast 
cancer, 14 out of 15 datasets have lower CXCL12 gene expression in cancer samples than 
in the normal samples of the dataset. The threshold settings in Oncomine were set to the 
following: p-value <10-4; fold change >2; and gene rank in top 10%.  
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Figure 6.2 Future directions in models of CXCR4/CXCR7 signaling 
Both CXCR4 and CXCR7 are implicated in cancer and they may interact with one 
another at many points in their signaling pathways. The two receptors not only form 
homodimers, but can also bind to one another, forming heterodimers. Models may be 
able to determine if differences in signaling in cells displaying heterodimers is due to an 
additive effect of both CXCL12/CXCR4 and CXCL12/CXCR7 pathways working 
simultaneously, or if the behavior arises from properties unique to the heterodimer 
structure. While CXCL12 has a monogamous relationship with CXCR4, CXCR7 may 
also bind CXCL11, and investigating how the presence of CXCL11 would further affect 
their shared signaling is of potential interest. Integrating more detailed models of G-
protein, metabolic, and ERK signaling may serve to link the model to more experimental 
outputs and better model validation, as well as suggest other drug targets.  
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Appendix A Supporting information for Cell, 
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and modulate chemotaxis 
Figure A.1: Microfluidic source-sink device 
Figure A.2: Agent-based model boundary conditions and validation for device setup  
Figure A.3: Model workflow  
Figure A.4: Validation of movement time step  
Figure A.5: Contribution of gradient-shaping events 
Figure A.6: Comparison of gradients within device between CXCL12-α, -β, and -γ 
Figure A.7: Effect of CXCR7 on CXCR4 surface receptors 
Figure A.8: CXCR4+ movement in gradients of CXCL12-α tumor simulations with 
adjusted parameters 
Figure A.9: Tumor simulations using an extended grid 
Table A.1: Multi-scale agent-based model parameters 
Table A.1a: Multi-scale model parameters 
Table A.1b: Molecular species involved in ligand-binding and internalization 
dynamics of CXCR4 and CXCR7 
Table A.1c: Description and values of CXCR4 kinetic and equilibrium parameters  
Table A.1d: Description and values of CXCR7 kinetic and equilibrium 
parameters.  
Table A.1e: Ordinary differential equations describing events of ligand binding 
and receptor dynamics 
Table A.1f: Ordinary Differential Equations describing the change in the 
concentration of species in CXCR4+ and CXCR7+ cells over time 
Table A.2: Total receptor numbers for the MDA-MB-231 cells transfected to express 
CXCR4 and CXCR7 used in the device as determined by flow cytometry 
Table A.3: Sensitivity Analysis for CXCR4 and CXCR7 molecular parameters 
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Figure A.1 Microfluidic source-sink device
(A) Bird’s eye view of in vitro microfluidic source-sink device. Cells are patterned into 
stripes of 200 µm width by use of inlet and outlet ports as described in [1,2]. (B) View of 
CXCL12+ (red), CXCR4+ (blue), and CXCR7+ (green) cells in device after initial 
seeding. The spacing between the cell stripes can be 200 µm (used for fitting 
experiments) or 400 µm (used for validation experiments). (C) Over time, CXCR4+ cells 
move in the direction of the CXCL12+ cells.  
 
 
 
Figure A.2 Boundary conditions and validation for source-sink device setup  
 
(A) Boundary conditions for agent movement and chemokine diffusion when modeling 
the source-sink device. (B) Reducing the grid to 25x200x10 gridspaces gives the same 
gradient calculations and average migration as a grid 10 times as large. Average is 
representative of 30 simulations.  
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Figure A.3 Model workflow 
 
We assume that receptors and β-arrestin within cells initially seeded in the device are at 
steady state. Prior to populating the agent based model with cells, we calculate the steady 
state values of free, surface, and internalized receptors and bound and free β-arrestin. In 
order to calculate multiple simultaneous events while minimizing computational 
requirements, we use operator splitting to decouple the equations and then employ the 
appropriate time step. Receptor-ligand dynamics occur on the smallest time scale and are 
solved using the molecular time step. Diffusion, extracellular degradation and 
extracellular binding events are solved using the diffusion time step. Cell behavior is 
calculated on a larger movement time step.  
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Figure A.4 Validation of movement time step 
Experimental data reproduced from [1] (Figure 1, E-G at 0% secretion).  Each data point 
(n=54) represents the average position of CXCR4 cells per view field of the device at 24 
hours. 
 
CXCR4+ cells in the absence of CXCL12 and cells that do not bear CXCR4 should move 
randomly (average migration = 0 µm) with a standard deviation that matches random 
movement within the experimental source-sink device. The model uses the same 
parameters as in Supporting Table 1, but with (1) an imposed linear CXCL12 gradient 
with a concentration on the left of the device as indicated in the y-axis, and a 
concentration of 0 nM on the right of the device and (2) CXCL12+ source cells and 
CXCR7+ sink cells replaced with cells that did not express the ligand and protein. For the 
simulation that lacks CXCL12, total number of CXCR4 on CXCR4+ cells is as listed in 
Supporting Table 1. For all other simulations, total CXCR4 was set to 0. Each data point 
(n=200) represents the average migration for one device simulation.  
 
In absence of CXCL12 or CXCR4, CXCR4 cells have average migration of 0. Standard 
deviation is same as experimental.   
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Figure A.5 Contribution of gradient-shaping events 
 
To understand the contribution of cellular and environmental effects on gradient shape 
over time and position, we systematically “turned off” events from the model. All 
parameters are as listed in Supporting Table 1. To turn off binding to the migration 
surface, we set the number of binding sites to 0. To turn off receptor ODEs, we inhibited 
the call of the ODE functions. Note that secretion and diffusion alone result in relatively 
shallow, linear gradients that increase in concentration over time. Removing binding to 
the migration surface limits total CXCL12 concentration. Removing CXCL12-CXCR4 
ODEs results in an increase in the gradient in the location of the CXCR4+ cells. 
Removing CXCL12-CXCR7 ODEs results in an overall increase in CXCL12 
concentration across the grid, as well as a significant increase in concentration in the 
region of the CXCR7+ cells.  
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Figure A.6 Comparison of gradients within device between CXCL12-#, -$, and -"  
 
Gradients using parameters in Table 1 and Supporting Table 1. Colorbars indicate total 
CXCL12 concentration in nM. CXCL12-! has highest overall concentration and steepest 
gradients compared to CXCL12-" and -#.  
 
 
 
 
Figure A.7 Effect of CXCR7 on CXCR4 surface receptors  
 
The average number of CXCR4 surface receptors per CXCR4+ cell across a range of 
CXCL12 secretion rate constants under conditions of no inhibition (all parameters same 
as listed in Supporting Table A), inhibition of 90% of CXCR7 receptors, and inhibition of 
99% of CXCR7 receptors. Reducing the number of CXCR7 receptors results in a 
decrease of CXCR4 surface receptors at higher CXCL12 secretion rates, but does not 
affect CXCR4 surface receptor expression at lower secretion rates. Model data are 
expressed as mean of 30 replications +/- standard deviation. The maximum standard 
deviation is ~1000 receptors, thus, error bars are not visible on the plot.   
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Figure A.8 CXCR4+ movement in gradients of CXCL12-α tumor simulations with 
adjusted parameters 
 
To determine whether CXCL12-α-like parameters can result in CXCR4+ migration in 
tumor simulations, we increased total CXCR4 from 5x103 to 5x104 receptors/cell, which 
significantly enhanced CXCR4+ migration. To examine which ligand-related parameters 
have the largest effect on CXCR4+ migration in tumor simulations, we systemically 
swapped CXCL12-α parameter values with CXCL12-γ parameter values (increased 
affinity to CXCR4: KD,R4,L12 = 10 nM; increased affinity to migration surface: KD,L,S = 
5nM; decreased secretion rate constant: CXCL12sec = 5 molecules/cell-s). Both the 
increase in affinity to the migration surface and to CXCR4 significantly enhance 
migration. All other parameters and initial conditions were the same as those used in 
Figure H-J. *** P < 0.0005.  
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Figure A.9 Tumor simulations using an extended grid 
 
Simulations with the same parameters and initial conditions as Figure 5H-J (5x103 total 
receptors/cell for both CXCR4+ and CXCR7+ cells), but with an extended grid of 
100x100x5. (A) Cell positions. Gradients of (B) CXCL12-α, (C) CXCL12-β, (D) 
CXCL12-γ on the migration surface at 24 hours. Colorbars indicate the total CXCL12 
concentration in nM. Similarly to the 2D grid, gradients of CXCL12-γ are characterized 
by steeper gradients and shorter maintained distances than those of CXCL12-α. (D) 
Consistent with the results in the 2D grid, CXCR4+ cells move significantly more 
towards CXCL12+ cells in gradients of CXCL12-γ than CXCL12-β or CXCL12-α. * P < 
0.05; ** P < 0.005; *** P < 0.0005. 
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Table A.1: Model parameters  
 
Table A.1a Multi-scale model parameters 
Parameter Description Value  Literature Range Reference 
Cell density 
(cells/mm2) 
Density of cells 
patterned in microfluidic 
device 
2500 
(125 cells of 
each type) 
 [1] 
CXCL12sec  
(molecules/cell-s) 
Secretion rate of 
CXCL12+ cells (Also 
shown in Table 1) 
20* 
 
15-25 
 
[1] 
DCXCL12 (cm2/s) CXCL12 diffusivity 
coefficient 
1.5x10-6 1.5x10-6 – 1.7x10-6 [2,3] 
kdeg (s-1) Extracellular CXCL12 
degradation rate 
2x10-5 6x10-5 – 4x10-3 [4-6] 
Total number of 
surface sites (S+
L ⋅S ) (#/gridspace) 
Number of surface 
bound sites per 
gridspace 
5x105  2.3x105-1.2x106 # 
 
[7,8] 
KD,L,S (nM) Dissociation constant of 
CXCL12-α to surface 
site 
100* 
 
93 
 
[9] 
kf,L,S (s-1) Forward rate constant of 
ligand to surface site 
0.001^ 0.001 [9] 
Total CXCR4 
(molecules/cell) 
Total number of CXCR4 
receptors per CXCR4+ 
cell 
7.1x105  This work 
Total CXCR7 
(molecules/cell) 
Total number of CXCR7 
receptors per CXCR7+ 
cell 
2x106  This work 
Total β-arrestin in 
CXCR4+ cells 
(molecules/cell) 
Total number of β-
arrestin per CXCR4+ 
cell 
5x105   [10] 
Total β-arrestin in 
CXCR7+ cells 
(molecules/cell) 
Total number of β-
arrestin per CXCR7+ 
cell 
7x105&  [10] 
* Fit to experimental data, as shown in Figure 3 
# Used number of cell surface heparan sulfate sites as a starting point. Sensitivity analysis (using LHS and 
PRCC as described in Methods) showed no dependence of average CXCR4+ at 24 hr on number of surface 
sites within this range. 
^ Assumed the forward rate constant for ligand binding to a surface site is the same as that for binding to 
heparan sulfate.  
& Increased to reflect that the majority of cell surface receptors on CXCR7+ cells are intracellular.  
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Table A.1b Molecular species involved in ligand-binding and internalization 
dynamics of CXCR4 and CXCR7 
We use the same equation framework and parameters as [10]; however, we do not include any probe-
labeled β-arrestin species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CXCR4 
Species 
Description CXCR7 
Species 
Description 
R4 (#/cell)  Free cell-surface CXCR4 R7 (#/cell) Free cell-surface CXCR7 
L12 (nM) Free extracellular CXCL12 L12 (nM) Free extracellular CXCL12 
Be (#/cell) Free endogenous  β-arrestin 2 Be (#/cell) Free endogenous  β-arrestin 2 
R4Be (#/cell) R4 bound to Be R7Be (#/cell) R7 bound to Be 
C4 (#/cell) R4 bound to L12 C7 (#/cell) R7  bound to L12 
C4Be (#/cell) R4Be bound to L12 C7Be (#/cell) R7Be bound to L12 
R4Bei (#/cell) Intracellular R4Be  R7Bei (#/cell) Intracellular R7Be  
C4Bei (#/cell) Intracellular C4Be  C7Bei (#/cell) Intracellular C7Be  
C4Beii (#/cell) C4Bei after Be dissociation R7Beii (#/cell) R7Bei  after Be dissociation 
C4Bpii (#/cell) C4Bpi after Bp dissociation C7Beii  (#/cell) C7Bei  after trafficking to late endosomes 
L12i (#/cell) Intracellular L12 C7Bpii  (#/cell) C7Bpi  after trafficking to late endosomes 
  L12i (#/cell) Intracellular L12 
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Table A.1c Description and values of CXCR4 kinetic and equilibrium parameters  
# All CXCR4 parameter values are taken from [10] unless otherwise noted.  
^ This reported range that was examined in [10] is the same used for sensitivity analysis. When the 
parameter value is outside the literature range (which happens because it was fit to experimental data), we 
extend the sensitivity analysis range to that value. 
* This value was increased from 6.9x10-5 (value in [10]) to 3x10-4 (4x increase) to better capture the slow 
decrease in surface receptor numbers seen in long time frame experiments.  
  
Parameter Description Value# Reported 
Range^ 
kf,L12,4  (nM-1s-1) Forward rate constant of L12 binding R4 /R4Be  2.1 x10-3 2.8 – 6.7 x10-3 
kf,B,4  ((#/cell)-1s-1) Forward rate constant of Be binding R4 /C4 8.5 x10-9   10-8 – 10-6 
KD,R4,L12 (nM) Equilibrium dissociation constant of L12 binding R4  40 2-27 
KD,R4,B  (#/cell) Equilibrium dissociation constant of Be from R4  7.8 x106  104 – 106 
KD,C4,B (#/cell) Equilibrium dissociation constant of Be from C4 5.1 x106 104 – 106 
ke,R4B (s-1) R4Be  internalization rate constant 2.3 x10-3 1 – 2 x10-3 
ke,C4B  (s-1) C4Be internalization rate constant 4.7 x10-3 3 x10-3 
koff,B,4 (s-1) Dissociation rate constant of Be from C4Bei  7.4 x10-4  
krec,R4Bi (s-1) R4Bei recycling rate constant 3x10-4 *  10-4 – 10-3 
kdeg,C4Bii  (s-1) C4Beii degradation rate constant 1.0 x10-4 10-5 – 10-4 
kdeg,L12i   (s-1) L12i degradation rate constant 1.0 x10-4 10-4 – 10-3 
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Table A.1d Description and values of CXCR7 kinetic and equilibrium parameters 
Parameter Description Value# Reported 
Range^ 
kf,L12,7  (nM-1s-1) Forward rate constant of L12 binding R7 /R7Be  1.4 x10-3 2.8 – 6.7 x10-3 
kf,B,7 ((#/cell)-1s-1) Forward rate constant of Be binding R7 /C7 1.4 x10-8  10-8 – 10-6 
KD,R7,L12 (nM) Equilibrium dissociation constant of L12 binding R7  0.84 0.2 – 0.4 
KD,R7,B   (#/cell) Equilibrium dissociation constant of Be from R7  2.3 x106 104 – 106 
KD,C7,B  (#/cell) Equilibrium dissociation constant of Be from C7 6.5 x105  104 – 106 
ke,R7B  (s-1) R7Be internalization rate constant 3.9 x10-3 1 – 2 x10-3 
ke,C7B  (s-1) C7Be internalization rate constant 2.1 x10-3 3 x10-3 
koff,B,7 (s-1) 
Dissociation rate constant of Be from R7Bei  2.5 x10-3  
ke,C7Bi (s-1) Rate constant of trafficking of   C7Bei to late 
endosomes 
5.5 x10-4  
krec,R7Bii  (s-1) R7Beii recycling rate constant 1.1 x10-3 10-4 – 10-3 
krec,C7Bii (s-1) C7Beii recycling rate constant 2.8 x10-4 10-4 – 10-3 
kdeg,L12i   (s-1) L12i degradation rate constant 1.0 x10-4 10-4 – 10-3 
# All CXCR7 parameter values are taken from [10]. 
^ This reported range that was examined in [10] is the same used for sensitivity analysis. When the 
parameter value is outside the literature range (which happens because it was fit to experimental data), we 
extend the sensitivity analysis range to that value. 
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Table A.1e Ordinary differential equations describing events of ligand binding and 
receptor dynamics 
 
Cellular Event CXCR4+ cells CXCR7+ cells 
Ligand binding to free 
receptors  
𝑣! = 𝑘!,!!" ,!( 𝑅! 𝐿!" − 𝐾!,!! ,!!" 𝐶! )  𝑣! = 𝑘!,!!" ,!( 𝑅! 𝐿!" − 𝐾!,!! ,!!" 𝐶! ) 
Ligand binding to receptor-
β-arrestin complexes 
𝑣!= 𝑘!,!!" ,!( 𝑅!!! 𝐿!"− 𝐾!,!!! ,!!" 𝐶!!! )  𝑣! = 𝑘!,!!" ,!( 𝑅!!! 𝐿!" − 𝐾!,!!! ,!!" 𝐶!!! ) 
β-arrestin binding to free 
receptors 
𝑣! = 𝑘!,!,!( 𝑅! 𝐵! − 𝐾!,!! ,! 𝑅!!! )  𝑣! = 𝑘!,!,!( 𝑅! 𝐵! − 𝐾!,!! ,! 𝑅!!! ) 
β-arrestin binding to 
ligand-bound receptors  
𝑣!! = 𝑘!,!,!( 𝐶! 𝐵! − 𝐾!,!! ,! 𝐶!!! )  𝑣!" = 𝑘!,!,!( 𝐶! 𝐵! − 𝐾!,!! ,! 𝐶!!! ) 
Internalization of cell 
surface receptor-β-arrestin 
complexes 
𝑣!" = 𝑘!,!!! 𝑅!!!   𝑣!" = 𝑘!,!!! 𝑅!!!  
 𝑣!" = 𝑘!,!!! 𝐶!!!   𝑣!" = 𝑘!,!!! 𝐶!!!  
Dissociation of  
β-arrestin from internalized 
receptor-β-arrestin 
complexes 
𝑣!" = 𝑘!"",!,! 𝑅!!!!   𝑣!" = 𝑘!"",!,! 𝐶!!!!  
 
Trafficking of internalized 
receptor-β-arrestin 
complexes to late 
endosomes   
N/A  𝑣!" = 𝑘!,!!!" 𝐶!!!!  
Recycling of internalized 
receptors  
 
𝑣!" = 𝑘!"#,!!!" 𝑅!!!!   𝑣!" = 𝑘!"#,!!!"" 𝑅!!!!!  
 N/A  𝑣!! = 𝑘!"#,!!!"" 𝐶!!!!!  
Degradation of internalized 
receptors and ligand 
𝑣!" = 𝑘!"#,!!!"" 𝐶!!!!!   
Degradation of 𝐿!"! 𝑣!" = 𝑘!"#,!!"! 𝐿!"!  𝑣!" = 𝑘!"#,!!"! 𝐿!"!   
Numbering of equations is consistent with that used in [10].  
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Table A.1f Ordinary Differential Equations describing the change in the concentration 
of species in CXCR4+ and CXCR7+ cells over time 
 
CXCR4 Equations (#/cell/s) CXCR7 Equations (#/cell/s)  d[R!]dt = −v! − v! − v! + v!" + v!" 𝑑[𝑅!]𝑑𝑡 = −𝑣! − 𝑣! − 𝑣!" + 𝑣!" + 𝑣!" + 𝑣!! + 𝑣!" d[R!!!]dt = +v! − v! − v!" 𝑑[𝑅!!!]𝑑𝑡 = +𝑣! − 𝑣! − 𝑣!" d[C!]dt = +v! − v!! − v!" 𝑑[𝐶!]𝑑𝑡 = +𝑣! − 𝑣!" − 𝑣!" d[C!!!]dt = +v! + v!! − v!" 𝑑[𝐶!!!]𝑑𝑡 = +𝑣! + 𝑣!" − 𝑣!" d[R!!!!]dt = +v!" − v!" 𝑑[𝑅!!!!]𝑑𝑡 = +𝑣!" − 𝑣!" d[C!!!!]dt = +v!" − v!" 𝑑[𝐶!!!!]𝑑𝑡 = +𝑣!" − 𝑣!" d[C!!!!!]dt = +v!" − v!" 𝑑[𝐶!!!!!]𝑑𝑡 = +𝑣!" − 𝑣!! ∗ d[L!"]dt = (−v! − v! − v!)× n!×10!V×N!"  ∗ 𝑑[𝐿!"]𝑑𝑡 = (−𝑣! − 𝑣! − 𝑣!)× 𝑛!×10!𝑉×𝑁!"  d[L!"#]dt = +v!" + v!" − v!" 𝑑[𝐿!"!]𝑑𝑡 = +𝑣!" + 𝑣!! − 𝑣!" d[B!]dt = −v! − v!! + v!" + v!" 𝑑[𝐵!]𝑑𝑡 = −𝑣! − 𝑣!" + 𝑣!" + 𝑣!! 
 𝑑[𝑅!!!!!]𝑑𝑡 = +𝑣!" − 𝑣!" 
*Units for this equation are (nM/s) 
NAV:Avogadro’s number 
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Table A.2 Total receptor numbers for the MDA-MB-231 cells transfected to express 
CXCR4 and CXCR7 used in the device as determined by flow cytometry. 
 
Cell Type Total receptor number (#/cell) 
CXCR4+  7.1x105 ± 1.0x105 
CXCR7+ 5.8x106 ± 6.5x105 
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Table A.3 Sensitivity Analysis for CXCR4 and CXCR7 molecular parameters 
 
CXCR4 
Average 
Migration 
Average 
Concentration 
Surface 
CXCR4 
Total 
CXCR4 
Surface 
CXCR7 
Ligand binding           
KD,R4,L12 --- --- +++     
KD,R7,L12   +++ --- ---   
β-arrestin binding   
KD,R4,B +++ +++   --   
KD,C4,B ++ --- +++ ++   
KD,R7,B +++ --- +++ +++ +++ 
KD,C7,B --- +++ --- ---   
Internalization  
ke,R4B ---   --     
ke,C4B   +++   +++ + 
ke,R7B   +++ --- --- --- 
ke,C7B   --- +++ +++   
Recycling and Degradation  
krec,R4Bi +++   +++     
kdeg,C4Bii   
 
  
 
  
koff,B,4 --- + --- --- -- 
krec,R7Bii ++ --- +++ +++ +++ 
krec,C7Bii   
 
  
 
  
koffB,7   - ++ ++ -- 
Each parameter was varied within the range reported in Supporting Table A4. Sign represents a positive or 
negative PRCC value. The number of signs represents the significance of the correlation: 
+/- : 10-5 < p < 10-2 
++/-- : 10-12 < p < 10-5 
+++/--- :  p < 10-12 
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